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Protein-protein interactions that form functional complexes, play an important role in 
many biological and physiological processes. In order to identify, characterize and 
quantify such interactions in mammalian cells, there has been a need for techniques that 
allows protein-protein interactions to be monitored in live cells specifically in the cellular 
compartments where they naturally interact. We describe here a method that allows us to 
detect protein-protein interactions on the cell surface of live mammalian cells. This 
method is based on the mechanism of TLR2 activation through extracellular (EC) 
domain-mediated heterodimerization with TLR1. In this assay, the EC domains of TLR2 
and TLR1 are replaced by the EC domains of test receptors to express hybrids with the 
transmembrane/cytoplasmic (TM/Cyt) domains of TLR1 and TLR2, i.e. tmTIR1 and 
tmTIR2. The hypothesis is that dimerization of test proteins causes TIR1/TIR2 
dimerization which is detected using NF-κB luciferase reporter plasmids. To evaluate 
whether TIR1/TIR2 dimerization can be used to detect receptor-receptor interactions, we 
expressed IL-4 and the EC domains of IL4Rα and γC as chimeras with tmTIR1 and 
tmTIR2. At low doses of expression plasmids, co-expression of IL-4Rα-TIR1 and γC-
TIR2 did not significantly activate NF-κB. However, it was efficiently induced by IL-4. 
Co-expression of IL4-TIR1 with IL4Rα-TIR2, but not γC-TIR2, led to NF-κB activation 
which is consistent with previous report that  IL-4 binding to IL4Rα and its lack of direct 
binding to γC. Co-expression of IL4-TIR1/TIR2, IL4Rα-TIR1/TIR2, or γC-TIR1/TIR2 
constitutively activates NF-κB suggesting that IL4, IL4Rα and γC naturally form 
constitutive homodimers. 
  X
 Next, this TIR1/TIR2-based two-hybrid assay was used to investigate CD14-CD14 
interactions. It showed that the CD14 form homodimers. CD14 was also predicted based 
on its crystal structure involving β13 and the ‘loop’ between β12 and β13. Mutation of 
amino acids L290 or L307 in this region markedly reduced CD14-CD14 interactions. 
Functionally, these two residues are also required for CD14-mediated LPS signalling of 
NF-κB activation involving TLR4. 
 
 Since IL-4 induced IL4Rα and γC dimerization effectively causes TIR1/TIR2, we used 
this to investigate whether FcγR dimerizaiton is sufficient to cause NF-κB activation. The 
TM/Cyt domains of TLR1 in the IL4Rα-TIR1 and γC-TIR1 chimeras were replaced by 
the TM/Cyt domain of FcγRIIA to generate IL4Rα-FcγRIIA and γC-FcγRIIA chimeras. 
IL-4 induced dimerization of these chimeras did not induce NF-κB activation suggesting 
that higher degrees of FcγR oligomerization are probably required to cause signaling. To 
address this, different forms of IgG i.e. plate-immobilized-IgG (imIgG), heat-aggregate 
IgG (HA-IgG), beads-coated IgG (IgG-beads) were used to induce FcγRs signaling on 
human macrophages. The result showed that imIgG is a more potent stimulus of cytokine 
production compared to IgG-beads and HA-IgG. In addition, the roles of different FcγR 
in cytokine induction by imIgG and IgG-beads were examined using blocking antibody 
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Chapter 1 Introduction (Literature review) 
 
1.1     Protein-protein interactions form the basis of diverse biological processes 
Protein-protein interactions are key to the regulation of diverse biological processes, 
representing dominant forms of molecular communications inside and between cells. 
These interactions can be homotypic (interactions between identical proteins) or 
heterotypic (interactions between different proteins), stable and constitutive or 
transient and inducible, forming dynamic associations in response to specific stimuli. 
Irrespective of the nature of the interactions, the temporal and spatial combinations of 
these interactions can generate considerable functional diversity by triggering distinct 
signaling cascades and leading to regulated cellular activation. How proteins interact                       
with each other to accomplish the diverse biological and physiological activities 
remains a formidable task to dissect. High through-put methods are particularly useful 
in this respect. 
 
1.1.1     Overview and historical aspects for detecting protein-protein interactions 
 A number of methods have been developed to detect protein-protein interactions that 
are, to various extents, amenable for high through-put detection (Zhu et al., 2003). In 
the next sections, the strengths and weaknesses of these methods will be discussed. 
 
(i) One method to understand the functions of a protein is to identify proteins it 
interacts with. The yeast two-hybrid assay (Y2H), developed by Stanley Field’s group 
(Fields and Song, 1989; Fields and Sternglanz, 1994) has been widely applied. This 
assay employed the modular nature of the yeast Saccharomyces cerevisi, GAL4 
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protein. GAL4 is a transcriptional activator required for the expression of enzymes 
involved in galactose utilization. GAL4 contains a DNA binding domain (BD) 
(Keegan et al., 1986) and a transcription activation domain (AD) (Brent and Ptashne, 
1985) which are separately folded and functions independently of each other. In the 
Y2H system (Fields and Sternglanz, 1994), the BD and AD of GAL4 was expressed 
as separate proteins; neither alone exhibits the transcriptional activity of GAL4. To 
test the interaction between protein X and Y, BD is expressed in fusion with protein 
X, whereas AD is fused to protein Y, yielding two hybrid molecules. These two 
hybrids are expressed in yeasts which are also transfected to express one or more 
reporter genes under the GAL4 promoter. The upstream of these reporter genes 
contain activation sequence (UAS) of GAL4. If the X and Y proteins interact with 
each other, they can regenerate a functional GAL4 by bringing AD into close 
proximity with BD which is detected by the expression of the reporter genes (Fig.1.1). 
This method has been widely used to investigate interactions between proteins, 
particularly intracellular soluble proteins. 
 
The Y2H assay is highly sensitive in the detection of protein-protein interactions in 
transfected yeasts. It allows the identification of binding partners for a known protein 
by expressing the protein in fusion with BD domain and then screening proteins in 
fusion with AD. It also allows the identification of specific binding sites on proteins 















While the use of this method yielded a large body of data in protein-protein 
interactions, it also has obvious limitations. Firstly, this method generally cannot 
detect interactions involving three or more proteins and those critically depending on 
post-translational modifications e.g. phosphorylation. Secondly, it is not suitable for 
the detection of lateral interactions between membrane-anchored proteins. This is 
Figure 1.1 Schematic illustration of the Y2H system. (A) A hybrid protein is generated 
that contains a BD (filled circle) and protein X. This hybrid can bind to DNA but will not 
activate transcription because protein X does not have an activation domain (B) Another 
hybrid protein is generated that contains an AD (open circle) and protein Y. This hybrid 
protein will not activate transcription because it does not bind to the upstream activation 
sequence (UAS) of the reporter gene. (C) Both hybrid proteins are expressed in the same 
transformant yeast. If X and Y bind to each other, this brings BD and AD together to 
activate the transcription reporter gene. Adopted from Fields et al., (1994). 
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because of the requirement for nuclear localization of the hybrid transcription factor 
to activate a reporter gene. Finally, in practice, the high-sensitivity of the assay is 
accompanied with reduced fidelity and the inferred interactions are often 
physiologically irrelevant. Therefore, although modified Y2H methods have been 
successfully applied by many laboratories, other methods are required to complement 
this assay 
 
(ii) Independently, a method has been developed that allows membrane protein 
interactions to be detected and it potentially allows protein-protein interactions to be 
monitored in real time in the cellular compartment where these interactions naturally 
take place. This method is based on two β-galactosidase (β-gal) mutants which 
individually lack activity. However, its enzymatic activity is restored after 
dimerization of the two mutants. Intracistronic β-gal complementation is a 
phenomenon whereby its mutants α and ω, which harbor inactivating mutations in 
different regions of the molecule, are capable of reconstituting an active enzyme by 
sharing their intact domains (Langley and Zabin, 1976; Marinkovic and Marinkovic, 
1977). In this method, two distinct but weakly complementing deletion mutants of β-
gal, α and ω, are each expressed in fusion with a test protein. If the two test proteins 











The strengths of this method are: (a) it allows protein-protein interactions to be 
investigated in live mammalian cells in the compartment in which they naturally take 
place, such as on the membrane or in the cytoplasm; (b) the enzymatic activity of β-
gal amplifies signals, allowing protein-protein interactions to be detected without 
over-expression; (c) it provides quantitative and kinetic readout of protein-protein 
interactions (Rossi et al., 2000). The major limitation of this method is the large size 
of the β-gal mutants. They are approximately 80 kDa and require the employment of 
retro-viral vectors. When plasmid vectors are used, limited capacity is left for the 
cloning of test proteins. The detection of protein-protein interaction by intracistronic 
complementation is also hindered by steric constraints that may prevent the formation 
of an active enzyme. 
 
Figure 1.2 Schematic illustration of β-gal-based method for detecting protein-
protein interactions. (A) When the ∆α and ∆ω β-gal mutants are fused to test proteins 
that do not dimerize, their association is not favored and β-gal activity not detected. (B) 
When the ∆α and ∆ω β-gal mutants are fused to proteins that dimerizes, the formation of 
active β-gal is favored where it reconstitutes the β-gal activity. Adopted from Rossi et al., 
(1997). 
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(iii) The method of fluorescence resonance energy transfer (FRET) allows detection 
of protein-protein interactions and protein conformational changes in live mammalian 
cells. This method is based on non-radioactive energy transfer from an excited 
fluorescent donor molecule to an acceptor molecule through the dipole-dipole 
coupling mechanism (Selvin, 2000). In this method, one test protein is labeled with a 
flruorochrome such as yellow fluorescent protein (YFP) which act as an energy 
acceptor and the other test protein is labeled with a different fluorochrome such as 
cyan fluorescent protein (CFP), acting as an energy  donor (Uster and Pagano, 1986; 
Truong and Ikura, 2001) (Fig 1.3). The emission spectrum of the donor fluorochrome 
significantly overlaps with the absorption spectrum of an acceptor. If the two test 
proteins interact with each other, the fluorochrome tags will be brought close to each 
other. Provided that dipoles of the donor and acceptor fluorochromes are in 
favourable mutual orientation, energy that directly activates the fluorochrome on the 
donor will indirectly activate the fluorochrome associated with the acceptor through 
energy transfer. This results in sensitized fluorescence emission from the acceptor, 
indicating that the test proteins are <10 nm apart or they bind to each other. The 











FRET can be performed to detect conformational changes within a protein as well as 
interactions between proteins. FRET microscopic imaging has the unique advantage 
to verify close molecular interactions between co-localized donor and acceptor 
labeled fusion proteins beyond the resolution of traditional fluorescent microscopy 
(Chen et al., 2003). However, the limitation of this method is the low expression of 
fluorescent labeled proteins which often results in insufficient amounts of donor and 
acceptor fluorochrome in close vicinity, reducing the efficiency of energy transfer. 
Figure 1.3 The principles of FRET. (A) Intramolecular FRET can occur when both the 
donor and acceptor chromophores are on the same host molecule, which undergoes a 
transition, for example, between ‘open’ and ‘closed’ conformations. In each square box 
corresponding to CFP or YFP (shown in cyan or yellow, respectively), a diagonal line 
represents the chromophore. The amount of FRET transferred strongly depends on the 
relative orientation and distance between the donor and acceptor chromophores. (B) 
Intermolecular FRET can occur between one molecule (protein A) fused to the donor (CFP) 
and another molecule (protein B) fused to the acceptor (YFP). When the two proteins bind 
to each other, FRET occurs. When they dissociate, FRET diminishes. Adopted from Truong 
et al., (2001). 
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The low expression is because FRET uses transfected cell cultures and the expression 
is influenced by a number of factors including transfection efficiency of the given cell 
type, the quality and quantity of DNA taken up by the cells, the cytotoxicity of the 
transfection reagent and the condition of the cells. These limitations have restricted 
the widespread use of this technique. 
 
As discussed above, each method has its own strengths and shortcomings which 
emphasize the need for additional methods to facilitate the investigation of protein-
protein interactions. In this study a novel method has been developed based on the 
principles of Toll-like receptor activation.  
 
1.2 Introduction to Toll-like receptors (TLRs) 
 
1.2.1 Discovery of TLRS 
The discovery of Toll-like receptors (TLR) began with the identification of the Toll 
protein in Drosophila which was  essential for establishing dorsoventral polarity 
during embryogenesis (Anderson et al., 1985; Hashimoto et al., 1988). It has a 
homologue in Drosophila, i.e.18-wheeler (18W), which is also required for 
embryogenesis (Eldon et al., 1994). Aside from their role in embryogenesis, Toll, 
18W and other homologues (Toll-3 to Toll-8) are also involved in Drosophila 
immunity (Tauszig et al., 2000). These proteins are essential for Drosophila immune 
responses against fungal and bacterial infections through the induction of anti-
microbial peptides (Lemaitre et al., 1996; Williams et al., 1997). An essential step in 
the activation of Toll involves the activation of a proteolytic cascade by microbial 
structures that cleave pro-Spätzle into Spätzle and Spätzle activates Toll. There are 
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common features found in the different Toll proteins. These are type I receptors and 
the extracellular regions are characterized by leucine-rich repeats (LRR) which are 
linked to the transmembrane domain through a cysteine-rich region. The cytoplasmic 
domains, known as Toll/IL-1R homology (TIR) domains, share striking homology 
with that of the type I IL-1 receptor (IL-1R) (Gay and Keith, 1991). Moreover, 
signaling through Toll follows the signaling pathways induced by IL-1R. One of the 
signaling pathways elicited through IL-1R is the NF-κB/I-κB pathway. In Drosophila, 
Toll mediates the activation of intracellular proteins Dorsal and Cactus, homologues 
of mammalian NF-κB and I-κB respectively (Hultmark, 1994). However, IL-1R 
differs from Toll in the extracellular domain as they have immunoglobulin-like rather 
than leucine -rich. The first mammalian homologue of Toll, i.e. hToll (human Toll), 
was discovered based on its homology to Toll and IL-1R over the TIR domain 
(Medzhitov et al., 1997). Poltorak et al (Poltorak et al., 1998) showed that TLR4 was 
responsible for host recognition of LPS leading to septic shock. 
 
To date, at least 11 mammalian genes have been identified encoding mammalian 
TLRs (TLR1-11) (Rock et al., 1998; Rock et al., 1998; Chaudhary et al., 1998; 
Takeuchi et al., 1999b; Sebastiani et al., 2000; Chuang and Ulevitch, 2000; Chuang 
and Ulevitch, 2001; Zhang et al., 2004). TLRs are pattern recognition receptors 
(PRRs) that enable host cells to recognize and differentiate between different 
pathogens to initiate appropriate signaling cascades and host cell activation. Antigen 
presenting cells (APCs) express many TLRs and TLR activation on APCs bridge 
innate and adaptive immunity by increasing the expression of various co-stimulatory 
molecules and effecter cytokines (Zhang and Ghosh, 2001). 
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All TLRs are type I transmembrane proteins with an extracellular domain consisting 
of LRRs that recognize conserved structures on pathogens and a cytoplasmic TIR 
domain. Based on sequence similarity, human TLRs can be divided into five 
subfamilies (Fig. 1.4): the TLR3, TLR4, TLR5, TLR2 and TLR9 subfamilies (Takeda 
et al., 2003; Gangloff et al., 2003). The TLR2 subfamily is composed of TLR1, 
TLR2, TLR6 and TLR10. TLR1 and TLR6 are highly similar in sequence (69.3% 
identity) with over 90% identities in their TIR domains (Takeuchi et al., 1999b). The 
TLR9 subfamily is composed of TLR7, TLR8 and TLR9. The other subfamilies 
consist of single members so far. With respect to amino acid sequences, among all 
known Drosophila Tolls (dTolls), only dToll9 exhibits significant similarity with 
human TLRs. The rest of dTolls are more related to each other than to human TLRs 
(Gangloff et al., 2003).  Cell signaling downstream of Toll, TLRs and IL-1R is very 





Figure 1.4 Phylogenetic tree of human TLRs. The phylogenetic tree was derived from 
an alignment of the amino acid sequences for the human TLR members using the
neighbor-joining method. Adopted from Takeda et al., (2003).
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1.2.2 Toll-like receptor 1 (TLR1) and Toll-like receptor 2 (TLR2) 
 
1.2.2.1 Genes and structure 
Human TLR1 and TLR2 genes have been mapped on chromosome 4p14 and 4q32 
respectively (Rock et al., 1998). Human TLR1, TLR6 and TLR10 have similar 
genomic structure, consisting of a single exon and are located in tandem on 
chromosome 4. They may represent the products of evolutionary duplicates. TLR2 is 
the next most homologous TLR to TLR1. TLR2 and TLR1 sequences share 32% 
identity and 53% similarity (Takeuchi et al., 1999b). Both human and mouse TLR2 
genes consist of three exons, of which the first and second exons are non-coding. The 
entire TLR2 open reading frame is located on exon three. Alternatively spliced forms 
also exist for TLR2 (Haehnel et al., 2002). 5’-flanking regions of both human and 
mouse TLR2 genes have been cloned (Matsuguchi et al., 2000; Musikacharoen et al., 
2001; Haehnel et al., 2002). Sequence homology has not been detected between the 
human and mouse TLR2 genes over the promoter region. In the 5’ untranscribed 
region of the mouse TLR2 gene, two NF-κB binding sites were identified which play 
a role in regulating TLR2 gene expression. TLR1 and TLR2 consist of 18-20 LRRs in 
the extracellular domains (Kirschning and Schumann, 2002). 
 
The LRR motif was first described in α2-glycoprotein as a 24-residue repeated 
sequence with characteristically spaced hydrophobic residues (Takahashi et al., 1985). 
Each LRR is a conserved 11 residue segment with the consensus sequence 
LXXLXLXXNXL (X=any amino acid; N=can be replaced by C, S or T; L=can be 
replaced by hydrophobic amino acids) followed by a variable region. LRR-containing 
proteins can be classified into subfamilies based on sequence similarity, length and 
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structure of the variable region (Kajava, 1998; Kobe and Kajava, 2001). These 
include typical (including TLRs and other LRR-contian portiens), ribonuclease-
inhibitor-like (RI) (e.g. GTPase-activating protein rna1p), SDS22-like (e.g. 
spliceosomal protein U2A’), cysteine-containing (e.g. SKp2), bacterial (e.g. YopM) 
and plant-specific subfamilies. The primary sequences of LRR in various proteins are 
shown in Figure 1.5 (Bell et al., 2003). The consensus sequence for majority of the 
LRRs in TLRs is a 24-residue motif that resembles the LRR of CD42b, exhibiting less 
curvature than RI. Two other LRR subtypes - SDS22 and bacterial - are also present 
in some TLRs. Large insertions that occur at positions 10 or 15 of the LRR are also 
present in some of the TLRs. Therefore, different TLRs can be distinguished by the 
presence of LRRs that deviate markedly from typical TLR-LRRs. The variations are 
conserved in TLRs of the same subfamilies e.g. TLR7, TLR8 and TLR9 have the 











Figure 1.5 Primary structures of LRRs. LRR consensus sequences. Shaded in green are 
the first ten residues that form the concave, β-face of the LRR solenoid (shown in Fig. 
1.6). This portion is common to all LRR subtypes. Shaded in pink are the portions that 
form the outer, convex side of the solenoid. This portion is variable between subtypes. 
Shown in the alignment are LRR consensus sequences for Toll-like receptors (TLRs), 
ribonuclease inhibitor (RI), CD42b, SDS22 (a yeast protein having 11 LRRs each with 22 
residues) and proline-rich subtypes. X refers to any amino acid, L and F are frequently 
replaced by other hydrophobic residues, and Φ is any hydrophobic residue. The 
















In CD42b, LRR represents its structural units. Each unit consists of a β-strand 
(formed by invariant residues 1-10) and an α-helix (formed by residues in the variable 
region) (Fig. 1.6A). In this unit, all the β-strands and helices are in parallel to a 
common axis, resulting in a non-globular, horseshoe-shaped molecule with the curved 
parallel β-sheet lining the inner circumference of the horseshoe and the helices 
flanking its outer circumference (Fig. 1.6B). TLRs seem to share features with CD42b 
based on their LRR similarity, but TLRs contain three times more LRRs than CD42b. 
Therefore, the LRR regions of TLRs are predicted to form a larger horseshoe structure 
with an extended concave β-sheet formed by 19-25 parallel β-strands. The LRRs of 
TLRs frequently contain insertions at positions 10 and 15. The insertion at position 10 
occurs in a loop that connects the β-face with the convex surface (Fig. 1.6B). It is 
expected to lie in proximity to the β-sheet. Insertions at position 15 might also contact 
the β-face but are more likely to be located near the convex surface, where they might 
Figure 1.6 Tertiary (A) and 
secondary (B) structure of the 
LRR proteins (CD42b). (A) 
Solenoid structure of CD42b is 
formed by tandem repeats of 
individual LRRs. The β-strands 
together form the concave 
surface of the 
horseshoe/solenoid structure and 
the α-helices form the convex 
surface, lining the outer 
circumference of the solenoid 
structure. (B) Residues shaded 
green form a strand within each 
LRR, whereas those shaded pink 
form a helix in CD42b. 
Insertions (In10, In15) occur in 
some of the LRRs of TLRs. 





interact with a large ligand that spills over the β-face or with an accessory molecule, 
such as MD2 for TLR4 (Bell et al., 2003). These variations in the LRR consensus of 
TLRs may provide individual TLRs with their ligand specificities. The properties of 
the TIR domain are discussed in section 1.2.3.1. 
 
1.2.2.2 Gene expression 
Studies on human TLR expression in tissues indicated that most tissues express at 
least one TLR (Zarember and Godowski, 2002). TLR2 has been found in lymphoid 
tissues, such as spleen, lymph node, thymus and bone marrow (Kirschning et al., 
1998; Yang et al., 1998). It is also found in the lung, heart, muscle and brain (Rock et 
al., 1998). With respect to cell types, TLRs are expressed by adipocytes (Lin et al., 
2000), fibroblasts (Mori et al., 2003), epithelial cells (Cario et al., 2000), 
keratinocytes (Pivarcsi et al., 2003), smooth muscle cells (Watari et al., 2000), and 
type II alveolar cells (Droemann et al., 2003). TLR1 is ubiquitously expressed and is 
apparently more abundant than other TLRs (Rock et al., 1998). Human TLR1 and 
TLR2 have been detected on the cell surface of monocytes, monocyte-derived 
immature dendritic cell and neutrophils (Visintin et al., 2001; Hayashi et al., 2003).  
The expression of TLR1 and TLR2 is modulated by various microbial products and 
inflammatory mediators (Miettinen et al., 2001; Mita et al., 2001; Liu et al., 2001; 
Talreja et al., 2004). Depending on the cell type and stimulus, TLR1 and TLR2 
expression is differentially regulated (Muzio et al., 2000). 
 
1.2.2.3 Ligands and functions 
 TLR2 recognizes many different microbial components, including peptidoglycan and 
lipoteichoic acid from Gram positive bacteria such as Staphylococcus aureus (Lien et 
al., 1999; Yoshimura et al., 1999; Opitz et al., 2001; Schroder et al., 2003), 
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lipoproteins from Gram-negative bacteria, mycoplasma and spirochetes (Hirschfeld et 
al., 1999; Brightbill et al., 1999; Aliprantis et al., 1999), lipoarabinomannan from 
mycobacteria (Underhill et al., 1999b; Means et al., 1999), zymosan from yeast 
(Underhill et al., 1999a), parasitic protozoa (Campos et al., 2001), a phenol soluble 
modulin from staphylococcus epidermis (Hajjar et al., 2001), and porins from the 
outer membrane of Neisseria (Massari et al., 2002). The recognition of peptidoglycan 
and lipoproteins by TLR2 has been shown using TLR2-/- mice (Takeuchi et al., 2000a; 
Takeuchi et al., 2000b; Wooten et al., 2002). Direct binding of peptidoglycan to 
soluble TLR2 has also been demonstrated (Iwaki et al., 2002).  
 
The ability of TLR2 to recognize many different ligands might be due to its ability to 
form heterodimers with other TLRs. The extracellular domains of the two TLRs can 
contribute to a combined ligand recognition site. TLR2 alone may be sufficient to 
recognize certain ligands e.g. peptidoglycan (Iwaki et al., 2002). TLR2 recognition of 
certain ligands require its pairing with other TLRs was first derived from the 
observation that dominant negative forms of TLR2 or TLR6 could inhibit monocyte 
TNF-α production elicited by zymosan (Ozinsky et al., 2000). TLR6 was also found 
enriched in macrophage phagosomes and physically associated with TLR2 through 
their extracellular domains. TLR1 association with TLR2 was shown by their co-
localizaiton on the membrane upon cross-linking (Sandor et al., 2003), TLR1 and 
TLR2 are both required for lipoarabionomannan or bacterial lipopeptide to stimulate 
cytokine secretion from mononuclear cells. These two TLRs are also required to 
recognize soluble factors released from Neisseria meningitides (Wyllie et al., 2000). 
Analysis of TLR1-deficient mice has demonstrated the importance of TLR1 in the 
recognition of triacylated lipopeptides (Pam3CSK4) (Takeuchi et al., 2002). 
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Macrophages from this TLR1-deficient mouse showed impaired production of 
inflammatory cytokines in response to triacyl lipopeptides and lipoproteins from 
mycobacteria. Involvement of TLR1 in recognition of the outer surface lipoprotein of 
B.burgdoferi was also reported (Alexopoulou et al., 2002). Thus, TLR2 functionally 
associates with TLR1 and TLR6 which increases the variety of microbial components 
that this TLR recognizes. 
 
Recognition of microbial products by TLRs activates innate and adaptive immunity. 
TLR4, TLR1 and TLR2 stimulation induces dendritic cell maturation (Tsuji et al., 
2000; Hertz et al., 2001; Michelsen et al., 2001). TLR2 may also mediate 
inflammation and tissue repair in responses to endogenous stimuli such as necrotic 
cells (Li et al., 2001). Recently, TLR2 has been shown to internalize antigens into 
endosomes which are  processed by conventional MHC II pathway for stimulation of 
antigen-specific CD4+ T cells and it could thus be an efficient vaccination target 
(Schjetne et al., 2003). 
 
Activation of TLR2 also has harmful effects. TLR2 has been suggested to be a ‘death 
receptor’ as it mediates bacterial lipoprotein-induced apoptosis (Aliprantis et al., 
1999; Aliprantis et al., 2000). TLR2 assists Mycobacterium tuberculosis  survived in 
host cells for chronic infection (Noss et al., 2001). Mycobacterium tuberculosis bacilli 
or its lysate inhibit macrophage expression of MHC II molecules and antigen 
presentation and thus decrease recognition by T-cells despite the innate immune 




1.2.3 TLR signaling 
 
1.2.3.1 TIR domain 
The principal function of the TIR domain is to recruit intracellular signaling 
molecules through homotypic protein-protein interactions (Kopp and Medzhitov, 
1999). The crystal structure for the TIR domains of human TLR1 and TLR2 have 
been determined and they contain a central five-stranded parallel β-sheet (βA-βE) 
surrounded by five helices (αA-αE) on both sides (Fig 1.7A and B) (Xu et al., 2000). 
The core TIR-domain starts from the conserved (F/Y) DA amino-acid motif and ends 
about eight residues carboxy-terminal to the conserved FW motif (Fig. 1.7C). Most 
conserved residues in TIR are located in the hydrophobic core with large insertions 
and deletions occuring in some loop regions in specific TIR domains. Therefore, the 
sizes of TIR domains from different TLRs can vary considerably between 135 and 
160 residues. 
 
A large conserved surface patch is present on TIRs, containing the BB loop, with 
contributions from the αA helix, βB strand and aromatic side chain of the (F/Y) DA 
motif. The BB loop, connecting the second β-strand and second helix, extends away 
from the rest of the TIR domain forming a protrusion on the surface. It contains 3 
highly conserved residues: Arg (BB3), Asp (BB4), Gly (BB8) in the box 2 motif 
RDXΦ1Φ2G (where X = any amino acid, Φ1 = hydrophobic amino acid). Φ2 is the 
conserved proline, i.e. Pro (BB7), present in all TIR domains except that of TLR3 in 
which the proline residue is replaced by an alanine residue. When this proline is 
mutated to histidine in TLR2 (Pro681His), it abolishes TLR2 response to yeast and 
Gram-positive bacteria (Underhill et al., 1999a). This conserved proline residue does 
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not have a major structural role, as no significant structural difference was observed 
between the mutant (Pro681His) and wild type TIR of  TLR2 (Fig. 1.7C). In TLR2, 
this conserved proline residue interacts with MyD88 (Xu et al., 2000). The crystal 
structures of TIR reveal structural differences between TLR1 and TLR2 despite of a 




















Figure 1.7 Crystal structures of the TIR domains for TLR1, TLR2 and TLR2 
mutant. The β-strands or α-helices are given alphabetical denotations. For example,
βA and αA are the first β-strand and the first α-helix, respectively. The loops are 
named by the alphabetical letters of the secondary structures they connect. For 
example, the BB loop connects the βB strand and αB helix. A residue in a β-strand, α-
helix or loop is numbered according to its position in the structure e.g. BB3 is the third 
amino acid in the BB loop. 
(A) Ribbon representation of the TIR domain of human TLR2, with a central five-
stranded parallel β-sheet (βA-βE) surrounded by five helices (αA-αE) on both sides. 
(B) Superposition of the TIR domains of human TLR1 (cyan) and TLR2 (yellow). 
Regions with differences between the two structures are labelled. These regions are the 
BB, CD and DD loops and the αB and αD helices. 
(C) Superposition of the TIR domains of human TLR2 (yellow) and the Pro681His 






Three interactive interfaces in the TIR domains for TLR signaling has been proposed 
by (Xu et al., 2000): 
 
i) The first interface (R face) mediates oligomerization between TIR domains, which 
might be facilitated by ligand-induced association of the extracellular domains of 
TLRs. 
ii) The second interface (A face, likely to be equivalent to the R face in the receptors) 
mediates interactions between cytosolic adaptor molecules that also contain TIR 
domains e.g. MyD88 and Mal. These adaptor molecules have been predicted to 
heterodimerize through hydrophobic residues at the end of the BB loop in the TIR 
domain and polar residues in the αD helix (Dunne and O'Neill, 2003). 
iii) The third interface (S face) mediates association between TIR domains of TLRs 
and adaptors. The formation of such TIR-TIR interactions recruits adaptors and 
activate receptor signaling. The S face might be highly conserved among TIR 
domains, as one common adaptor molecule MyD88 can interact with the TIR domain 
of most TLRs. An S face has been identified in TLR2 to contain the conserved proline 
residue, but this does not seem to be conserved in TLR4. TLR4 interaction with 
MyD88 does not involve this conserved proline residue. TLR4 is predicted to interact 
with MyD88 via the CD loop and interact with Mal via the αC helix (Dunne and 
O'Neill, 2003). 
TIRs play a pivotal role in TIR signal transduction since mutations in this domain can 
completely abolish TLR signaling of cell activation (Poltorak et al., 1998; Qureshi et 
al., 1999). The signaling cascades elicited by TLRs are initiated through TIR 
interaction with different adaptor molecules. 
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1.2.3.2 MyD88-dependent TLR signaling pathway 
Most members of the IL-1R and TLR family transduce signals by recruiting MyD88. 
Evidence of MyD88 as a universal adaptor has been provided in studies with MyD88-
/- mice. These mice do not produce IL-1, TNF-α, IL-6 and IL-12 in response to 
immuno-stimulatory microbial structures such as LPS (Kawai et al., 1999), PGN 
(Takeuchi et al., 2000c), lipoproteins (Takeuchi et al., 2000b), CpG DNA (Hacker et 
al., 2000), flagellin (Hayashi et al., 2001) and imidazoquinolines (Hemmi et al., 
2002). Thus, MyD88 is essential to common signaling events of TLRs leading to 
inflammatory cytokine production. The MyD88-dependent pathway is illustrated in 
Figure 1.8. 
 
Upon activation, TLRs or the IL-1R family of receptors interact with MyD88. MyD88 
contains TIR domain in its C-terminal portion and a death domain (DD) in its N-
terminal portion. Activation of TLR or IL-1R recruits MyD88 to the receptor. The 
TIR domain of MyD88 binds to the TIR domains of activated TLRs, whereas the 
death domain interacts with the death domain of IL-1R associated kinase I (IRAK1) 
and (IRAK4) (Medzhitov et al., 1998; Burns et al., 1998; Muzio et al., 1997; Wesche 
et al., 1997). Thus, the kinase domains on IRAK1 and IRAK4 are brought in close 
association. In the MyD88/IRAK1/IRAK4 complex, activated IRAK4 phosphorylates 
IRAK1 to activate the kinase activity of IRAK1, leading to IRAK4 phosphorylation.  
IRAK-4 is a central molecule in IL-1R/TLR signaling, as IRAK4-/- mice have almost 
completely lost response to IL-1, LPS or other bacterial components (Suzuki et al., 
2002). The phosphorylated IRAK1 associates with tumor necrosis factor receptor-
associated factor 6 (TRAF6) (Cao et al., 1996). The formation of the 
IRAK4/IRAK1/TRAF6 complex causes conformational change, leading to their 
 21
disengagement from the receptor complex. The IRAK4/IRAK1/TRAF6 complex 
interacts at the membrane with another preformed complex consisting of TGF-β-
activated kinase (TAK1) and its two adaptor proteins, TAK1-binding protein (TAB) 1 
and TAB2. TAB2, an adaptor linking TAK1 to TRAF6, is associated with cell 
membrane under unstimulated conditions. TAK1 is a MAPKKK (i.e. mitogen-
activated protein kinase kinase kinase), is activated by TAB1, and is essential for IL-1 
and TNF-α induced NF-κB activation (Jiang et al., 2002). Interaction of the 
IRAK4/IRAK1/TRAF6 and TAK1/TAB1/TAB2 complexes induces phosphorylation 
of TAB2 and TAK1, resulting in the translocation of both complexes into the cytosol. 
TAK1 is then activated in the cytoplasm through ubiquitination, leading to the 
activation of IκB kinase (IKK), IKKα and IKKβ (Wang et al., 2001). Inactive IκBα 
sequesters NF-κB in the cytoplasm. Activation of IKK leads to the phosphorylation 
and degradation of IκB, resulting in the release and translocation of NF-κB from 
cytoplasm into the nucleus (Mercurio et al., 1997; Zandi et al., 1997). NF-κB is a 
transcription factor that induces the production of inflammatory cytokines such as 
TNF-α and IL-6 and expression of co-stimulatory molecules on APCs (Medzhitov et 
al., 1997). 
 
TAK1 also activates the p38, JNK and p42/p44 MAPK signaling pathways. p38 in 
turn activates the transcription factor activation protein 1 (AP-1) (Johnson and 
Lapadat, 2002). 
 
A second TIR domain-containing molecule TIRAP or Mal is also required exclusively 
for MyD88-dependent signaling of TLR2 and TLR4 (Horng et al., 2001; Fitzgerald et 
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al., 2001). In Mal/TIRAP-/- mice there was delayed NF-κB activation and no induction 
of TNF-α, IL-6 or IL-12p40 (Yamamoto et al., 2002).  
 
1.2.3.3 MyD88-independent signaling pathway 
MyD88-independent signaling was initially suggested by responses of MyD88-/- mice 
to LPS and poly (I:C) stimulation (Kawai et al., 1999; Kaisho et al., 2001; 
Alexopoulou et al., 2001). The MyD88-/- macrophages exhibited NF-κB and MAPK 
activation in response to LPS but the response was delayed. LPS stimulation of 
MyD88-/- macrophages also leads to interferon regulatory factor-3 (IRF-3) activation 
and induced production of IFN-β and IP-10 (Kawai et al., 1999). Therefore, 
macrophage response to LPS can be mediated through both MyD88-dependent and 
independent pathways. Response to poly (I:C) through TLR3 is not impaired in  
MyD88-/- macrophages (Akira, 2003). TLR3 signaling induces the production of a 
large amount of type I IFNs and activates many IFN-inducible genes although it also 
induces a small amount of inflammatory cytokines. This suggests that TLR3 utilizes 
MyD88-independent signaling pathway. 
 
Through MyD88-independent signaling, TLR3 and TLR4 can mediate the activation 
of IRF-3 and this induces IFN-β expression. IFN-β in turn activates signal transducer 
and activator of transcription 1 (STAT1) leading to the production of several IFN-
induced genes which are protective against viral infection (Doyle et al., 2002; 
Toshchakov et al., 2002). However, not all TLRs utilize this alternative signaling 
pathway. Apart from TLR3 and TLR4, stimulation of TLR7 and TLR9 with 
respective ligands also causes IRF-3 activation in a MyD88-dependent manner 
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(Hoshino et al., 2002). Therefore, there seems to be a common MyD88-dependent 
pathways and distinct MyD88-independent pathways utilized by different TLRs. 
 
The upstream molecular mechanism of MyD88-independent signaling involves two 
adaptor proteins; i.e TIR domain-containing adaptor inducing IFN-β (TRIF) and 
TRIF-related adaptor molecule (TRAM). Studies from TRIF-/- mice showed no 
activation of IRF-3 and impaired expression of IFN-inducible genes in response to 
TLR3 and TLR4 ligands (Yamamoto et al., 2003a; Hoebe et al., 2003). In contrast, 
TRAM-/- mice showed defects in cytokine production only when they were challenged 
with TLR4 ligand. IFN-β production was abolished in these mice when the TLR4-
mediated MyD88-independent signaling pathway was stimulated but not the TLR3 
signaling pathway (Fitzgerald et al., 2003b; Yamamoto et al., 2003b). Thus, TRIF 
functions downstream of TLR3 and TLR4 whereas TRAM functions downstream of 
TLR4 only.  
 
TLR3-mediated NF-κB and MAPK activation involves an IRAK-independent 
pathway where the TLR3-TRAF6-TAK1-TAB2-PKR (dsRNA protein kinase) 
cascade is employed. It has been demonstrated that Tank-binding kinase 1 (TBK1) 
and IKKε/IKK, (kinases that are distantly related to IKKα and IKKβ) are required for 
activation of IRF3 elicited by TRIF and TLR3 (Fitzgerald et al., 2003a). Embryonic 
fibroblast cells lacking both  TBK1 and IKKε/IKK showed impaired activation of 
IRF-3 and expression of IFN-β and IFN inducible genes in response to TLR3 and 
TLR4 ligands (McWhirter et al., 2004; Hemmi et al., 2004). Thus, TBK1 and 











1.2.4     Mechanism of TLR1 and TLR2 activation 
Molecular studies of the IL-1R family suggest that ligand-induced heterodimerization 
might be the mechanism for signal activation in TIR domain containing receptors. The 
extracellular domain of IL-1RI binds IL-1α and IL-1β (Vigers et al., 1997) which 
then recruits the IL-1R accessory protein IL-1RAcP (Greenfeder et al., 1995; Casadio 
et al., 2001) to form a heterodimer. Optimal IL-1RI response requires the synergistic 
actions of IL-1RAcP and IL-1RI to recruit MyD88 (Wesche et al., 1997). Lack of IL-
1RAcP results in non-responsiveness to IL-1 (Korherr et al., 1997; Cullinan et al., 
1998). 
Figure 1.8 TIR domain-containing adaptors and TLR signaling. MyD88 is an 
essential TIR domain-containing adaptor for the induction of inflammatory cytokines via 
all the TLRs. TIRAP/Mal is a second TIR domain-containing adaptor that specifically 
mediates the MyD88-dependent pathway via TLR2 and TLR4. In the TLR4 and TLR3-
mediated signaling pathways, a MyD88-independent pathway exists that leads to 
activation of IRF-3 via TBK1 and IKKε/IKKi. The TIR domain-containing adaptor TRIF 




Signaling induced by TIR heterodimers has been observed in some TLRs. Dominant 
negative TLR6-/- and TLR2-/- independently and completely inhibited TNF-α 
production induced by Gram-positive bacteria. This suggests that the two receptors 
co-operate to elicit inflammatory cytokine production. In fact, TLR6 was also found 
enriched in macrophage phagosomes and physically associated with TLR2 through 
interactions between the two extracellular domains (Ozinsky et al., 2000). TLR2 
requires TLR1 to recognize soluble factors released from Neisseria meningitides 
(Wyllie et al., 2000). Confocal microscopy and cross-linking studies have shown 
TLR2 association with TLR1 on the cell surface and the requirement for both TLR1 
and TLR2 to recognize lipoarabinomannan and lipopeptide (Sandor et al., 2003). 
TLR2 was also shown to physically associate with TLR1 upon co-transfection and the 
association between TLR2 and TLR1 is ligand-independent (Tapping and Tobias, 
2003). 
 
The requirement of dimerization with another TLR for TLR2 signaling is further 
demonstrated by expression of the CD4 extracellular domain (EC) in fusion with the 
transmembrane and cytoplasmic domains of TLRs (CD4-TLRs). The CD4 
extracellular domain naturally form homodimers and CD4-TLR chimeras therefore 
form constitutive TLR dimers  (Wu et al., 1997). CD4-TLR2 homodimers could not 
activate TNF-α production in macrophages. In contrast, CD4-TLR4 homodimers 
constitutively induce  TNF-α  production (Medzhitov et al., 1997). When the 
extracellular domains of TLR1, TLR2, TLR4 or TLR6 were similarly expressed as 
CD4-TLR fusion proteins, only CD4-TLR4 homodimer induced TNF-α production in 
macrophages. In contrast, homodimers of CD4-TLR1, CD4-TLR2 and CD4-TLR6 
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failed to induce TNF-α production (Ozinsky et al., 2000). These data indicate that the 
signaling domains of TLR1, TLR2 and TLR6 are not functionally equivalent to that of 
TLR4. The finding that CD4-TLR2 homodimers are not active suggests that TLR2 
needs a signaling partner to activate TNF-α production. When CD4-TLR2 was co-
expressed with CD4-TLR6 or CD4-TLR1, TNF-α production was induced.  Co-
expression of CD4-TLR1 and CD4-TLR6 did not induce cytokine production. Thus, 
TLR2 can pair with either TLR6 or TLR1 to induce cell signaling. An independent 
study using integrin αV and β5 to express TIR fusion proteins subunit showed the 
same result (Zhang et al., 2002). When αV-TLR2 was co-expressed with β5-TLR6 or 
β5-TLR1 in 293T transfected cells, NF-κB was activated. These data may imply that 
TLRs form pairs in response to different pathogens and may induce different 
signaling pathways.  
 
In this project, we examine whether it is feasible to detect protein interactions by 
expression of test proteins as the EC domains of TLR1 and TLR2. The well-
characterized interactions between IL-4 and its receptors were used to evaluate this 
method. 
 
1.3 Interleukin-4 (IL-4) 
 
1.3.1  IL-4 and its functions 
Human IL-4 is a 129 residue cytokine initially characterized as a proliferation and 
differentiation factor for B cells (Howard et al., 1982; Vitetta et al., 1985). It is now 
known as a pleiotropic cytokine  that can stimulate a wide variety of cell types 
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including T cells, macrophages, fibroblasts and endothelial cells (Paul, 1991), mast 
cells (Plaut et al., 1989), and basophils (Seder et al., 1991). 
 
By analysis of the DNA of human and mouse somatic cell hybrids and in situ 
chromosome hybridization, its gene has been mapped to 5q23-3, where the IL-3 and 
GM-CSF genes are also found (Le Beau et al., 1989). Functionally, these cytokines 
are designated as the ‘IL-4 family of lymphokines’. IL-4 is one of the short chain, 
four-helix-bundle cytokines (Rozwarski et al., 1994).  
 
IL-4 plays a central role in regulating the differentiation of antigen-stimulated naïve 
T-cells. It causes such cells to develop into Th2-like cells capable of producing IL-4 
and a series of other cytokines including IL-5, IL-10 and IL-13 (Seder et al., 1992; 
Hsieh et al., 1992). In particular, IL-4 has a major physiological role in controlling the 
specificity of immunoglobulin class switching. For example, stimulation of human B 
cells with anti-CD40 or anti-CD58 antibody, or with Epstein-Barr virus, induces the 
production of IgE and IgG4 (Thyphronitis et al., 1989; Gauchat et al., 1990; Gascan et 
al., 1991; Diaz-Sanchez et al., 1994). In IL-4-/- (Kuhn et al., 1991) and IL-4R-/- 
(Noben-Trauth et al., 1997) mice as well as in mice that lack a principal signaling 
substrate of the IL-4 receptor, Stat-6 (Shimoda et al., 1996; Kaplan et al., 1996), IgE 
production is diminished by 100 fold or more. The productions of IgE antibodies 
induced by IL-4 that are associated with atopic diseases, associated with allergens 
suggest a pre-eminent role for IL-4 in the regulation of such conditions. IL-4 also 
exerts a wide variety of effects on hematopoietic and non-hematopoietic cells. It 
enhances the expression of CD23 (Defrance et al., 1987) and MHC class II molecules 
(Noelle et al., 1984) in B cells and upregulates surface expression of the receptor 
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complex for IL-4 (Ohara and Paul, 1988). On vascular endothelial cells, IL-4 together 
with TNF-α induces the expression of vascular cell adhesion molecule-1 (VCAM-1) 
(Thornhill et al., 1991) and downregulates the expression of E-selectin (Bennett et al., 
1997) thereby changing the adhesive characteristics of endothelial cells. The altered 
adhesive characteristics of endothelial cells facilitate tissue infiltration by allergic 
inflammatory cells, such as eosinophils.  
 
1.3.2  IL-4 and its receptor complex 
IL-4 mediates its biological responses by binding to the IL-4 receptor complex 
(Nelms et al., 1999). The IL-4 receptor complex consists of two subunits. One subunit 
is the IL-4R α-chain (IL-4Rα), a high-affinity receptor present in hematopoietic and 
non hematopoietic cells including human fibroblasts, epithelial cells, hapatocytes, 
endothelial cells and muscle (Mosley et al., 1989; Idzerda et al., 1990; Galizzi et al., 
1990). IL-4Rα is a member of the type I cytokine receptor super family which is 
characterized by the presence of four  conserved cysteine residues and a WSXWS 
motif (W, tryptophane; S, serine; X, non conserved amino acid) in their extracellular 
domain (Bazan, 1990). The WSXWS motif is required for maintaining the receptor in 
a conformation favourable to cytokine binding (Livnah et al., 1996). The cytoplasmic 
domain of IL-4Rα contains a short amino acid sequence termed box 1 which is 
conserved among members of this cytokine receptor-family (Fukunaga et al., 1991; 
Murakami et al., 1991).  In addition to this conserved domain, IL-4Rα bears a region 
termed insulin-IL-4 receptor (I4R) motif in amino acids 437-557 in the cytoplasmic 
domain. This region is essential for cellular proliferation (Harada et al., 1992; Seldin 
and Leder, 1994; Keegan et al., 1994; Nelms et al., 1999). 
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The other IL-4R subunit is the common γ-chain (γC), which also belongs to the type I 
cytokine receptor super-family. It was initially identified as the third component of 
the IL-2 receptor complex (Takeshita et al., 1992). It is now known that γC is a 
common component for several receptors: IL-2 (Takeshita et al., 1992), IL-4 (Russell 
et al., 1993), IL-7 (Noguchi et al., 1993a) and IL-15 (Giri et al., 1994). Mutation of 
the human γC gene can cause X-linked severe combined immunodeficiency (XSCID) 
syndrome, which is characterized by the absence of T cells (Noguchi et al., 1993b). 
Mice deficient for the γC gene exhibit more severe forms of the syndrome than 
humans, displaying the absence of B cells, natural killer cells and T cells (Cao et al., 
1995; Sugamura et al., 1996). These phenotypes reflected the loss of cytokine 
functions mediated through γC and an essential role for γC is the development of a 
normal immune system. 
 
1.3.3  Mechanism of IL-4R activation 
IL-4 triggers the formation of a heterodimer consisting of IL-4Rα and γC (Duschl and 
Sebald, 1996). This elicits an ordered sequential mechanism. Soluble IL-4 primarily 
binds with IL4Rα. Subsequently, this intermediate IL-4/IL-4Rα complex recruits the 
γC to form a  IL-4Rα/ γC heterodimer (Russell et al., 1993; Kondo et al., 1993).  
The crystal structure of the IL-4/IL-4Rα complex has been characterized (Hage et al., 
1999; Mueller et al., 2002). It revealed that the IL-4 binding site on IL4Rα is a 
mosaic-like structure consisting of three discrete clusters of trans-interacting residues. 
Two of them exhibit a conspicuous amphipathic structure with an outer surface of 
hydrophobic side chain moieties and an inner core of polar groups. These two clusters 
have been termed the ‘avocado cluster’, since an avocado fruit also has a core that is 
surrounded by a hydrophobic layer (Hage et al., 1999; Mueller et al., 2002). The 
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amino acid residues involved in IL-4 binding to IL-4Rα have also been identified by 
mutational and quantitative analysis and the findings support the functional 
significance of these residues and also confirm the existence of a mosaic binding 
structure between IL-4/IL-4Rα  (Wang et al., 1997).  
 
γC interaction with IL-4 is distinct from that of IL-4 and the IL-4Rα. Cells expressing 
γC alone cannot bind to IL-4 even at concentrations as high as 100 nM (Sugamura et 
al., 1995). However, direct interaction between IL-4 and γC has been shown in cells 
that express both the IL-4Rα and γC (Sugamura et al., 1995). Iodinated IL-4 becomes 
efficiently cross-linked to γC if IL-4Rα is also present. The binding affinity between 








Figure 1.9 Model of the two-step mechanism for IL-4R activation. (1) Soluble IL-4 
binds via site 1 to the IL4Rα-chain first. (2) Dimerization on the membrane is driven by 
interaction between IL-4 site 2 and γC as well as by a weak direct interaction between 
the receptor chains site 3. Adopted from Letzelter et al., (1998). 
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It was proposed by (Letzelter et al., 1998) that the ligand-induced IL-4Rα/γC 
dimerization proceeds in a two-step mechanism. Soluble IL-4 binds to the 
extracellular domain of IL-4Rα first which is a three-dimensional reaction and this is 
followed by lateral or two-dimensional recruitment of γC to the binary IL-4/IL-4Rα 




CD14 is discussed here because TIR1/TIR2-based two-hybrid-based assay was 
applied to investigate interactions of this molecule. CD14 is related to TLRs in 
function and structure.  
 
1.4.1  The CD14 gene and its expression 
CD14 was first described as a leukocyte cluster differentiation (CD) antigen mainly 
expressed on the surface of monocytes, macrophages and, at a lower level, on 
neutrophils (Ziegler-Heitbrock and Ulevitch, 1993; Antal-Szalmas et al., 1997). CD14 
is a 55 KDa glycoprotein that exists as a glycosylphosphatidylinositol (GPI)-linked 
protein on the surface of these myelomonocytic cells (Haziot et al., 1988; Simmons et 
al., 1989; Haziot et al., 1993) and soluble CD14 is also found in the serum (Bazil et 
al., 1986; Bazil et al., 1989). 
The CD14 gene was mapped to chromosomes 5q23-31 (Ferrero and Goyert, 1988). In 
this region of the genome, the genes for other growth factors and their receptors such 
as IL-3, granulocyte macrophage-colony stimulating factor (GM-CSF), macrophage-
colony stimulating factor (M-CSF), the platelet-derived growth factor (PDGF) 
receptor, and the adrenergic receptor are also found (Goyert et al., 1988). CD14 
consists of 356 amino acids which are predominantly LRRs as in the extracellular 
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domains of TLRs. Its   gene contains two exons separated by a 88-bp intron with the 
first exon coding for the first methionine residue (Ferrero et al., 1990). 
1.4.2  Structure 
The human CD14 transcripts encodes 375 residues with the first 19 residues forming 
the signal peptide (Ferrero et al., 1990). The C-terminal end is a 21 residue 
hydrophobic domain, but it lacks the characteristic basic residues for a typical 
transmembrane domain. Human CD14 (hCD14) has four potential N-linked 
glycosylation sites (Asn-X-Thr/Ser) and in addition bears O-linked carbohydrates. All 
these sites are conserved in mouse CD14 (mCD14). Carbohydrates account for 20% 
of the CD14 protein (Setoguchi et al., 1989; Stelter et al., 1996). It contains 10 
cysteine residues which are important in determining the conformation of CD14 
through the formation of specific disulfide bridges. CD14 contains 10 LRRs located 
between residues 86 and 329 (Ferrero et al., 1990; Setoguchi et al., 1989). These 
LRRs can mediate protein-protein interactions in other proteins (Hofsteenge et al., 
1988; Tan et al., 1990; Krantz and Zipursky, 1990; Kobe and Deisenhofer, 1995). 
Alignment of the amino acid sequences of hCD14 and mCD14  revealed 66% amino 
acid identity (Setoguchi et al., 1989). 
Crystallographic studies have shown that a monomeric CD14 contains thirteen β 
strands, and eleven of them, from β3 to β13, overlap with conserved LRRs (Fig. 
1.10A). The concave surface of the horseshoe-shaped structure consists of a large β-
sheet of 11 parallel and two anti-parallel β strands. The convex surface of CD14 
contains both helices and loops in an irregular pattern. CD14 has been suggested to 
form a dimer based on the crystallographic data (Fig. 1.10B). CD14 dimerization is 
likely to involve residues in β13 and in the ‘loop’ between β12 and β13. Parallel β-
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sheets from two CD14 monomers interact in an anti-parallel fashion which form a 
large and continuous β-sheet encompassing the entire CD14 dimer (Kim et al., 2005). 
The most striking feature of the CD14 structure is the NH2-terminal pocket. The 
pocket is located on the side of the horseshoe near the NH2-terminus and it is entirely 
hydrophobic (Fig. 1.10B). The main pocket contains a smaller sub-pocket at the 
bottom. This sub-pocket is formed by hydrophobic residues from β4 to β6, α4, α5, 






















































Figure 1.10 Overall structure of mouse CD14. (A) Alignment of mouse, human, rabbit, and 
bovine CD14. Secondary structures are shown schematically above the sequences. N-
Glycosylation sites identified in the crystal structure are marked with an asterisk. Cysteines 
involved in disulfide bridges are linked by broken yellow lines. Residues on the rim of the 
NH2-terminal pocket are written in yellow, residues on the walls and base of the main pocket 
are written in orange, and residues on the sub-pocket are written in purple. LPS-binding 
regions identified are labeled R1–R4 and enclosed within blue boxes. Residues important for 
LPS signaling (36–38) are enclosed within green boxes and labeled T1–T3. (B) Overall 
structure of the CD14 dimer. Two CD14 monomers in the crystal are colored in gray and 
cyan. Disulfide bridges are shown in orange. The position of the NH2-terminal pocket is 





1.4.3  CD14 functions  
CD14 plays a key role in the recognition of LPS and induces leukocytes to produce 
inflammatory cytokines and  upregulate integrin functions (Wright et al., 1990; 
Wright et al., 1991). Blocking of cell surface CD14 using anti-CD14 antibody 
abolishes the cytokine production from myeloid cells in response to LPS. Recognition 
of LPS by CD14 requires LBP (LPS-binding protein), an acute-phase reactant found 
in serum (Wright et al., 1990; Mathison et al., 1992; Hailman et al., 1994). LBP also 
plays a role in LPS internalization as LBP antibodies have been reported to prevent 
LPS endocytosis (Gegner et al., 1995). 
 
Cross-linking experiments showed that LPS directly associate with membrane-bound 
CD14 on macrophages and LPS binding to CD14 is essential for macrophage 
activation (Tobias and Ulevitch, 1993). These findings were supported by data 
derived from CD14-/- mice. CD14-/- mice were resistant to septic shock induced either 
by LPS or Gram-negative bacteria (Haziot et al., 1996). The ability of peripheral 
blood mononuclear cells from CD14-/- mice to respond to LPS was partially restored 
after addition of soluble CD14 (sCD14) to this assay (Haziot et al., 1996). In contrast, 
over-expression of hCD14 in transgenic mice rendered these mice hypersensitive to 
LPS as evidenced by increased susceptibility to endotoxic shock (Ferrero et al., 1993). 
These results indicate that membrane-bound CD14 plays a central role in LPS-
induced cell activation. sCD14 may play the role as either an activator or inhibitor in 
LPS-mediated cell activation. At high concentrations, sCD14 dampens response to 
LPS. Recombinant sCD14 can inhibit oxidative burst in isolated human monocytes 
(Schutt et al., 1992), inhibit TNF-α release from whole blood (Haziot et al., 1994), 
inhibit LPS priming of neutrophils (Troelstra et al., 1997), and protect mice from 
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LPS-induced lethality (Haziot et al., 1995). Therefore, membrane-bound and soluble 
CD14 play important roles in LPS recognition. 
 
1.4.4  LPS binding  to CD14 
Early work on LPS binding to CD14 was performed using 3H-labeled LPS (Couturier 
et al., 1991).  It was shown that, in the presence of serum, LPS could bind to 
monocytes in a dose dependent, saturable and displaceable fashion. This specific LPS 
binding to monocytes was demonstrated to occur through CD14 on the cells.  
Heumann et al (1992) showed similar results using fluorescent-labeled LPS and the 
MY4 anti-CD14mAb and by enzymatically removing CD14 from monocyte surface. 
The LBP-dependent binding of LPS to CD14 was further established using serum 
depleted of LBP with anti-LBP antibodies (Heumann et al., 1992). Studies using 3H-
labeled LPS and human CD14 expressed on transfected Chinese hamster ovary cells 
or the human monocytic cell line (THP-1) indicated that LPS binding occurred within 
10 min and was relatively unaffected by temperature over the range of 4-37°C. 
Quantitative binding studies were performed at 10°C and 30°C using cells depleted of 
ATP to prevent LPS internalization. At 10°C, each CD14 bound 20 LPS molecules 
and it was reduced to 8 LPS molecules at 37°C, which was very different from the 
expected 1:1 stochiometry. It was suggested that each CD14 might have multiple 
binding sites for LPS or alternatively CD14 bound to small LPS aggregates (Kirkland 
et al., 1993). This idea of multiple LPS binding by CD14 was also raised in another 
study  where it was demonstrated that, in addition to its ability to compete with LPS 
for binding to LBP and CD14, deacylated LPS potently antagonized LPS-induced cell 
activation at an unknown site distal to the LPS binding site of CD14 (Kitchens and 
Munford, 1995). 
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Studies using soluble CD14 mutants have demonstrated that the NH2-terminal (152 
aa) portion of the molecule was sufficient for LPS binding and cell response (Juan et 
al., 1995c; Viriyakosol and Kirkland, 1995; Viriyakosol and Kirkland, 1996). In 
another mutational study, specific amino acids in regions  9-13 and 57-64 were found 
to be critical for LPS binding (Juan et al., 1995a; Stelter et al., 1997). Epitope-
mapping studies using LPS blocking antibodies revealed that four different 
hydrophilic regions over the NH2-terminal portion of CD14, which were located on 
one side of the protein surface, were involved in LPS binding. These studies suggest 
that CD14 employs a charged surface, in a manner similar to the macrophage 
scavenger receptor, to ‘capture’ LPS and ‘present’ them to other components of the 
innate host defense system (Cunningham et al., 2000). Interestingly, different LPS 
(from E.coli to P. gingivalis) may have distinct binding sites on CD14. For example, a 
point mutation at E47 does not affect the  binding of E.coli LPS to CD14 but it 
abrogated P.gingivalis LPS binding (Shapiro et al., 1997).  
 
Kim identified the regions on CD14 for LPS binding by crystallographic studies (Kim 
et al., 2005).  Residues from the turn between the β1 and β2 strands constitute region 
1. Region 2 is the loop between the β2 strand and the α1 helix (Fig. 1.10 A). 
Monoclonal antibodies that recognize this area inhibited LPS binding (Viriyakosol 
and Kirkland, 1995; Dziarski et al., 1998; Cunningham et al., 2000). Region 3 
consists of residues from the β3 strand. Region 3 is the most frequent target of LPS 
blocking antibodies. At least nine monoclonal antibodies that recognize region 2 and 
3 reduced LPS binding to soluble CD14 (Viriyakosol and Kirkland, 1995; Dziarski et 
al., 1998; Cunningham et al., 2000). Region 4 includes residues from the loop 
connecting α2 and α3 helices. This area is liable to proteolysis in the absence of 
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bound LPS (McGinley et al., 1995). Collectively, these mutagenesis and epitope 
mapping data strongly suggest that the NH2-terminal pocket is the principal LPS-
binding site on CD14. In terms of LPS signaling, some studies showed that some 
CD14 mutants may have minor defects in LPS binding, but they have virtually lost 
signaling activity (Juan et al., 1995b; Stelter et al., 1999; Muroi et al., 2002). They are 
alanine mutations of Glu7-Asp10, Asp9-Phe13, or Leu91-Glu101 in human CD14 or 
Pro151-Leu153 in mouse CD14. These regions are labeled as T1-T3 in Fig. 1.10A. 
 
1.4.5  CD14 and its receptor complex 
CD14 has been recognized for many years as a major receptor mediating LPS effects 
on monocytes, macrophages and neutrophils (Wright et al., 1990). However, 
numerous studies suggested that CD14 alone is not able to induce signaling and needs 
to associate with a transmembrane signal-transducing receptor. Beutler and coworkers 
mapped the Lps locus in the LPS-resistant C3H/HeJ mice and identified TLR4 as a 
candidate gene responsible for LPS hypo-responsiveness of these mice (Poltorak et 
al., 1998). The TLR4 gene was found deleted in the LPS non-responsive 
C57B1/10ScCr mouse (Qureshi et al., 1999; Hoshino et al., 1999). TLR4-/- mice also 
exhibited hyporesponsiveness to LPS (Takeuchi et al., 1999a). In contrast, TLR2-/- 
mice remained responsiveness to LPS. These results consistently show the critical role 
of TLR4 in host response to LPS. TLR4 alone was not fully functional but required an 
additional protein, MD2, to confer LPS responsiveness of cells (Shimazu et al., 1999). 
MD2 lacks a membrane anchoring domain but after secretion, it physically associates 
with the extracellular portion of TLR4 (Akashi et al., 2000; Yang et al., 2000). These 
results suggest a CD14, TLR4 and MD2 receptor complex for LPS. Biochemical 
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studies have shown that LPS binds directly to all three members of this tripartite LPS 
receptor complex (da Silva et al., 2001; Visintin et al., 2003).  
 
1.4.6  CD14 and its signaling cascade 
As TLR4 has been found to be involved in LPS signaling, the LPS-induced 
intracellular signaling cascade leading to NF-κB activation has been studied in depth 
which has been described in the TLR signaling section (section 1.2.3). The current 
hypothesis is that, in the presence of LPS, CD14 binds to TLR4 and MD2. This 
induces homodimerization of TLR4 which in turn recruits MyD88 or TRIF/TRAM to 
initiate MyD88-dependent and MyD88-independent signaling. 
 
1.5 Fc gamma Receptors (FcγRs) 
These families of receptors are discussed here because TIR1/TIR2-based two-hybrid 
assay was used to study FcγRIIA dimerization and activation.  
 
1.5.1  Overview of FcγRs 
Antibodies represent an important arm of the humoral immune system which 
enhances cell mediated immunity through immunoglobulin Fc receptors on 
leukocytes (FcRs). FcRs exist for all antibody isotypes and different FcRs may be 
expressed on different leukocytes.  These include: FcαR (IgA), FcδR (IgD), FcεR 
(IgE), FcγR (IgG), and FcµR  (IgM) (Lefranc, 2001). 
 Fc receptors for IgG (FcγRs) were first identified through the analysis of cytophylic 
antibodies and their mechanism of interaction with macrophages when presented as 
opsonized RBCs (Berken and Benacerraf, 1966). In mammals four different classes of 
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FcγRs have been identified: FcγRI (CD64), FcγRII (CD32), FcγRIII (CD16), and 
FcγRIV (Nimmerjahn and Ravetch, 2006). 
 
All the FcγRs belong to the Ig super-family of molecules. The FcγRs share a common 
ancestral gene and highly homologous Ig-like extracellular (EC) domains. Most of 
their structural differences are located in the transmembrane and cytoplasmic regions, 
suggesting that they transduce different signals (Daeron, 1997). In mouse, each class 
is encoded by a single gene, whereas in human a total of eight genes have been 
identified: three genes for the high-affinity receptor FcγRI (A, B, C) and five genes 
for the two low-affinity receptors FcγRII (A, B, C) and FcγRIII (A, B) (Qiu et al., 
1990). The structural charecteristics of the different FcγRs are shown in Fig. 1.11.  
 
FcγRI displays a high affinity for the constant region of IgG with restricted isotype 
specificity, whereas FcγRII and FcγRIII have low affinity for the Fc region of IgG but 
a broader isotype binding pattern (Ravetch and Kinet, 1991; Hulett and Hogarth, 
1994). In addition to the variation in FcγR affinity, each FcγR binds an IgG subclass 
with distinct specificities (Table 1.1).  Very recently mouse FcγRIV has been mapped 
in the 75 Kb genomic interval between FcγRII and FcγRIII (Mechetina et al., 2002; 
Davis et al., 2002; Nimmerjahn et al., 2005). It binds to IgG2a and IgG2b antibody 
with intermediate affinity. The surface expression of FcγRIV is γ-chain dependent and 
restricted to myeloid lineage cells. There is a putative human FcγRIV gene, but the 
biological functions of the protein, such as ligand specificity and cellular expression, 
are as yet unknown (Nimmerjahn et al., 2005). The general characteristics of human 
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FcγRs are summarized in Table 1.1. In the following section, the three best known 














Figure 1.11 Structural diversity and heterogeneity of human FcγRs. All receptors belong 
to the Ig super-family, with their extracellular regions (ECs) composed of disulfide (S–S)-
bonded domains. FcγRI, FcγRIIa and FcγRIIIa are activating receptors, characterized by the 
presence of an immunoreceptor tyrosine-based activation motif (ITAM) in the cytoplasmic 
domain of the receptor (FcγRIIa) or in co-receptors in signaling subunit (γ and/or ζ chains 
associated with FcγRI and FcγRIIIa). FcγRIIb is an inhibitory receptor, containing an 
immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain. FcγRIIIb 
is linked to the plasma membrane by a glycosyl phosphatidylinositol (GPI) anchor. Functional 
polymorphisms in FcγRIIa, FcγRIIIa and FcγRIIIb are indicated by red circles. NA refers to 
neutrophil antigen polymorphism. Adopted from Dijstelbloem et al., (2001). 
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FcγRI FcγRIA FcγRIa 72  1,3>>4>>>
2 
108−109 M-1 
(CD64) FcγRIB FcγRIb1     
  FcγRIb2     
 FcγRIC FcγRIc     
FcγRII FcγRIIA FcγRIIa1 40  1,3>>>2,4  







< 107 M-1 
 
< 107 M-1 
 FcγRIIB FcγRIIb1 41  3≥1>4>>>2 < 107 M-1 
  FcγRIIb2 37    
  FcγRIIb3     
 
FcγRIIC FcγRIIc     
FcγRIII 
(CD16) 
FcγRIIIA FcγRIIIa 45–72 on 
monocyte 
  3 ×107 M-1 
   47–58 on 
lymphocyte 
   
 












3> 1>> 2,4 
 
3 ≥ 1 >> 2,4 
108 M-1 
5 × 108 M-1 
Table with modification from van de winkel et al., (1993) 
 
1.5.2  Genes, structure and cellular distribution of Human FcγRs. 
 
FcγRI (CD64) 
Human FcγRI (CD64) is encoded by three homologous genes, i.e. FcγRIA, FcγRIB 
and FcγRIC (van de Winkel et al., 1991; Ernst et al., 1992), mapped to chromosome 1 
band q21.1 (de Wit et al., 1993). FcγIA is a 72 KDa transmembrane glycoprotein 
distinct from the other FcγR members by having three extracellular Ig-like domains 
(Fig. 1.11). Of the three hFcγRI genes (A, B, C), only FcγRIA encodes a high-affinity 
receptor. FcγRIB has two transcripts, one with a stop codon in extracellular domain 3 
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(EC3) and the other lacking this domain. Although it is expressed in myeloid cells, 
this transcript resides in the endoplasmic reticulum and therefore does not contribute 
to known cellular activation (van Vugt et al., 1999). It has not yet been clarified 
whether FcγRIC encodes for a functional protein (Porges et al., 1992). 
 
FcγRI binds monomeric IgG with high affinity (KA=108-109 M-1) as well as 
aggregated IgG. This unique high affinity is dependent on the additional third Ig 
domain. The affinity for IgG subclasses is IgG1=IgG3>IgG4>>>IgG2 (Allen and 
Seed, 1989) (Table 1.1). It has been shown that FcγRI associates with the FcRγ chain, 
a 20 KDa disulfide-linked homodimeric signaling subunit (Ernst et al., 1993) 
(Fig.1.11). Although FcRγ is not needed for FcγRI folding and targeting to the cell 
surface, it is critical for FcγRI signaling and stable expression in vitro and in vivo 
(van Vugt et al., 1996). The association of FcRγ with FcγRI and FcγRIIIA also 
increases affinity for IgG (Miller et al., 1996). FcγR association with FcRγ is 
mediated through the FcRγ transmembrane domain and the cytoplasmic domain of the 
receptor is not involved. 
 
In humans, FcγRI is constitutively expressed on monocytes, macrophages and 
granulocytes (van de Winkel and Capel, 1993; Hulett and Hogarth, 1994) and can also 
be induced on neutrophils and eosinophils by IFN-γ (Guyre et al., 1983; Perussia et 
al., 1987). Monocyte FcγRI expression can also be up-regualted by IFN-γ or IL-10 (te 








The three FcγRII genes, i.e. FcγRIIA, FcγRIIB and FcγRIIC, are located on 
chromosome 1q23-24 (Ravetch and Kinet, 1991; Hulett and Hogarth, 1994). All three 
FcγRII genes encode 40 KDa glycoproteins, containing two extracellular Ig-like 
domains (Fig. 1.11). FcγRIIC is likely to result from an unequal crossover event 
between the first part of FcγRIIB and the terminal part of FcγRIIA (Warmerdam et 
al., 1993) and has been postulated to be a pseudogene. 
 
FcγRII binds monomeric IgG with low or undetectable affinity (KA=106 M-1) specific 
for human IgG1 and IgG3 (van de Winkel and Capel, 1993) (Table 1.1). Under 
physiological conditions, the low affinity of FcγRII for monomeric IgG ensures that 
this receptor interacts only with aggregated IgG through multivalent interactions. A 
functional polymorphism has been identified in FcγRIIA (Warmerdam et al., 1990). 
Sequencing revealed that FcγRIIA either expresses an arginine (R) or a histidine (H) 
at amino acid position 131 (Fig. 1.11). These polymorphic variants have been shown 
to interact differently with various ligands, with FcγRIIA-H131 binding to human 
IgG2 whereas FcγRIIA-R131 showing no binding (Parren et al., 1992). 
 
FcγRII is the only family member known to contain its own signaling motif. FcγRI 
and FcγRIII are dependent on association with other subunits for signal transduction. 
Several isoforms of FcγRII exist, which are highly homologous in their extracellular 
and transmembrane regions but differ in their intracellular domains (Brooks et al., 
1989; Warmerdam et al., 1990). FcγRII contains, depending on the isoform, either an 
immunoreceptor tyrosine-based activation motif (ITAM) or an immunoreceptor 
tyrosine-based inhibitory motif (ITIM). FcγRIIA and FcγRIIC contain an ITAM motif 
 45
and are therefore activating receptors, whereas FcγRIIB contains an ITIM motif and is 
thus an inhibitory receptor (Fig. 1.11) (Van den Herik-Oudijk IE et al., 1995; Van den 
Herik-Oudijk IE et al., 1994). 
 
hFcγRIIs are the most widely expressed FcγRs and are present on almost all 
leukocytes, including neutrophils, eosinophils, basophils, platelets, Langerhans cells, 
B cells and some T-cell subsets (Hulett and Hogarth, 1994; van de Winkel and 
Anderson, 1991). Monocytes have also been shown to express both FcγIIA and 
FcγRIIB2 (Pricop et al., 2001). Interestingly, IFN-γ and IL-4 influence the balance of 
FcγRIIA and FcγRIIB2 on monocytes; IL-4 upregulates FcγRIIB2 while it 
simultaneously downregulates FcγRIIA, whereas IFN-γ has the opposite effect 
(Pricop et al., 2001). FcγRIIB1 are expressed mainly on B cells and are the only 
FcγRs on these cells and its co-ligation with the B cell receptor (BCR) inhibits BCR 
activation (Van den Herik-Oudijk IE et al., 1994). NK cells have been reported to 
express FcγRIIC which enhances the cytotoxicity of these cells (Metes et al., 1998; 





There are two homologous FcγRIII genes, i.e. FcγRIIIA and FcγRIIIB, both being  
located on chromosome 1q23-24 (van de Winkel and Anderson, 1991; Hulett and 
Hogarth, 1994). Both gene products show heterogeneous sizes, ranging between 50-
80 KDa, as a result of variable N-linked glycosylation. FcγRIIIA and FcγRIIIB have 
two extracellular Ig-like domains and their extracellular domains differ by only 6 
amino acids. In contrast to FcγRIIIA, FcγRIIIB does not contain a transmembrane 
domain or a cytoplasmic tail but it is anchored to the cell membrane via a 
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glycosylphosphatidylinositol (GPI) anchor (Fig. 1.11) (Ravetch and Perussia, 1989). 
Unlike FcγRI, FcγRIIIA is critically dependent on  FcRγ and/or  FcRζ for trafficking 
to the cell surface as FcγRIIIA has an endoplasmic reticulum retention signal 
(Kurosaki et al., 1991). 
 
Like FcγRII, FcγRIII is a low affinity receptor (KA=5.5 x 105 M-1) and it preferentially 
interacts with immune complexes containing human IgG1 and IgG3 (Galon et al., 
1997) (Table 1.1). Genetic polymorphisms affecting IgG subclass specificites have 
been found in both FcγRIIIA (de Haas et al., 1996; Koene et al., 1997) and FcRIIIB 
(Huizinga et al., 1989). In FcγRIIA, a polymorphism at amino acid 158, a valine or 
phenylalanine, has been identified (Fig. 1.11). As a result, FcγRIIIA-V158 has a 
higher affinity for IgG1 and IgG3 than FcγRIIIA-Phe158 (de Haas et al., 1996; Koene 
et al., 1997). Allelic variations in FcγRIIIB have been found in four amino acids, 
referred to as neutrophil antigen 1(NA1) and NA2 (Fig. 1.11) (Huizinga et al., 1990). 
FcγRIIIB-NA1 internalizes IgG1- or IgG3-opsonized particles more efficiently than 
FcγRIIIB-NA2 (Huizinga et al., 1989).  
 
Monocytes and natural killer (NK) cells are the major cell population expressing 
FcγRIIIA (van de Winkel and Anderson, 1991; Hulett and Hogarth, 1994) whereas, 
FcγRIIIB is solely expressed by neutrophils and eosinophils (Huizinga et al., 1988). 
FcγRIIIA can be induced by TGF-β on monocytes (Wahl et al., 1992). In contrast, IL-




1.5.3  Functions of FcγRs 
The current understanding of FcγR functions has been greatly enhanced by the 
generation of mice deficient in the different FcγRs. Analysis of FcγR-/- mice 
confirmed the importance of FcγRs in mediating IgG effector functions and the 
development of inflammatory disease (Ravetch and Bolland, 2001; Takai, 2002). 
 
FcγRI (CD64) and FcγRIII (CD16) 
FcγRI mediates multiple biological functions upon cross-linking. This includes 
phagocytosis of opsonized particles (Anderson et al., 1990; Davis et al., 1995), killing 
of opsonized cellular targets via antibody dependent cell cytotoxicity (ADCC) 
(Graziano and Fanger, 1987), superoxide production (Pfefferkorn and Fanger, 1989) 
and cytokine release (Debets et al., 1990; Krutmann et al., 1990). The role of FcγRIII 
is associated with clearance of immune complexes and ADCC (Fossati-Jimack et al., 
2000).  
 Macrophages from FcRγ-/- mice, lacking FcγRI, FcγRIII and FcεRI, are unable to 
phagocytose IgG-opsonized particles (Takai et al., 1994). These mice also exhibit 
defective ADCC by NK cells and diminished mast cell-mediated allergic response. 
The specific roles for FcγRI (Barnes et al., 2002; Ioan-Facsinay et al., 2002) and 
FcγRIII (Hazenbos et al., 1996) have been studied with cells from mice deficient for 
the specific receptors. FcγRI-/- mice showed multiple inflammatory and immune 
responses such as (i) loss of uptake of immune complexes of the T cell-independent 
immunoglobulin IgG3 as well as a profound reduction in IgG2a uptake; (ii) reduction 
in antibody-dependent killing of cells by macrophages; (iii) impaired immune 
complex-dependent antigen presentation to primed T cells; (iv) decreased immune 
complex-induced inflammation; and (v) enhancement of antibody responses (Barnes 
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et al., 2002). FcγRIII-/- mice lack NK cell-mediated ADCC and phagocytosis of IgG-
coated particles by macrophages (Hazenbos et al., 1996; Hazenbos et al., 1998). 
These mice also lack IgG-mediated mast cell degranulation and are resistant to IgG-
dependent passive cutaneous anaphylaxis and exhibit an impaired Arthus reaction.  
 
Targeting of FcγRI, FcγRII or FcγRIII by Ag/anti-FcγR conjugates on the human 
monoctyes in vitro resulted in enhanced Ag presentation, although Ag presentation 
was most efficient by targeting FcγRI (Gosselin et al., 1992). Moreover, mice with 
transgenic FcγRI expressed selectively on myeloid cells have enhanced Ab responses 
when targeted by Ag-mAb conjugates in vivo (Heijnen et al., 1996). In addition, 
macrophages from FcRγ-/- mice, which are required for FcγRI and FcγRIII signaling, 
failed to upregulate IL-10 production in response to immune complexes (ICs). 
However, mice lacking either the FcγRII or the FcγRIII were fully capable of 
upregulating IL-10 production, implicating FcγRI in this process. IL-10 down-
regulates pro-inflammatory responses in these processes, suggesting FcγRI also 
mediates immunostimulatory functions (Sutterwala et al., 1998). 
 
FcRγ-/- mice, lacking FcγRI and FcγRIII are resistant to the development of 
experimental immune hemolytic anaemia and experimental immune 
thrombocytopenia (Takai et al., 1994; Clynes and Ravetch, 1995). FcRγ has also been 
shown to play a major role in IC-mediated inflammatory reactions since FcRγ-/- mice 
are impaired in Arthus reaction, i.e protected from fatal glomerulonephritis (Sylvestre 
and Ravetch, 1994). In addition, FcRγ-/- mice are protected from the development of 
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experimental autoimmune arthritis induced by collagen, suggesting an additional role 
for FcγRI and/or FcγRIII in the development of arthritis (Kleinau et al., 2000). 
FcRγ-/- mice also showed enhancement of mast cell degranulation and IgG1-mediated 




FcγRIIA has been shown to have very similar biological functions as FcγRI. The role 
of FcγRIIA has been demonstrated in vivo by generating human FcγRIIA transgenic 
mice. In comparison with matched wild-type littermates that are negative for the 
FcγRIIA transgene, induction of thrombocytopenia by Abs was more severe. In 
contrast, FcRγ-/- mice that lack functional expression of FcγRI and FcγRIII on splenic 
macrophages did not demonstrate anti-platelet Ab-mediated thrombocytopenia. This 
suggests that  hFcγRIIA plays a significant role in the immune clearance of platelets 
and independent of FcγRI, FcγRIII and FcRγ (McKenzie et al., 1999). Study on 
transgenic mice that expresses human FcγRIIA are susceptible to collagen induced 
arthritis (Tan et al., 2005). A surprising characteristic of the FcγRIIA transgenic mice 
was the spontaneous development of multisystem autoimmune disease with features 
of rheumatoid arthritis, systemic lupus erythematosus, pneuminitis and 
glomerulonephritis. In addition immune complex induced TNF-α and IL-1β 
production was observed from FcγRIIA transgenic macrophages. 
 Signaling initiated by ITAM-containing receptors such as BCR, FcγRII or FcγRs 
associated FcRγ can be attenuated by ITIM-containing receptors (Daeron et al., 
1995a). This can be caused by BCR co-ligation with FcγRIIB which also leads to B 
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cells apoptosis (Ashman et al., 1996; Pearse et al., 1999). FcγRIIB stimulation also 
affect B cell proliferation (Phillips and Parker, 1984; Sidman and Unanue, 1979), 
signaling (Choquet et al., 1993; Muta et al., 1994), and antigen presentation (Minskoff 
et al., 1998; Wagle et al., 1999). Co-ligation of FcγRIIB with FcεRI on mast cells 
inhibits degranulation and cytokine production, suggesting that FcγRIIB is able to 
modulate mast cell activation through FcεRI (Daeron et al., 1995b).  
 
FcγRIIB-/- mice show augmented Ab responses and mast cells from FcγRIIB-/- mice 
are more sensitive to degranulation, resulting in increased passive cutaneous 
anaphylaxis reaction (Takai et al., 1996). Moreover, FcγRIIB-/- mice are more 
susceptible to IC-related autoimmune diseases such as collagen-induced arthritis 
(Yuasa et al., 1999; Nabbe et al., 2003) and Goodpasture’s syndrome (Nakamura et 
al., 2000). It has also been indicated that FcγRIIB is crucial for maintaining self-
tolerance. Depending on the genetic background, FcγRIIB-deficient mice can develop 
a spontaneous autoimmune disease (Bolland and Ravetch, 2000; Yajima et al., 2003). 
Increased ADCC against  tumors has also been observed in FcγRIIB-/- mice (Clynes et 
al., 2000). Although FcγRIIB contains an ITIM, this receptor has been shown to have 
phagocytic capacity in mice in the absence of inflammation. In the absence of the 
activating receptors FcγRI and FcRγIII, using FcγRI/III-/- and FcγRI/II/III-/- double-
knock out mice, FcγRIIB reduces joint inflammation in arthritis by promoting 





1.5.4  FcγR-mediated signal transduction 
FcγRs are characterized by the presence of, or association with, the ITAM motif 
(Ravetch and Kinet, 1991; Daeron, 1997). The ITAM motif consists of two pairs of 
tyrosines and leucines within the consensus sequence D/E-X7-D/E-X2-Y-X-X-L-X7-
Y-X-X-L, (X is any amino acid)  (Cambier, 1995; Isakov, 1997). It has been shown to 
be important for the activation of signal transduction. On the other hand, FcγRIIB 
harbors an ITIM (the consensus sequence is I/V/L/Sx/YxxL/V) motif (Unkeless and 
Jin, 1997; Long, 1999; Bolland and Ravetch, 1999), which recruits signaling 
molecules to  inhibit ITAM-mediated cellular activation. The signaling cascades 
elicited by activating FcγRs (FcγRI, FcγRIIA and FcγRIII) is similar to that elicited 
by BCRs and TCRs (Kurosaki, 1999; Ravetch and Bolland, 2001). This is illustrated 
in Figure 1.12. 
(i) Upon cross-linking of activating FcγRs, tyrosine residues in the ITAM motif is 
phosphorylated by the action of non-receptor tyrosine kinases of the Src family with 
subsequent recruitment of Src homology domain-containing signaling molecules that 
bind to the phosphorylated ITAM, most notably the Syk kinase family molecules. 
Depending on the particular cell types, FcγR triggers the activation of different 
tyrosine kinases. For example, FcγRIIIA aggregation activates Lck in NK cells 
(Salcedo et al., 1993), while FcγRIIA or FcγRIIIA activate Lyn and Hck in monocytic 
and mast cells (Wang et al., 1994; Ghazizadeh et al., 1994). Likewise, Syk is activated 
in mast cells and macrophages (Agarwal et al., 1993; Crowley et al., 1997), whereas 
the related kinase ZAP70 is activated in NK cells (Cone et al., 1993). 
(ii) In turn, phosphorylated Syk activate numerous downstream signaling molecules. 
One is the recruitment and activation of phospahtidylinositol 3-kinase (PI3-K) 
(Chacko et al., 1996). It has been shown that PI3-K activity is decreased in 
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macrophages from Syk-/- mice when PI3-K was immunoprecipitated with anti-
phosphotyrosine antibodies (Crowley et al., 1997). PI3-K activity is essential for 
phagocytosis. Phagocytic cells incubated with wortmanin, which binds to the catalytic 
subunit of most PI3-K and inhibits their function, bind particles but are unable to 
internalize them. It catalyzes the generation of phosphatidylinositol (3,4,5)-
triphosphate (PIP3) from a membrane phospholipid phosphatidylinositol (4,5)-
biphosphate (PIP2) (Ninomiya et al., 1994; Araki et al., 1996).  
(iii) PIP3 recruits molecules containing pleckstrin homology (PH) domains such as 
phospholipase-Cγ (PLCγ) and Tec kianses (Ferguson et al., 1995; Salim et al., 1996). 
Myeloid cells contain several Tec kinases, e.g. Btk, Itk and Emt (Kawakami et al., 
1996), that can be activated upon FcγR aggregation. The PLCγ1 and PLCγ2 of PLCγ 
family are  responsible for the break down of membrane-bound PIP3 to inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG) (Ting et al., 1992; Divecha and Irvine, 
1995). 
(iv) IP3 is the principal second messenger to induce cytosolic calcium (Ca2+) rise 
(Berridge, 1993). IP3 binds its receptors (IP3Rs) on the endoplasmic reticulum (ER) 
leading to calcium release from this internal Ca2+ stores. Calcium (Ca2+) induces some 
isoforms of protein kinase C (PKC) translocation to the plasma membrane where it is 
activated by DAG. An increase in cytoplasmic Ca2+ concentration is necessary for the 
granule release from NK cells involved in the delivery of the lethal hit (Kagi et al., 
1994; Gumperz and Parham, 1995). 
(v) GTP-binding protein such as Ras and Rac also participates in FcγR signaling 
pathway. The Ras family together with PKC, regulate the mitogen-activated protein 
kinsae (MAPK) cascades (Galandrini et al., 1996). Ras directly activates Raf-1. Raf-1 
inturn activates MEK (MAPK kinase), and MEK activation directly leads to ERK 
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(extracellular signal-regulated kinase) activation (Macdonald et al., 1993; Marshall, 
1994). The JNK pathway is activated by FcγR through Rac1 and Cdc42 GTPases 
(Minden et al., 1995). Regulation of p38 MAPK is also achieved through PKC (Akiba 
et al., 1999), Rac and Cdc42 (Zhang et al., 1995; Rose et al., 1997). These signaling 
cascades ultimately activates  transcription factors nuclear factor κB (NF-κB) 
(Sizemore et al., 1999; Reddy et al., 2000). 
 
However, when the FcγRIIB is crosslinked with activating FcRγs, the ITIM motif on 
FcγRIIB is phosphorylated by the protein tyrosine kinases lyn. The phosphorylated 
ITIM recruits phosphatases such as Src homology 2 (SH2) domain-containing inositol 
polyphosphate phosphatase (SHIP) which inhibit ITAM-triggered calcium 
mobilization and cellular proliferation (Fig. 1.13) (Daeron et al., 1995a; Ono et al., 
1996). These inhibitory activities result from the   hydrolysis of PIP3 by SHIP and 
thus dissociation of PH domain-containing proteins like Btk and PLCγ from the 
membrane (Ono et al., 1996; Bolland et al., 1998). As a result calcium influx is 
inhibited which prevents sustained calcium signaling and calcium dependent 
processes such as degranulation, phagocytosis, ADCC and cytokine release. B cell 
proliferation can be Arrested through ITIM-dependent activation of the adaptor 
protein Dok and subsequent inactivation of MAP kinases (Yamanashi et al., 2000; 
Tamir et al., 2000).Through its phosphatase domain, SHIP can prevent recruitment of 
the PH domain survival factor Akt by hydrolysis of PIP3 (Aman et al., 1998; 
Helgason et al., 2000). 
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Figure 1.12 FcγRIII signaling 
This figure shows an example of the possible signaling pathways initiated upon FcγR 
ITAM phosphorylation, (Ravetch et al., 2001). 
Figure 1.13 Signaling pathways triggered by BCR-FcγRII co-ligation. 
SHIP-mediated inhibition of FcγRs mediated signaling. FcγRIIB is shown as an example 
of this class of inhibitory receptors, (Ravetch et al., 2001) 
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1.6 Inflammatory cytokines 
Cytokines consist of a large group of soluble polypeptide mediators which regulate 
diverse events, including inflammation, hematopoiesis, development, tissue repair, 
etc.  Micro-organisms induce cytokine secretion by host cells through TLRs (Haddad, 
2002). Immune-complexes cause cytokine secretion through stimulation of FcγRs 
signaling. 
The activation of NF-κB is common to these receptors signaling leading to 
transcriptional activation of various cytokine genes. 
These cytokines can be pro-inflammator or anti-inflammatory. Pro-inflammatory 
cytokines such as IL-1 and TNF-α is produced soon after infection to induce tissue 
inflammation. Anti-inflammatory cytokines, such as IL-10, are counteractive which 
restrict the scale of infalmamiton (Haddad, 2002). Some cytokines that will be 
investigated in this study are briefly described below. 
 
1.6.1  Tumor necrosis factor-α (TNF- α) 
TNF-α was first discovered as a serum factor produced in LPS-treated mice. Later, it 
found to have strong anti-tumor activity against tumors implanted in the mouse skin 
(Carswell et al., 1975) and molecularly defined as Tumor necrosis factor (Aggarwal et 
al., 1985). TNF-α is expressed by macrophages, lymphocytes, fibroblasts, Kuppfer 
cells and many other cells. It is secreted by monocytes in response to immune 
complex (Debets et al., 1988; Debets et al., 1990). In immune complex-mediated 
diseases, such as rheumatoid arthritis, high concentrations of TNF-α is secreted by 
tissue macrophages (Tan et al., 2003; Tan et al., 2005). 
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It is synthesized as a trimeric type II membrane protein which is cleaved by a 
membrane-bound enzyme into a soluble, pyramid-like 51 KDa homotrimer. There are 
two types of TNF-α receptors: TNFα-RI and TNFα-RII. TNFα-RI is responsible for 
most of the biologic effects of TNF-α (Darnay and Aggarwal, 1999). 
TNF-α has many biological effects. It induces the production of other cytokines, e.g. 
IL-1 (Dinarello et al., 1986) and IL-6 (Zhang et al., 1988), induces T-cells apoptosis 
(Screaton and Xu, 2000), proliferates of fibroblast, upregualtes adhesion molecules of 
endothelial cell and differentiate of myeloid cells (Cain et al., 1999; Suryaprasad and 
Prindiville, 2003; Aggarwal, 2003). TNF-α promotes macrophage oxidative burst and 
increase the killing of intracellular pathogen (Drapier et al., 1988; Vassalli, 1992).  In 
sepsis, it induces the production of prostaglandin, resulting in fever (Beutler and 
Cerami, 1987). In liver, it induces the production of acute pahse proteins (Perlmutter 
et al., 1986). It may cause cardiac dysfunction by disturbing the calcium influx in 
cardiac myocytes and thereby inhibitng contractility (Bolger and Anker, 2000). It also 
interfere insulin-signaling mechanism by inhibiting the tyrosine kinase activities of 
the insuling receptor and serine phosphorylaiton of the insulin receptor substrate 
(Hotamisligil et al., 1994).  
 
1.6.2  Interleukin-1 (IL-1) 
IL-1 is another pro-inflammatory cytokine which possesses many characteristics of 
TNF-α. There are two isoforms of IL-1, i.e. IL-1α and IL-β, and their biological 
activities are thought to be similar. The naturally occurring IL-1 receptor antagonist 
(IL-1ra) is a third member of the IL-1 family. It is structurally similar to IL-1β but has 
antagonistic activity (Bresnihan et al., 1998). The main cellular source of IL-1 is 
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activated macrophages by bacterial components and other cytokines. Both IL-1α and 
IL-1β are synthesized as 33 KDa precursors which are then enzymatically cleaved 
into the 17 KDa bioactive forms and secreted. IL-1α is also  active in its precursor 
form but remains mostly intracellular (Dinarello, 1996). It is also induced by immune 
complexes from monocytes and macrophages (Chou et al., 1985; Remvig et al., 1990) 
IL-1activates a wide range of cells including endothelial cells, fibroblasts, epithelial 
cells, dendritic cells and T lymphocytes. IL-1 activates target cells through IL-1 
receptor type I (1L-IRI) (Labow et al., 1997). A type II receptor, which lacks a 
cytosolic domain, appears to act as a decoy receptor, through competitionwith IL-1RI 
in IL-1 binding (Slack et al., 1993). 
The physiological effects of IL-1 are in some aspect, very similar to that of TNF-α 
and  the two cytokines often exhibit additive or synergistic effects to induce 
inflammatory reactions 
 
1.6.3  Interleukin-6 (IL-6) 
IL-6 was first known as a BSF-2 (B cell stimulator factor-2), because it was identified 
as a T cell factor that induces B cells differentiation (Hirano et al., 1986). It is 
constitutively produced by some tumor cells. In normal cells, its expression must be 
induced. TLR ligands are potent in IL-6 induction as for TNF-α and IL-1 (Akira et al., 
1993). Immune complex also induces IL-6 production in monocyte (Krutmann et al., 
1990). High levels of IL-6 is found in the plasma of patients with acute bacterial 
infections (Helfgott et al., 1989).  
The IL-6 receptor consists of two different subunits, i.e. IL-6R and the signaling 
subunit gp130. Binding of IL-6R by IL-6 induces homodimerization of gp130, which 
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initiates the signal transduction cascade. IL-6R is mainly expressed in 
immunocompetent cells and hepatocytes, whereas gp130 is ubiquitously expressed 
(Saito et al., 1992). IL-6 has many biological functions including stimulation of Ig 
secretion by B cells, activation of  osteoclasts, maturation of megakaryocytes and 
growth of T cells and myeloma cells (Kishimoto, 1989; Kishimoto et al., 1992). 
 
1.6.4  Interleukin-10 (IL-10) 
IL-10 is an anti-inflammatory cytokine expressed by activated T-cells, B-cells, 
monocytes, macrophages, mast cells and keratinocytes. Its physiological function is 
the limitation and final shut-off of inflammatory reaction in immune defense once 
invading pathogens have been eliminated. IL-10 expression by T-cells is activated by 
anti-CD3 antibodies and phorbal esters and is inhibited by IL-4 and IFN-γ (de Waal et 
al., 1991a; de Waal et al., 1992). IL-10 is also produced by monocytes in response to 
immune complex and it inhibits the production of pro-inflammatory cytokines TNF-α 
and IL-1β (Berger et al., 1996). IL-10 also inhibits MHC class II. However, it co-
stimulates the growth of several hematopoietic cells, including T-cells, B-cells, mast 
cells, megakaryocytes and erythroid (Fiorentino et al., 1991; de Waal et al., 1991b). It 
also inhibits the production of reactive oxygen species (ROS) and nitric oxide (NO) 
by macrophages (Bogdan et al., 1991). 
 
1.6.5  Granulocyte macrophage-colony stimulating factor (GM-CSF) 
GM-CSF is a 144 residue glycoprotein secreted by activated monocytes and 
macrophages upon LPS stimulation (Hamilton, 1994). It also secreted by endothelial 
cells, fibroblast cells and chondrocytes upon proinflammatory cytokine stimulation 
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such as IL-1 and TNF-α (Bagby, Jr. et al., 1986; Leizer et al., 1990; Campbell et al., 
1991). Solid-phase IgG also induce the secretion of GM-CSF from monocytes 
(Herrmann et al., 1992). In inflammatory and non-inflammatory arthritis the affected 
joint contained detectable amount of GM-CSF(Feldmann et al., 1996). 
The functions of GM-CSF are mediated by binding to high-affinity receptors 
comprising a GM-CSF-specific α-chain and a signal transducing β-subunit, which is 
shared by IL-3 and IL-5  receptors (Kitamura et al., 1991; Tavernier et al., 1991). It 
amplifies the inflammatory response by increasing the production of IL-1 and TNF-α 
by macrophages. Moreover, this cytokine has a role as a growth factor by maintaining 
the survival and by stimulating the proliferation and the differentiation of granulocyte, 
macrophage and eosinophil (Lopez et al., 1992).  
 
1.6.6  Interleukin 8 (IL-8) 
IL-8 was discovered as neutrophil chemotactic factor (Yoshimura et al., 1987). It is a 
chemokine secreted by activated macrophages, monocytes, neutrophils, natural killer 
cells and other cell types in response to TNF-α, IL-1 (Matsushima et al., 1988) or 
directly in response to bacterial products (Baggiolini et al., 1997; Oppenheim et al., 
1991). It also secreted by monocytes via FcγR in response to immune complexes such 
as Immobilize IgG (Marsh et al., 1995). In immune complex-mediated diseases, such 
as rheumatoid arthritis, high concentrations of both IL-8 and neutrophils are present in 
monocyte and macrophage rich compartments (Seitz et al., 1991; Verburgh et al., 
1993),. 
IL-8 mediates its functions by binding to two distinct receptors, IL-8RI and IL-8RII 
with a similar high affinity (Holmes et al., 1991; Murphy and Tiffany, 1991). IL-8 is 
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responsible for the various functions of neutrophils, including degranulation and 
respiratory burst (Mukaida, 2000). It induces chemotaxis of eosinophils together  with 
IL-3 or GM-CSF (Warringa et al., 1991). It also induces basophils to exhibit 
chemotaxis (Geiser et al., 1993) and to adhere to endothelial cells (Bacon et al., 
1994). In the presence of shear stress, monocytes adherence to endothelium cells is 
markedly increased in responses to IL-8, also suggest a potential role of IL-8 in 
macrophage migration (Gerszten et al., 1999).  
 
1.7 Aims of the Study 
The overall aims of this study are as follows: 
(1) Develop a novel method for the detection of ligand-induced receptor-receptor 
interactions and interactions between secreted protein ligands and their receptors in 
live 293T cells. 
In earlier studies, it was shown that heterodimerization between the cytoplasmic 
domains of TLR1 and TLR2 i.e. TIR1 and TIR2, caused by the CD4 extracellular 
domains led to TLR signaling for NF-κB activation (Ozinsky et al., 2000). In another 
word, TIR1 and TIR2 can report interactions between proteins that are fused with 
them. In a recent study, TIR1 and TIR2 were also found to detect interactions between 
the extracellular domains of integrin αV and β5 (Zhang et al., 2002). Based on these 
results, we decided to evaluate the TIR1/2 pair for general application in the detection 
of interaction between proteins on the cell membrane. The well-known interactions 
between IL-4 and the extracellular domains of its receptors IL-4Rα and γC in 
conjunction with TIR1 and TIR2 are chosen for investigation. Results obtained using 
a well established pair like the above chosen system will help to validate the efficacy 
of the TIR1/TIR2 assay. IL-4 like many other growth factors and cytokines transmits 
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a signal into the cell by promoting the dimerization of receptor chains (i.e. IL4Rα and 
γC) in the plasma membrane (Stahl and Yancopoulos, 1993; Heldin, 1995). The 
nature of the interactions between the cytokines and their receptors is therefore of 
fundamental importance to the understanding of the immune response. It is important 
to have a system where we can detect IL-4-induced receptor-receptor interactions   
and interactions between secreted protein ligands and their receptors. This type of 
studies will provide new insights into more general protein-protein interactions.   
 
(2) Evaluate CD14-CD14 interactions and significance of this interaction in TLR4-
mediated NF-κB activation. 
CD14 plays an essential role in host response to LPS. The molecular mechanism of 
LPS binding and transferring to CD14 has been intensively investigated through 
mutagenesis and antibody-based binding site mapping. In this study, CD14 is fused 
with TIR1 and TIR2 respectively the CD14-TIR1 and CD14-TIR2 hybrid molecules 
are expressed on 293T cells. NF-κB activation was examined. Furthermore, amino 
acid residues implicated in CD14-CD14 interactions based on the crystallography 
study (Kim et al., 2005) are mutated to assess their roles in LPS signaling. 
 
(3) Investigate whether dimerization of FcγRIIA is sufficient to elicit cell signaling 
using this TIR1/TIR2-based two-hybrid system. 
FcγR elicit cell signaling through cytoplasmic ITAM motif which is found in FcγRIIA 
but not FcγRIIB which contain ITIM motif instead of ITAM. FcγRIIA is an activating 
receptor whereas FcγRIIB is an inhibitory receptor that serves to recruit phosphatases 
to the receptor to reduce cellular activation (Van den Herik-Oudijk IE et al., 1995) . 
Although FcγRIIA contains ITAM motif in its cytoplasmic tail, FcγRI and FcγRIIIA 
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rely on FcRγ chain for signal transduction. In addition, these three classes of FcγR can 
elicit different cellular responses depending on the cell types. FcγR cross-linking in 
myelomonocytic cells causes the production of cytokines which are important in 
tissue inflammation, such as IL-6, TNF-α, IL-1 and IL-8. Cytokine induction by 
specific FcγRs is not fully characterized. In this study, the transmembrane and 
cytoplasmic domain of FcγRIIA is fused with the extracellular domains of IL-4Rα 
and γC respectively and expressed in 293T cells. The cells are stimulated with IL-4 







Chapter 2 MATERIALS AND METHODS 
 The preparation of media and solutions, unless otherwise described in this chapter is 
given in the Appendix. 
 
2.1     Molecular biology 
2.1.1     Materials 
2.1.1.1     Bacterial strains 
Escherichia coli (E. coli) DH5α (Hanahan, 1983) was used for plasmid propagation. 
Working stocks of DH5α were prepared as colonies on LB agar plates and kept at 
4oC. The bacteria were restreaked once a month on fresh LB agar plates. The bacteria 
were kept at -80oC for long term storage. In this case, the bacteria were stored in the 
respective culture medium containing 20% glycerol.  
 
2.1.1.2    Plasmid vectors and primers 
 
Plasmid vectors used in this study are listed in Table 2.1.1. The vector based primers 
used for sequencing purposes, are included in the Table. All plasmids were 
propagated in E. coli DH5α. Either ampicillin (100 µg/ml LB broth) or kanamycin 









Table 2.1.1 Plasmid vectors and primers 
Vectors (Sources) Description Antibiotic 
selection     
in E.coli 
Primers flanking the 
multiple cloning sites 
for sequencing  
       (5’…..3’) 
pcDNA3.1/Myc-
His (Invitrogen) 
A 5.5 kb vector for constitutive protein  
expression with C-terminal myc/His-tags 
under the CMV promoter 







A 5.7 kb reporter vector that expresses 
the  firefly luciferase under 5 copies of 






A 4 kb control reporter that expresses the 
Renilla luciferase constitutively with a 






2.1.1.3     DNA primer synthesis  
 
Primers for PCR were designed using the PrimerSelect software (DNAStar) to avoid 
primer dimer and hairpin loop formation. Primers for PCR and site-directed 
mutagenesis were designed as described in section 2.4 and 2.5. Primers used for PCR 
and site-directed mutagenesis were synthesized by Research Biolabs (Singapore) or 
AlphaDNA (Montreal, Canada).  
 
2.1.2     Methods  
2.1.2.1     Isolation of total RNA from cell culture 
Total RNA was isolated using the TRIZOL Reagent (Gibco BRL), according to the 
manufacturer’s instructions. Briefly, 2 x 106 cells were lysed in 1ml of TRIZOL 
Reagent and incubated for 5 min at room temperature to allow complete dissociation 
of nucleoprotein complexes. 0.2 ml of chloroform was added to the lysate with 
vigorous mixing for 15 sec. After 2 min of phase separation, it was centrifuged at 4°C 
for 15 min at 12,000 rpm. The aqueous phase was transferred to a fresh tube. 0.5 ml 
of isopropyl alcohol was added for RNA precipitation and incubated for 10 min at 
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room temperature. RNA was pelleted by centrifugation for 10 min at 12,000 rpm, 
washed with 1ml 75% (v/v) ethanol and air-dried. The purified RNA was dissolved in 
20 µl of DEPC-treated water and stored at -80°C. DEPC-treated water was obtained 
from Sigma.  
 
2.1.2.2     Quantitation of RNA 
2 µl of RNA samples were diluted in 0.5 ml of DEPC-treated water (i.e. 250 x 
dilution factor) and optical density was measured at 260 nm (OD260) using a DU® 
640B spectrophotometer (Beckman). RNA concentration, in µg/ml, was estimated 
according to the following formula:  
1OD260 = 40 µg/ml. Absorption at 280 nm (which measures protein contamination) 
was also taken, and the ratio of OD260/OD280 was used to determine RNA purity. 
Samples with an OD260/OD280 ratio greater than 1.7 were used.  
 
2.1.2.3     Reverse transcription 
Reverse transcription was performed using the Advantage RT-for-PCR Kit (Clontech 
Laboratories, Palo Alto, CA), according to the manufacturer’s instructions. Briefly, 
RNA (0.2-1.0 µg) was mixed with 1 µl random hexamers and 1 µl oligo (dT) 18 
primers. The samples were heat-denatured for 2 min at 70°C and rapidly chilled on 
ice to prevent RNA re-annealing. Reverse-transcription was carried out for 1hr at 
42°C in a master mix reaction of 20 µl (Table 2.1.2). The reaction was terminated by 
heating at 94°C for 5 min and the synthesized cDNA was either used immediately or 











MMLV: moloney murine leukaemia virus 
 
2.1.2.4     Polymerase chain reaction (PCR) 
PCR was used to exponentially amplify target DNA sequences. Two types of DNA 
polymerase were used in PCRs. Taq DNA polymerase (Promega) was used in PCR 
reactions to identify and verify cloned DNA sequences in plasmid vectors. The Pfu 
DNA polymerase (which has 3’ Æ 5’ proofreading activity) (Promega) was used to 
generate DNA fragments for cloning into plasmid vectors. 2 µl of cDNA from each 
reverse transcription reaction or less than 500 ng of plasmid DNA was used as 
template in each 50 µl PCR reaction. The rest of a PCR reaction contains 10 x 
reaction buffer, 0.2 mM of each dNTP, 0.5 µM of each primer, 1-2 U of Taq or Pfu 
DNA polymerase. For Taq DNA polymerase, MgCl2 was added to a final 
concentration of 1.5 mM. When Pfu DNA polymerase was used, MgSO4 was added to 
2 mM. Thermal cycling was typically carried out as follows: 
 
(i) 1 cycle at 94oC for 1 min for initial DNA denaturation; (ii) 35 cycles each at 94oC 
for 45 sec (DNA denaturation), 50-65o C* for 45 sec (primer annealing), 72oC for a 
defined time** (extension) and (iii) a final cycle at 72oC for 10 min (extension).  
Reagent Volume (µl) Final concentration/ amount 
RNA+ DEPC-H2o 12.5 0.2-1.0 µg total RNA 
 
Random hexamer primer 1 20 pmol 
Oligo (dT)18 primer 1 20 pmol 
5× reaction buffer 4 50 mM Tris-HCl (pH 8.3) 
75 mM KCl 
3 mM MgCl2 
 
dNTP mix (10 mM each) 1 0.5 mM each 
RNase inhibitor 0.5 1 unit/µl 
MMLV reverse trancriptase 1 ≥200 units/µg RNA  
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* Primer melting temperature is calculated based on  4oC for every C or G base and 
2oC for every A or T base and PCR annealing temperature is used at 2-4oC below 
melting temperature. 
** For Taq polymerase, extension was carried out at 1 min/kb of expected DNA 
products, whilst for Pfu polymerase, it is 2 min/kb of expected DNA products. 
 
2.1.2.5     Ethanol precipitation of DNA  
To precipitate DNA, 1/10 volume of 3M sodium acetate (pH 5.4) is added to DNA 
solutions followed by 2.5 volumes of ice cold 100% ethanol. The solution was mixed 
by brief vortexing and then left at -80ºC for 30 min. The mixture was centrifuged for 
20 min at 13,000 rpm in a microcentrifuge. The pellet was washed with 70% (v/v) 
ethanol at room temperature, then air-dried and dissolved in an appropriate volume of 
deionized water or the TE buffer (Appendix). 
 
2.1.2.6     DNA agarose gel electrophoresis 
 DNA separation was carried out by agarose gel electrophoresis (Sambrook et al., 
1989). Agarose was added to Tris-acetate-EDTA (TAE) buffer (Appendix) at 1% 
(w/v) and boiled in the microwave for 1 min to melt the agarose. The melted agarose 
is cooled down to approximately 60°C and then ethidium bromide (10,000 µg/ml, 
Bio-Rad, USA) were added to a final concentration of 0.5 µg/ml. The agarose was 
then poured in a gel-casting set (Bio-Rad), avoiding bubbles. DNA samples were 
mixed with 1/5 volumes of 5x sample loading buffer (Appendix), e.g. an 8 µl of DNA 
sample is mixed  with 2 µl of DNA loading dye and loaded to the gels. As a control, 
1Kb Plus DNA Size Standard (Gibco BRL) is loaded in parallel. Electrophoresis was 
carried out at 100V in TAE buffer and stopped when the dye front reached 3/4 of the 
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gel-length. Ethidium bromide chelates DNA to produce fluorescence signal upon UV 
illumination. Results were recorded by photography using a Polaroid MP-4 Land 
camera and Polaroid type 667 films (Polaroid Corporation, UK). 
 
2.1.2.7     Isolation and purification of DNA from agarose gels  
DNA separated on agarose gels was isolated using the GFX PCR DNA and Gel Band 
Purification Kit (Amersham Biosciences, USA). Agarose gel containing the desired 
DNA band was excised and placed into an Eppendorf tube. 10 µl of capture buffer 
was added per 10 mg of the gel slice and the contents were vortexed vigorously and 
incubated at 60oC for 5 to 15 min. After the agarose slice was completely melted, the 
sample was transferred to a GFX column and incubated for 5 min at room 
temperature. The column was then centrifuged at 13,000 x g for 30 sec and the flow-
through was discarded. 500 µl of wash buffer was added to the column which was 
then centrifuged at 13,000 x g for 30 sec. This was followed by the addition of 50 µl 
of autoclaved deionized water to the GFX column and incubation at room temperature 
for 5 min. The column was then centrifuged at 13,000 x g for 1 min to recover the 
purified DNA in the flow-through. 
 
2.1.2.8     Rapid isolation of plasmid DNA 
The Wizard(R) Plus SV Minipreps DNA Purification System (Promega Co, Madison 
WI) provides a simple and reliable method for rapid and small scale isolation of 
plasmid DNA. Briefly, a single colony of transformed E.coli DH5α was inoculated in 
10 ml LB containing 100 µg/ml ampicillin. After overnight culture, bacteria was 
pelleted by centrifugation and then resuspended in 250 µl of resuspension solution. 
Cells were then lysed by adding 250 µl of lysis solution. After incubation for 5 min 
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with 10 µl of an alkaline protease solution, the cell lysates were neutralized with 350 
µl of neutralization buffer to precipitate cell debris. The lysates were centrifuged for 
10 min and then transferred to Spin Column. The column was washed twice with 
wash solution and column-bound DNA was eluted with deionized water and collected 
into a fresh tube by centrifugation. The purified plasmid was used directly for 
automated DNA sequencing or restriction enzyme digestion. 
 
2.1.2.9     Plasmid purification for transfection 
QIAGEN plasmid Maxi kit (QIAGEN GmbH, Germany) was used for the purification 
of grade plasmids required for transfection according to manufacturer’s instructions. 
For Maxi-scale plasmid preparation, a single plasmid-bearing bacteria colony was 
picked from a freshly streaked ampicillin selective agar (LA) plate and inoculated into 
a starter culture of 2-5 ml LA selective medium. The culture was grown for 8 hr at 
37oC with shaking (200 rpm). This starter culture was diluted 1/500 into 250 ml of LA 
selective medium and cultured overnight (12-16 hr) at 37oC with shaking (200 rpm). 
The bacterial cells were pelleted by centrifugation for 15 min at 6,000 x g and at 4oC 
and re-suspended in 10 ml of Buffer P1 (resuspension buffer). 10 ml of buffer P2 
(lysis buffer with NaOH and SDS) was then added, mixed and incubated for 5 min at 
room temperature. This was followed by addition of 10 ml of chilled buffer P3 
(neutralization buffer with NaOAc). After mixing, the lysate was incubated on ice for 
20 min and centrifuged for 30 min at ≥ 20,000x g and at 4oC. The supernatant was 
passed through the QBT buffer-equilibrated QIAGEN-tip 500 column (containing 
proprietary DNA binding resin). The column was washed two times and the bound 
DNA was eluted with 15 ml of Buffer QF. To precipitate the eluted DNA, 10.5 ml 
isopropanol was added and mixed, followed by centrifugation for 30 min at ≥ 15,000 
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x g and at 4oC. The DNA was pelleted with 5 ml of 70% ethanol at room temperature 
and centrifuged at ≥ 15,000 x g for 10 min. The DNA pellet was air-dried for 5-10 
min, dissolved in autoclaved deionized water and stored at -20oC. 
 
2.1.2.10   Quantitation of DNA 
DNA was quantitated using the Hoefer DyNA Quant 200 fluorometer (Pharmacia 
Biotech), which measures fluorescence emitted by the DNA-chelating dye 
bisbenzimide Hoechet No. 33258 trihydrochloride (Pharmacia Biotech). 2 ml of assay 
buffer, containing 0.1 µg/ml of dye and 1 x TNE (0.2 M NaCl, 10 mM Tris-HCl and  
1 mM EDTA), (pH 7.4) was used as blank. 2 µl of calf thymus DNA standard (100 
µg/ml) (Sigma-Aldrich) was added for calibration. 2 µl of diluted DNA (i.e 50-100 x 
dilution of prepared plasmid) sample was used for quantitation, and DNA 
concentration was obtained in µg/ul. 
 
2.1.2.11   Restriction endonuclease digestion 
The presence of restriction sites in a DNA sequence (e.g. plasmid) was analyzed using 
the Webcutter 2.0 software (http://www.firstmarket.com/cutter/cut2.html). Restriction 
digestion of DNA was carried out using restriction enzymes from Promega except for 
SfuI (Roche Molecular Biochemicals, Germany) and PmeI (New England Biolabs, 
USA). Digestion was carried out in a total volume of 20-50 µl reaction containing the 
appropriate restriction enzyme buffers (as supplied for each enzyme), DNA (2-5 µg of 
PCR products or plasmid vector), specific restriction enzyme and 10 µg/µl of 
acetylated BSA. The digestion was carried out at 37°C for 2 hr. For double digestions, 
DNA was either simultaneously digested with two enzymes using the multicore buffer 
or sequentially digested using optimal buffers for each enzyme. A useful website for 
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identifying suppliers of restriction enzymes and restriction sites is 
http://rebase.neb.com/rebase/ 
The digested DNA fragments were separated by electrophoresis and purified from the 
gel slices as described in section 2.1.2.7. 
 
2.1.2.12   DNA ligation 
T4 DNA ligase and the ligase buffer (containing 1 mM ATP) (New England Biolabs, 
USA) were used in 20 µl ligation reactions. The molar ratios between inserts and 
vectors ranged from 3:1 to 5:1 and ligation was carried out for 2 hr or overnight at 
22○C for cohesive-end ligations. 
 
2.1.2.13   Preparation of competent cells 
DH5α was streaked onto LB plate and cultured overnight at 37ºC. A single colony 
was inoculated into 10 ml LB and cultured overnight at 37ºC with shaking at 200 rpm.  
2 ml of the overnight culture was transferred to 200 ml of fresh LB (1:50 or 1:100) in 
a 500 ml flask. When the OD600 of the culture has reached 0.5-0.6, the culture was 
centrifuged at 3000 rpm for 10 min and at 4ºC to pellet the cells. Each pellet was then 
re-suspended in 10 ml of pre-chilled filtered 0.1M CaCl2 (Stock 1M). The cells were 
centrifuged at 2500 rpm and 4ºC. The pellet was resuspended in 10 ml of cold CaCl2 
and incubated on ice for 30 min. After centrifugation, the pellet was re-suspended in 2 
ml of ice cold CaCl2 solution with 14% glycerol (v/v). 200 µl aliquots of this 
competent cells preparation were dispensed in 1.5 ml chilled eppendorf tubes. 




2.1.2.14   Transformation of competent cells 
Competent cells were thawed on ice and either 50-100 ng of DNA or 10 µl (or more) 
of the 20 µl ligation reaction was mixed gently with 100 µl of competent cells and            
incubated for 30 min on ice. Upon heat-shock for 2 min at 42oC, 300 µl of pre-
warmed LB was added and the cells were further cultured for 1 hr at 37oC. 50 µl or 
200 µl fractions of the transformed cells were plated on LB plates with the 
appropriate selective antibiotic and cultured overnight at 37oC.  
 
2.1.2.15   Identification of positive clones by PCR 
Between ten to twenty transformant colonies were each inoculated in 1 ml LB 
containing the appropriate antibiotics. After 6 hr of culturing, PCR was carried out for 
30 cycles using 1 µl of each culture as templates and primers specific to the insert 
DNA in 20 µl reactions. 10 µl of each reaction mixture was examined on an agarose 
gel to identify positive clones. Plasmid DNA was purified (described in section 
2.1.2.8) from the culture containing the expected PCR products obtained.  
 
2.1.2.16   Identification of positive clones by restriction enzyme digestion 
An alternative method for identifying positive clone, involves restriction digestion. 
Five transformant colonies were each cultured in 10 ml LB containing the appropriate 
antibiotics. Plasmid DNA was isolated from the cultures as described in section 
2.1.2.8. The purified plasmids were digested with appropriate restriction enzymes and 





2.1.2.17   Site-directed mutagenesis 
QuikChange™ XL Site-directed Mutagenesis Kit (Stratagene) was used to introduce 
point mutations into a cloned DNA fragment. This was used to create restriction 
enzyme cutting sites or to change a codon for amino acid mutation. Primers used are 
designed according to the following considerations: 
i) Both mutagenic primers must contain the desired mutation and anneal to the same 
sequence on opposite strands of the DNA fragment in which mutations are to be 
introduced. 
ii) Primers should ideally be between 25-45 bases in length, and the melting 
temperature (Tm) of the primers should be ≥ 78o C.  
Tm = 81.5 + 0.41(% GC) - 675/N - % mismatch (where N is the primer length in 
bases and % GC and % mismatch are whole numbers) 
iii) The desired mutation should be in the middle of the primer with about 10-15 bases 
of correct sequence on both sides.   
iv) The primer should optimally have a minimum GC content of 40% and should 
terminate in one or more C or G bases. 
 It was recommended by the manufacturer to use FPLC or PAGE purified primers, 
PCR-grade primers (desalted) from Research Bio Labs worked just as well in our 
case. A 50 µl reaction mixture contains 10 ng of plasmid DNA, 125 ng of each primer 
and the supplied dNTP mix, QuikSolution, 10 x reaction buffers and Pfu Turbo DNA 
polymerase (2.5 U/µl). PCR cycling parameters include a first cycle at 95o C for 1 
min, followed by 18 cycles each at 95oC for 50 sec, 60oC for 50 sec and 68oC for an 
appropriate length of time (2 min/kb of plasmid length). The PCR is extended with a 
final cycle at 68oC for 7 min. The reaction products was then treated with 1 µl of DpnI 
restriction enzyme (10 U/µl) at 37oC for 1 hr to digest the parental (nonmutated) 
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double-stranded DNA. 2 µl of DpnI-treated DNA was then used to transform the 
XL10-Gold ultracompetent cells as provided by the manufacturer.  
 
2.1.2.18   Sequencing  
The Bigdye Terminator cycle sequencing reagent (Perkin Elmer) was used to carry 
out fluorescence-based dideoxy sequencing reactions (Sanger et al., 1977). 200-500 
ng of plasmid DNA or 20-50 ng of PCR product was used in a 20 µl reaction mix, 
containing 5 pmol of primer and 8 µl of terminator ready reaction mix. Cycle 
sequencing was carried out using a total of 25 cycles, each comprising a DNA 
denaturation step at 96oC for 30 sec, a primer annealing step at 50oC for 15 sec, and a 
primer extension step at 60oC for 4 min. After the reaction, sequencing products were 
precipitated with 2 volumes of cold ethanol after addition of sodium acetate (pH 7.4) 
to a final concentration of 0.3M. The DNA pellets were washed once with 70% 
ethanol and air-dried. Polyacrylamide gel electrophoresis or capillary electrophoresis 
was carried out for the sequencing products using the ABI 374 or 310 DNA sequencer 











2.2     Cell biology 
2.2.1     Materials 
2.2.1.1     Stimulant  
Table 2.2.1 Molecular and microbial stimuli used in this study  
Stimulant Bacterial Strain Supplier  
 
Working concentration 





Sigma-Aldrich 0.5 µg/ml 
Bacteria  Escherichia coli 
DH5α 
Invitrogen 50 bacteria : 1 cell 
Purified human IgG  Zymed  
Laboratories 
100 µg/ml 
Polymyxin B  Fluka 20 µg/ml 
Polystyrene 
Microsphere 2.0 µm 
 PolySciences, Inc 50 beads : 1 cell 
 
2.2.2     Methods 
2.2.2.1     Mammalian cell culture  
The 293T human embryonic kidney cells were originally obtained from the American 
Type Culture collection (ATCC) (Rockville, MD).  The cell were maintained at 37°C 
in the presence of 5% CO2, in DMEM (Sigma-Aldrich) supplemented with 10% fetal 
calf serum (HyClone), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml 
penicillin and 100 µg/ml streptomycin (complete medium). The medium was replaced 
with fresh media every 3 days. The cells were subculture at a ratio of 1:5. To 
subculture cells, the medium was removed from the flask and the cells were gently 
washed with 1x PBS (Appendix). Trypsin/0.5 mM EDTA (Sigma-Aldrich) was added 
to dislodge the cells and incubated the washed cells for 2-5 min at 37°C. The 
complete DMEM medium was added to the cells to quench the trypsin. Cell clusters 




2.2.2.2     Storage of cells  
To make cell stocks, cells were pelleted at 300x g for 5 min and then resuspended to 
0.5 _1 x 107 cells/ml in appropriate medium. 20% DMSO was freshly made in the 
medium and then an equal volume was slowly added to the cell suspension with 
mixing. The cell suspension was left at room temperature for 5 min to allow for 
equilibration of DMSO across the cell membrane and then transferred to cryogenic 
vials (Nalge Nunc International A/S. Roskilde, Denmark). The final storage medium 
is 10% DMSO in the desired culture medium. The vials were frozen at -80oC and then 
transfered to liquid nitrogen for long term storage. The cells were maintained at -80oC 
for short term storage.  
To revive stored cells from frozen vials, a cryogenic vial was thawed rapidly in a 
37oC water bath and then transfered to the cultured medium (5-10 ml). The cells were 
centrifuged at 300 x g for 5 min and the pellet was resuspended in appropriate 
medium and tranfered to culture plates or flasks. All reagents used for mammalian 
cell culture were sterilized by autoclaving or filtration. 
 
2.2.2.3    Liposome-based cell transfection 
Approximately 5 x 105 cells were seeded into each well in 6-well plates and cultured 
at 37oC for 16-24 hr in the presence of 5% CO2. Transfection of these cells was 
carried out using the liposome-based GenePORTERTM 2 Transfection Reagent (Gene 
Therapy Systems, La Jolla, CA) following the manufacturer’s instructions. Briefly, 3 
µg of plasmid DNA was diluted with 75 µl of the DNA diluent buffer (known as new 
diluent B) and incubated for 5 min at room temperature. The DNA solution was added 
to dilute GenePORTER 2 reagent and incubated for 5-10 min at room temperature. 
This is to allow GenePORTER 2/DNA complex formation (DNA-liposome). The 
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cultured medium in each well was adjusted to 1 ml by removing the extra medium 
and the DNA-liposome mixture was added directly to cells. The cells were incubated 
for 24 hr before stimulation or analysis in functional assays.  
 
2.2.2.4     Using calcium phosphate cell transfection 
This is employed when cell transfection is carried out in larger scales.  4 x 106 cells 
were seeded in a T75 cell culture flask the day before transfection and incubated at 
37oC in the presence of 5% CO2. In this setting, the cells were transfected with 20 µg 
of the expression vectors (details in section 2.4 and 2.5). As negative controls, cells 
were transfected with the empty pcDNA3.1 vector. Briefly, 20 µg DNA was diluted in 
1.2 ml sterile water. 1.4 ml of 2 x HBS buffer (Appendix) was added to the diluted 
DNA and mixed properly. 150 µl of 2.5 M CaCl2 was added to the DNA mixture 
dropwisely. The DNA mixture was immediately vortexed for 5 sec and then incubated 
for 45 min at room temperature before adding to the cells. This DNA mixture was 
added to the cells and then incubated for 6-8 hr at 37oC in 5% CO2. After 6-8 hr, the 
cells were washed once with the DMEM media and then cultured for 24-48 hr before 
analysis by immunoprecipitation or western blotimg. 
 
2.2.2.5     Dual luciferase assay 
In this assay, 293T cells were seeded in 24-well plates at the densitiy of 1.5 x 105 
cells/well. After 24 hr, the cells were transfected with the plasmids at a total of 300 
ng/well using the GenePORTERTM 2 transfection reagent. In negative controls, cells 
were transfected with the empty pcDNA3.1 vector rather than the test plasmids. When 
test plasmids were used at < 300 ng/well, pcDNA3.1 was used to normalize the total 
plasminds in each well to 300 ng/well. The p5×NF-κB-luc (Stratagene) and pRL-
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CMV (Promega) luciferase reporter plasmids were co-transfected at 200 ng/well in 
each experiment.  
For example, the chimeric IL4-TIR1/TIR2, IL4Rα-TIR1/TIR2, γC-TIR1/TIR2 and 
CD14-TIR1/TIR2 expression vectors were used at 19 ng/well each. The IL4Rα-
FcγRII and γC-FcγRII expression vectors were also used at this dosage. In every case, 
pcDNA3.1 was used at 262 ng/well. 
 
To express the LPS receptor complex in 293T cells, TLR4 and MD2 were each used 
at 5 ng/well and the CD14 plasmid was used at 20 ng/well. To express FcγRs in 293T 
cells, the FcγRIIA, FcγIIIIA and FcRγ expression vectors were each used at 150 
ng/well. Cells were stimulated with different stimuli where stimulation was required. 
Luciferase expression was determined 24 hr after stimulation with the Dual 
Luciferase Assay kit (Promega).  
Briefly, culture media was removed and the cells were washed once with PBS. Cells 
were lysed in the wells using 1 x PLB (known as passive lysis buffer). Expression of 
firefly luciferase (which is directed by the NF-κB promoter) was read upon addition 
of Luciferase Assay Reagent II (LAR II). Following this, the Stop and Glo® Reagent 
which contains substrate for the Renilla luciferase, was added to measure Renilla 
luciferase expression under the CMV promoter. All experiments were performed in 
triplicates and in each experiment, the firefly luciferase values were normalized to the 
Renilla luciferase values.  
 
2.2.2.6     Treatment of cells with specific stimuli 
293T cells were cultured for 24 hr after tranasfection. Where the cells were 
transfected with IL4-TIR1/2, IL4Rα-TIR1/2, and γC-TIR1/2 vectors, the cells were 
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stimulated with IL-4 at 1, 10 and 100 ng/ml. Where the CD14-TIR/2 vectors were 
used to transfect 293T cells, LPS (E. coli O55:B5, Sigma-Aldrich) was used to 
stimulate the cells at 200 ng/ml. Where 293T cells were co-transfected with TLR4 or 
MD2 or CD14 vectros, LPS was used to stimulate the cells at 500 ng/ml. Cells that 
were transfected with FcγR expression vectors, were stimulated with the bacteria 
DH5α opsonized with human IgG at 50 bacteria:1 cell.                                                                          
 
2.2.2.7     Flow cytometry 
In 24-well plates 293T cells were transfected with IL4-TIR1/2, IL4Rα-TIR1/2 or γC-
TIR1/2 expression vectors (100 ng/well). As a control, cells were transfected with the 
pcDNA3.1 plasmid. The cells were cultured for 24 hr before analysis by flow 
cytometry. Cells were harvested by incubation with 0.5 mM EDTA at 37oC for 5 min 
and pelleted by centrifugation at 300x g for 5 min. Cells were reuspended in culture 
media at 2 x 106/ml and 5 x 105 cells were used for antibody staining. Specific 
primary antibodies (Table 2.3) were diluted in FACSwash (PBS containing 2.0% 
(v/v) BCS and 0.05% (w/v) sodium azide).  50 µl of the cells were then incubated 
with each antibody for 45 min on ice. If secondary antibodies were used, the cells 
were preblocked for 20 min using 20% (v/v) serum of the same species in which the 
secondary antibody was raised. The cells were then incubated with specific primary 
antibodies. This was followed by incubation with flourescent antibody for 30 min. 
The cells were washed twice with FACSwash and fixed in 1% (v/v) formaldehyde in 
PBS. 
Antibodies against IL4, γC, CD14, FcγRIIA and FcγRIIIA were fluorescently 
conjugated whereas that for, IL4Rα, was not. Direct conjugated primary antibody was 
also used for staining macrophage cell surface markers (Table 2.3). 
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Antibody-stained cells were analysed using FACScalibur (Becton Dickinson 
Immunocytometry Systems) and 10,000 cells were collected for each sample. Data 
was analyzed using the WINMDI software, version 2.8 (Scripps Institute, La Jolla, 
CA). 
 
2.2.2.8     Isolation of human peripheral blood monocytes 
Peripheral blood leukocytes were obtained from the NUH blood Donation Centre in 
the form of buffy coat preparations derived from healthy donors. Monocytes were 
isolated from the buffy coats essentially as previously described with minor 
modifications (Lu et al., 1996). Briefly, 15 ml buffy coats were diluted with 30 ml 
PBS in a 50 ml tube. 30 ml of the diluted buffy coat was layered on 12 ml Ficoll-
Paque (Amersham Bioscience Corp) and centrifuged for 30 min at 400x g without 
brake. Peripheral blood mononuclear cells (PBMCs) were collected from the gradient 
interface and topped up with PBS to 50 ml. PBMCs were pelleted down by 
centrifugation at 200x g for 15 min. This was repeated once and followed by two 
washes at 100x g each for 10 min. The washed cells were resuspended in 60 ml RPMI 
containing 5% (v/v) iron-supplemented bovine calf serum (BCS) (HyClone) and 
splitted into three T75 cell culture flasks and cultured for 2 hr at 37oC.  Non-adherent 
cells, mainly lymphocytes, were removed and the adherent cells were washed three 
times each with 10 ml warm RPMI containing 5% BCS. The adherent fraction, 
mainly monocytes, was harvested by gentle scraping. Cells were washed once with 
RPMI supplemented with 10% (v/v) BCS and then cultured in the same medium after 
addition of M-CSF or GM-CSF. Monocytes isolated by this method were ~95% pure 
as judged by the expression of CD14. 
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2.2.2.9     Generation of macrophages from monocytes 
Monocytes were cultured in 6-well tissue culture plates at a density of 1 x 106/ml in 
complete RPMI containing 10% (v/v) BCS, 100 units/ml penicillin, 100 µg/ml 
streptomycin, 2mM L-glutamine, 1mM sodium pyruvate, and 0.0012% (v/v) β-
mecaptoethanol. THe cells were cultured for 6 days in the presence of 20 ng/ml GM-
CSF (R & D Systems Inc, Minneapolis, MN). Every other day, half volume of the 
culture medium was removed and replenished with fresh media containing GM-CSF. 
During the culture, monocytes underwent morphologic changes, which were 
characterisitc of macrophages, such as an increase in cell size and adherenace.  
 
2.2.2.10   Cell activation 
Macrophages were harvested, washed once with PBS and resuspended at 1 x 106/ml 
in RPMI containing 10% (v/v) heat-inactivated BCS, 100 units/ml penicillin and 100 
µg/ml streptomycin. 1x105 cells were cultured in each 96-well. After 24 hr, 
macrophages were stimulated with immobilized IgG (ImIgG), heat-aggregated IgG 
(HA-IgG) or soluble IgG at a concentration of 100 µg/ml. In some experiments, IgG 
was coated on latex beads (IgG-beads). As controls, BSA was coated on the beads 
(BSA-beads). These beads were used to stimulate macrophages. 
 
2.2.2.11   Preparation of ImIgG, Heat aggregated-IgG (HA-IgG) and IgG-beads                    
 Immobilize IgG was prepared by incubating tissue culture plates with purified human 
IgG (100 µg/ml in PBS) at 4°C overnight. As a negative control, the plates were 
coated with BSA (100 µg/ml). The plates were washed three times using PBS before 
macrophages were cultured on these IgG-coated plates. In some experiments, 
polymyxin B was included to eliminate any endotoxin contamination of human IgG. 
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HA-IgG was prepared by heating IgG (5 mg/ml in PBS) at 65oC for 60 min. Large 
precipitates, which are not often observed,  were removed by centrifugation at 
10,000g for 20 min. HA-IgG in the supernatant was determined by spectrophotometry 
at 280 nm. IgG was coated on latex beads by incubating polystyrene microspheres 
(2.0 µm in diameter) (2 x 108/ml) with human IgG (5 mg/ml) over night at 4oC. The 
mixture was gently rotated. BSA was similarly coated on latex beads. Beads were 
then pelleted by centrifugation for 10 min at 3000 rpm. The supernatant was removed 
without disturbing the beads and the pelleted beads were washed two times with ice-
cold PBS. The amount of IgG bound to the beads was estimated by measuring IgG 
concentration in the supernatant at 280 nm.   
 
2.2.2.12   Macrophage stimulation with different forms of IgG  
Macrophages were stimulated with IgG or BSA-beads at a ratio of 50 beads:1 cell. 
The cells were stimulated with soluble and HA-IgG at 100 µg/ml.  In some 
experiments, macrophages were incubated with blocking antibodies (20 µg/ml) 
against different FcγRs. The incubation was carried out for 1h at 4°C in medium 
containing heat-inactivated BCS. The cells were then stimulated with the different 
forms of IgG.  With regard to 293T cells transfected to express FcγRs, the cells were 
stimulated with human IgG-opsonized bacteria. Opsonization of DH5α was achieved 
by incubating bacteria (2 x 108/ml) with human IgG (5 mg/ml) for 1 hr at 37°C.  The 
opsonized bacteria were centrifuged for 5 min at 3000 rpm. The bacteria washed three 
times in PBS and re-suspended at desired concentrations. 293T cells were stimulated 
in serum free media for 6 hr at 37oC in 5% CO2 incubator with opsonized bacteria at a 
ratio of 100:1. 
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2.3     Protein Chemistry 
2.3.1     Materials 
2.3.1.1     Antibodies used in this study 
All antibodies used in this study have been listed in Table 2.3.1, together with 
information of their source, isotype and working concentrations. 
 
2.3.2     Methods 
2.3.2.1     Protein concentration determination 
Protein concentration was determined using the Bio-Rad protein assay kit (Bio-Rad). 
It was based on the method by Bradford (Bradford, 1976). Assays were performed 
according to the manufacturer’s protocol. Briefly, eight serial dilutions of a standard 
BSA solution were prepared. The linear range of this assay is 0.04 mg/ml to 
approximately 0.4 mg/ml. Diluted BSA (10 µl) and protein samples (10 µl) were 
added into 96-well microtiter plate. The dye reagent was diluted (1 part Dye Reagent 
Concentrate with 4 parts distilled water, filtered through 0.45 µm filter to remove 
particulates) and 200 µl was added to each well. After mixing thoroughly using a 
multichannel pipette, it was incubated at room temperature for at least 5 min. The 
plates should not be incubated at room temperature for more than 1 hr. Absorbance 
was measured at 595 nm. The standard curve was constructed by plotting the known 
BSA concentrations. Protein concentration in samples was determined by comparison 
with the BSA standard curve. 
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Table 2.3.1 Antibodies used in this study 
Antibody (anti-) Clone, isotype 
Conjugate and stock 




Human IL-4 MP4-25D2, Rat IgG1 




Human CD124  
(IL-4Rα chain) 
















R & D Systems, Inc 
Human IL-4Rα 25463.111, mouse 
IgG2, 500 µg/ml 
Western blot 
(1:500) 
R & D Systems, Inc 




R & D Systems, Inc 
Mouse IgGs  goat polyclonal, RPE Flow cytometry 
(1:25) 
DakoCytomation 
c-myc tag 9E10, mouse monoclonal 
IgG1, 200µg/ml 
Western blot (1:200) Roche Molecular  
Biochemicals 
Human CD14 UCHMI, mouse IgG2a, 
FITC, 0.5 mg/ml 
Flow cytometry (1:50) Ancell 
Human CD14 Sheep IgG, 500 µg/ml Western blot 
(1:2000) 
R & D Systems, Inc 






















Human CD16 3G8, mouseIgG1, 1 mg/ml Blocking(2: 100) 
 
Ancell 
Human CD32 7.3, mouse IgG1,  1 mg/ml Blocking (2: 100) 
 
Ancell 
Human CD64 10.1. mouse IgG1, 1 mg/ml Blocking (2: 100) Ancell 
Isotype control MOPC 31C, mouse IgG1,  
1 mg/ml 
 
Blocking  (2: 100)  Ancell 
β-actin AC-15, mouse IgG` Western blot (1:5000) Sigma-Aldrich 
Mouse IgGs  Goat poly clonal, AP 
conjugate 
Western blot (1:1000) Bio- rad 
Sheep IgGs Rabbbit polyclonal, AP 
conjugate 
Western blot (1:3000) Upstate biotechnology 
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2.3.2.2     Immunoprecipitation Study 
293T cells (approximately 1.3 x 107 cells in a T75 flask) were transfected with 20 µg of 
the following expression vectors either singly or in 1:1 pairs: pIL4tm-MH/pIL4tm-
TIR2, pIL4Rαtm-MH/ pIL4Rαtm-TIR2, pγCtm-MH/ pγCtm-TIR2 (details of plasmid in 
section 2.4.3). The cells were harvested after 36 hr and lysed at approximately 2.5 x 107 
cells/ml in lysis buffer (Appendix) by rotating for 45 min at 4°C. Protease inhibitors (10 
µg/ml aprotinin, 10 µg/ml leupeptin and 2 mM PMSF) were included in the lysis buffer. 
The lysates were centrifuged for 15 min at 13,000 rpm. The cleared supernatants were 
either directly analyzed by Western blotting or used for immunoprecipitation. For the 
latter, the supernatants were pre-cleared for 1 hr at 4°C with protein G-Sepharose 
(Roche applied science, Germany). The lysates sepharose mixtures were centrifuged for 
1 min at 13,000 rpm and the supernatants were removed and incubatated overnight with 
an anti-myc antibody (1 µg/ml). As controls, the supernatants were incubated with 
isotype-matched mouse IgG.  The cleared lysates were incubated with 50 µl of protein 
G-Sepharose beads. After 3 hr of rotation at 4°C, the lysate bead mixtures were 
centrifuged at 13,000 rpm for 2 min. The supernatants were discarded and the beads 
were washed three times with washing buffer (Appendix) containing protease inhibitor. 
The bead-bound proteins were eluted in SDS-PAGE sample buffer. 
 In some experiments, the pre-cleared supernatants were incubated overnight with Ni-
NTA-agarose (Sigma) which binds His tags. In this case, the bead-precipitated proteins 
were eluted with immidazole (250 mM). The eluted proteins were separated on 10% or 
12.5% (w/v) SDS-PAGE gels and detected by Western blotting using IL-4, IL-4Rα or 




2.3.2.3     Cell surface biotinylation  
293T cells were cultured in 6-well plates and transfected with the following CD14 
expression plasmids (3 µg /well). The first group of plasmids expresses CD14-TIR 
hybrids and mutants based on these hybrids: pCD14-TIR1, pCD14-TIR2, loopdelCD14-
TIR1, β13delCD14-TIR1, and pCD14-TIR1 mutants (CD14290A, CD14294A, CD14298A, 
CD14299A, CD14300A, CD14302A, CD14305A, CD14307A and CD14290A, 307A). The second 
group of plasmids include full-length CD14 and CD14 mutants based on full-length 
CD14 (CD14290A, CD14294A, CD14298A, CD14299A, CD14300A, CD14302A, CD14305A, 
CD14 307A, CD14290A, 307A). Details of these plasmids were in section 2.5.  After 36 hr, 
the cells were washed three times with ice-cold PBS (pH 8.0) and incubated for 30 min 
at 20°C with membrane-impermeable biotinylation reagent (1 mg/ml) (LinkTM sulfo-
NHS-LC-biotin; Pierce, Rockford, IL). The biotin reagent was dissolved in PBS (pH 
8.0) immediately before use. The reaction was stopped by addition of 20 mM glycine 
followed by incubation for another 15 min.  The cells were lysed in 200 µl lysis buffer 
(Appendix) and centrifuged to remove insoluble materials. The cell extracts were 
diluted in 0.5 volume of 1:1 slurry immobilized streptavidin-agarose beads (Pierce) and 
then incubated with the beads overnight at 4°C under constant shaking. The beads were 
pelleted by centrifugation at 5,000xg for 1 min and washed three times in the washing 
buffer containing protease inhibitor (Appendix). Bound proteins were eluted by boiling 
the beads in SDS-PAGE sample buffer (Appendix) and then subjected to SDS-PAGE 
and Western blotting. 
 
2.3.2.4     DTSSP-based protein-protein cross-linking on the cell surface  
293T cells in 6-well plates were transfected with plasmids for wild type or mutant 
CD14 (3 µg/well) using the GenePorter 2 reagent. After 36 hr, the cells were washed 
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three times with PBS and pelleted into 1.5 ml microcentrifuge tubes. The cells were 
resuspended to 2 x 106/ml in PBS and then incubated with membrane-impermeable 
bifunctional cross-linking reagent, 3,3’-Dithiobis(sulfosuccinimidylpropionate) 
(DTSSP, Pierce) (1mg/ml) in dark for 45 min at 20°C with rocking. The cross-linking 
reaction was stopped by adding 1M Tris-HCl (pH 7.4) and incubates for 10 min. Next, 
cells were washed and lysed in the lysis buffer containing the protease inhibitors. THe 
lysates were subjected to SDS-PAGE in the presence or absence of β-mercaptoethanol 
and followed by Western blotting. 
 
2.3.2.5     SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Cells were lysed on ice in the lysis buffer containing protease inhibitors. After removing 
insoluble materials by centrifugation, protein concentration of the lysates was 
determined using the BCA reagent (Bio-Rad) (section 2.3.2.1). 50-100 µg protein 
samples were mixed with 1/5 volume of a 5 x SDS-PAGE sample loading buffer with or 
without β-mercaptoethanol (Appendix). The samples were boiled for 10 min at 95°C 
before loading into the SDS-PAGE gels. The gels were run in 1x SDS/Glycine buffer 
(25 mM Tris, 250 mM glycine, 0.1% SDS, pH 8.3) at 120V until the dye front is 
approximately 1cm from the bottom (Sambrook et al., 1989).  
 
2.3.2.6     Western blotting 
Proteins separated on the SDS-PAGE gels were electro-blotted onto nitrocellulose 
membranes (Bio-Rad) in the transfer buffer (Appendix) at 100V and 250 mA for 1.5 hr 
at room temperature using an electroblotting apparatus set (Bio-Rad).  The blots were 
blocked at 4°C overnight in 5% non-fat milk dissolved in the TBS-T buffer (50 mM 
Tris (pH 7.5), 150 mM NaCl, 0.1% (v/v) Tween-20). The blots were washed three times 
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(10 min each) and then incuabted with specific primary antibodies for 2 hr at room 
temperature with constant shaking. The blots were washed three times and then 
incubated with alkaline phosphatase (AP)-conjugated secondary antibodies for 1hr. 
After washing the blots were finally developed using the Immun-StarTM Stubstrate Pack 
(Bio-Rad). The signals were detected using the ECL protein detection system 
(Amershem). 
 
2.3.2.7     Human cytokine array assay  
The Human Cytokine Antibody arrays (RayBiotech, Norcross, GA) provide a highly 
sensitive approach to the simultaneous detection of multiple cytokine expression in 
conditioned media. Briefly, membranes are dotted with antibodies in duplicates that are 
specific for different cytokines. Incubation of the membrane with conditioned media 
cultures cytokines to the spots. This is detected with secondary antibody for each 
cytokines. Monocytes derived GM-CSF macrophages (approximately 1 x 106) were 
stimulated with ImIgG, HA-IgG, IgG-beads or soluble IgG. HA-IgG and soluble IgG 
were used at at 100 µg/ml. IgG-beads or as a control, BSA-beads were used at 50 
beads:1 cell. After incubation for 24 hr at 37°C in the presence of 5% CO2, the 
conditioned media was harvested and centrifuged for 5 min at 3,000 x g to remove cell 
debris. Meanwhile, the array membranes (RayBiotech) were blocked with 1x blocking 
buffer by rotating for 30 min at room temperature. 1 ml of conditioned media was 
mixed with an equal volume of fresh media and then incubated for 2 hr with array 
membrane at room temperature by rotating. The membrane was washed with washing 
buffer I for three times (each  for 5 min) and then washed with buffer II (both wash 
buffers are provided in the kit) for two times. 1 ml of biotin-conjugated primary 
antibody mixture was added and incubated with membrane at room temperature for 2 
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hr. The membrane was washed and then incubated with 2 ml of horseradish peroxidase-
conjugated streptavidin at room temperature for 1 hr. The membranes were developed 
using substrate detection buffer A and detection buffer B (provided in the kit) mixed at 
1:1 ratio.  The membrane was exposed to X-ray films and the films were processed by 
autoradiography.   
 
2.3.2.8     Enzyme-linked Immunosorbent  Assay (ELISA) 
Cytokines secreted into the culture medium from IgG-stimulated GM-CSF macrophages 
or 293 T cells was measured by ELISA using the human DuoSet ELISA Development 
kits (R&D Systems Inc). These assays were performed according to the manufacture’s 
instructions. Briefly, 96-well BD FalconTM ELISA plates (BD Biosciences) were added 
with 1 capture antibodies diluted in PBS (100 µl/well), sealed with parafilm and 
incubated overnight at 4°C. The plates were washed with wash buffer (0.05% Tween 
®20 in PBS, pH 7.2 - 7.4) three times (250 µl/well) and blocked with the Reagent 
Diluent (1% BSA 5 in PBS, pH 7.2 - 7.4, 0.2 mm filtered) (200 µl/well) for 2 hr at room 
temperature. The plates were washed three times with wash buffer and samples or 
purified cytokine standard diluted in Reagent Diluent were added into each well (100 
µl/well). Dilution of conditioned media was made in Reagent Diluent so as to achieve 
the final reading within the linear range of the standard curve. Plates were sealed and 
incubated overnight at 4°C. The plates were washed three times and biotinylated 
detection antibodies diluted in Reagent Diluent were added to each well (100 µl/well). 
After incubation at room temperature for 2 hr, plates were washed three times and 
incubated with streptavidin-HRP conjugate in Reagent Diluent (100 µl/well) for 1hr at 
room temperature in the dark. Plates were washed 5 times. Substrate solution was 
prepared within 15 min prior to use by mixing equal volume of Substrate reagent A 
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(hydrogen peroxide in a buffered solution) and Substrate B (3,3’,5,5’ 
tetramethylbenzidine in an organic solvent) provided in the kit (BD Biosciences). 100 µl 
substrate solutions were added to each well and the plates were incubated in dark for 30 
min. The colormetrical reaction was stopped by adding 50 µl Stopping Solution (1M 
phosphoric acid) to each well. The optical density was determined immediately using a 
microplate reader (TECAN) at 450 nm with a wavelength correction at 570 nm. The 
linearized standard curve was constructed by plotting the cytokine concentrations versus 
that of the OD reading value (log scale).  The concentration of each sample was derived 
by comparing with the standard curve and then multiplied by the dilution factors.  
 
2.4     Molecular biology techniques 
2.4.1     Construction of vector for the expression of TLR chimeras 
2.4.1.1     Expression vectors for integrin-TLR chimeras (pβ5-TLR vectors) 
Expression vectors were constructed to express the extracellular domains of integrin β5 
with the transmembrane and cytoplasmic domain of TLR1 or TLR2. These vectors were 
constructed by Dr. Zhang Haifeng. Briefly, cDNA encoding the transmembrane and 
cytoplasmic domains (TM/Cyt) of TLR1 and TLR2 were amplified by PCR using the 
specified primer pairs: 
 TLR1 Forward 5’cccttcgaaaacataactctgctgatcgtc3’;  
Reverse 5’cgggtttaaacgactatttctttgcttgctctg3’;  
TLR2 Forward 5’cccttcgaaacagcactggtgtctggc 3’; 
Reverse 5’cgggtttaaacaacctaggactttatcgacg 3’; 
A SfuI site was introduced at the 5’ end of each forward primer and a PmeI site was 
introduced at the 5’ end of each reverse primer. All PCR products were therefore 
flanked by SfuI/PmeI sites and cloned in the pβ5/MH vectors which replaced the 
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Myc/His-coding sequence (Zhang et al., 2002). This led to the pβ5-TIR1/2 expression 
vectors (Fig. 2.4A). 
 
2.4.1.2     Expression vectors for fusion receptors between IL-4 or the extracellular 
(EC) domains of IL-4Rα, γC or CD14 and the TM/Cyt domains of TLR1 or TLR2   
cDNA encoding IL-4 or the EC domains of IL-4Rα, γC, and CD14 were amplified by 
RT-PCR using monocyte RNA and the listed primer pairs in Table 2.4. The cDNA 
fragmants were cloned into the pβ5TLR1 and pβ5TLR2 vectors (Zhang et al., 2002) at 
the indicated restriction site (Table 2.4), to replace sequences encoding the EC domain 
of integrin β5 in these vectors. This yields the pIL4-TIR1/2; pIL4Rα-TIR1/2; pγC-
TIR1/2; and pCD14-TIR1/2 expression vectors (Fig. 2.4B). 
 









IL-4 XM_004053 cggggtaccaccatgggtctcacctcccaact (bases 66 to 85) 
tttgttcgaagctcgaacactttgaata (bases 507 to 525) 
KpnI/SfuI 
IL-4Rα NM_000418 tgtggaattccagcctggtgccttggca (bases 150 to 169) 
tttgttcgaagtgctgctcgaagggctc (bases 854 to 871) 
EcorI/SfuI 
γC NM_000206 cttggtaccgaagagcaagcgccatgt (bases 1 to 18) 
gaagggcccggcttccaatgcaaacag (bases 783 to 801) 
KpnI/ApaI 
CD14 NM_000591 cggggtaccaccatggagcgcgcgtcc (bases 120 to 134) 






















2.4.2     Expression vectors for the expression of fusion receptors between the EC 
domains of IL-4Rα or γC and the FcγRIIA TM/Cyt domains 
To generate the pIL4Rα-FcγRIIA and pγC-FcγRIIA expression vectors, which express 
the IL4Rα and γC with the Tm/Cyt domain of FcγRIIA, a pair of primers were used to 
amplify sequence encoding the FcγRIIA TM/Cyt domain 
(5’tttgttcgaatcaccaatggggatcattg3’/5’cgggtttaacttagttattactgttgacatgg3’). This fragment 
was flanked by 5’-SfuI and 3’-PmeI sites and was cloned into the pIL4Rα-TIR1 and 
pγC-TIR1 vectors in place of the TM-TIR1 sequences. Sequences for the TM/Cyt 
domain of TIR1 vectors were flanked by 5’-SfuI and 3’-PmeI sites. This led to the 
IL4Rα-FcγRIIA and γC-FcγRIIA expression vector (Fig. 2.5). 
Figure 2.4 Scheme of expression vector construction. A) Sequences encoding the TM/TIR 
domains of TLR1 and TLR2, in the pβ5TLR1 and pβ5TLR2 vectors (Zhang et al., 2002). The 
TIR1 and TIR2 sequences are flanked by SfuI/PmeI sites in frame with 5’ sequence encoding 
the exttracellular domain) of human integrin β5 (β5EC). B) Sequences encoding IL-4 and the 
EC domain of IL4Rα , γC and CD14 were amplified by RT-PCR using specific primers (Table 
2.4). The IL-4 sequence was directly cloned in the pβ5TLR1 and pβ5TLR2 vectors to replace 
the β5EC sequence. To clone IL4Rα, γC and CD14, EC sequences encoding the TM/Cyt 
domains of TLR1 and TLR2 were first subcloned into the pcDNA3.1 vector. The PCR-
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2.4.3     Expression vectors for the expression of fusion receptors between IL-4 or 
the EC domains of IL4Rα and γC and the transmembrane (TM) domain of TLR2 











































Figure 2.5 Scheme of expression vectors for chimeras between the EC domain of IL-
4Rα , γC and Tm/Cyt domain of FcγRIIA. Sequences encoding TM/Cyt domain of 
FcγRIIA was amplified by RT-PCR using specific primers. This fragment was flanked by 
5’-SfuI and 3’-PmeI and was cloned into the pIL4Rα-TIR1 and pγC-TIR1 vectors in place 
of TM-TIR1 sequences. This led to the IL4Rα-FcγRIIA and pγC-FcγRIIA expression 
vectors. All vectors were confirmed by sequencing.
Figure 2.6 Scheme of expression vectors for chimeras between IL4, IL-4Rα , γC and 
tm-MH. The IL4/TM, IL4Rα/TM and γC/TM sequences were amplified from the pIL4-
TIR2, pIL4Rα-TIR2 and pγC-TIR2 vectors by PCR and then subcloned into the 
pcDNA3.1 vector to generate the pIL4tm-MH, pIL4Rαtm-MH and pγCtm-MH vectors. 
All vectors were confirmed by sequencing. 
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The following expression vectors were generated to express IL-4, IL4RαEC and γCEC in 
fusion with the TM domain of TLR2, followed by Myc/His tags rather than TIR2. 
Sequences encoding IL-4, IL4RαEC, and γCEC, each followed by the C-terminal TLR2 
TM domain, were amplified from the pIL-4-TIR2, pIL4Rα-TIR2 and pγC-TIR2 vectors 
(Fig. 2.4). This was achieved using the same three sense primers as described in Table 
2.4 and a common specific reverse primer (5’gaagggccccgcacaggacccccgtgag 3’; 
nucleotides 1939 to 1956; accession number U88878) and cloned into the KpnI/ApaI site 
of the pcDNA3.1vector (pIL4tm-MH). Another reverse primer 
(5’tgctctagagcacaggacccccgtgag 3’), which is identical to the above primer except for a 
different 3’ restriction site, was used to amplify sequences encoding IL4RαEC and γCEC 
fused with the C-terminal TLR2 TM sequence, from the pIL4Rα-TIR2 and pγC-TIR2 
vectors (Fig. 2.4). These vectors were cloned respectively into the EcorI/XbaI and 
KpnI/EcorV sites of the pcDNA3.1 Myc/His vector. Thus, this yielded the pIL4Rαtm-
MH and pγCtm-MH expression vectors (Fig. 2.6). All DNA inserts were verified by 
sequencing before use. 
 
2.4.4     Expression of full-length FcγRIIA, FcγRIIIA and FcR γ chain 
Full-length cDNA encoding human FcγRIIA, FcγRIIIA and FcRγ were amplified from 
RNA isolated from human macrophages with the primer pairs listed in Table 2.5. These 
cDNA fragments were subsequently cloned into the pcDNA3.1 Myc/His vector at the 
indicated restriction sites to generate the respective expression vectors. All these vectors 
were constructed with the concensus Kozak sequence CCACC immediately 5’ to the 
ATG codon (Kozak, 1987; Kozak, 1990). In these vectors, the stop codon at the 3’end of 
the coding sequences was retained and therefore, the 3’ Myc/His sequences were not 
fused to the C-terminal ends of these receptors. 
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Table 2.5 Primers used to clone FcγR cDNA 
FcγR Genebank 
Accession 
Primer pairs (5’…….3’) 
(forward/reverse) 
Restriction sites on 
pcDNA3.1 ligated into 
(5’/3’) 
FcγRIIA NM_021642 cggggtaccaccatggagacccaaatgtctc 
gaagggcccttagttattactgttgacatgg 
KpnI/ApaI 
FcγRIIIA NM_000569 cgcggatccaccatgggtggaggggctgg 
gaagggccctcatttgtcttgagggtcc 
BamHI/ApaI 




2.5     Expression vectors for CD14 mutants 
2.5.1     CD14 mutations introduced to the pCD14-TIR1 vector 
Two CD14 deletion mutants were generated in the pCD14-TIR1 by removing amino acids 
290-300 (the ‘loop’ between β12 and β13) or 301-315 (β13). This was achieved by 
introducing new restriction site in the pCD14-TIR1 vector as the backbone (Fig. 2.7) by 
site-directed mutagenesis (Stratagene, La Jolla, CA). To delete residues 290-300, a pair of 
primers was used to introduce EcoRI restriction cutting sites individually (5’….3’): 
cagagtgctcgatctcagctgcaacgaattcaacagggcgccgcagcctg (EcoRI); 
gcgccgcagcctgacgagctgcccgaattcgataacctgacactggacggg (EcoRI).  The mutated pCD14-
TIR1 vector was digested with EcoRI and simultaneously religated into the pCD14-TIR1. 
To delete amino acids 301-315, the following primer was used in which SfuI cutting site 
was introduced (5’….3’): cctgacgagctgcccgagttcgaaaacctgacactggacggg. The original 
pCD14-TIR1 expression vector, have a transmembrane and cytoplasmic domain of TLR1 
which was flanked by a 5’ SfuI and 3’ PmeI site. The mutated pCD14-TIR1 vectors was 
digested with SfuI and simultaneously ligated into the pCD14-TIR1 vector. This led to 
generate the ploopdelCD14-TIR1 and pβ13delCD14-TIR1 vector (Fig. 2.7). The Quick 
change site-directed Mutagenesis kit was also used to introduce alanine substitution in the 
ploopdelCD14-TIR1 and pβ13delCD14-TIR1 vector. Alanine substitution mutants of 
CD14 were generated in the same region and Table 2.6 summarizes the names and the 
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amino acids residues substituted in each mutant. Here the specific amino acid residues 
which were conserved among mouse, human and rabbit were substituted to alanine. The 
different sets of primers used for each mutant are listed in the Table 2.7.  To generate 
double mutant (L290 and L307 together) CD14, the same set of primers were used as to 
generate single mutant of L290A and L307A. This was carried out by introducing one 
after another mutation in the same mutant CD14 plasmid. The introduction of the 





















Mouse   260    LNLSFTGLKQVPKGLPAKLSVLDLSYNRLDRNPSPDELPQVGNLSLKGNPFL--
Human   262   LNLSFAGLEQVPKGLPAKLRVLDLSCNRLNRAPQPDELPEVDNLTLDGNPFLVP
Rabbit    259   LNLSFTGLQQVPKGLPAKLNVLDLSCNKLNRAPQPGELPKVVNLSLDGNPFLVP
TM TIR1 CD14 TM TIR1 CD14
pβ13delCD14-TIR1
290 300 301 315
Figure 2.7 Scheme of expression vectors for loopdelCD14-TIR1, β13delCD14-TIR1 and 
CD14 mutants. Amino acid sequence alignment of mouse , human and rabbit CD14 are shown 
here. Two deletion mutants were generated in the pCD14-TIR1 by removing amino acids 290-300 
(the ‘loop’ between β12 and β13) or 301-315 (β13). The removed amino acids were highlighted in 
green and brown. This was achieved by introducing new restriction site (i.e EcorI or SfuI
individually) in the pCD14-TIR1 vector as the backbone by site-derected mutagenesis. The 
mutated pCD14-TIR1 vectors was digested with the respective restriction enzyme and ligated into 
the pCD14-TIR1 vector. This led to generate the ploopdelCD14-TIR1 and pβ13CD14-TIR1 
vector. A specific amino acid mutant of these regions was also carried out by site-directed 
mutagenesis. The amino acid codons (underlined) of human CD14 were mutated to that coding for 
alanine. 
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Table 2.6  Alanine substitution in CD14 by mutagenesis   
Serial 
No 
Name  Position and name of  
amino acid of  CD14 
mutants 
1 L290A 290Leucine 
2 P294A 294Proline 
3 E298A 298Glutamine 
4 L299A 299Leucine 
5 P300A 300Proline 
6 V302A 302 Valine 
7 L305A 305 Leucine 
8 L307A 307 Leucine 




Table 2.7  Primers used in site-directed mutagenesis for CD14 










L290A and L307A 
(double mutant) 
The same set of primers was used to generate double mutant 
as to generate single mutant of L290A and L307A.  
 
 98
2.5.2     Mutations introduced to Wild type (Wt) CD14 vectors  
Expression vectors for CD14 mutants (i.e. L290A, P294A, E298A, L299A, P300A, 
V302A, L305A, L307A and L290AL307A) were obtained by site-directed mutagenesis, 
using the same set of primers as listed in Table 2.7.  
 
2.6       Brief description of other expression vectors 
The expression vectors for the TLR4, MD2 and CD14 were obtained as described by 
(Zhang et al., 2002). Briefly, cDNA was amplified by RT-PCR from THP-1 with the 
primer pairs in Table 2.8. The fragments obtained were digested with the respective 
restriction enzymes and cloned into pcDNA3.1 vector. 
 






sites on  
pcDNA3.1 
pTLR4 gcttggtaccgggccactgctgctcac/gaagggccctcagatagatgttgcttcctg KpnI/ApaI 
pCD14 cggggtaccaccatggagcgcgcgtcc/gagtctagattaggcaaagccccgggc KpnI/XbaI 












Chapter 3 Development of a TLR-based two-hybrid assay for the 
detection of protein-protein interactions 
 
3.1  Hypothesis: TLR2 signaling mechanism can be utilized to detect protein-
protein interactions 
The experiment was designed based on the mechanism by which TLR2-mediated NF-
κB signaling is activated. TLR2 transduces signals when it dimerizes with TLR1 
(Ozinsky et al., 2000) which causes the dimerization of cytoplasmic TIR domains of 
TLR1 and TLR2 (i.e. TIR1 and TIR2). When TIR1 and TIR2 was expressed as CD4-
TIR1 and CD4-TIR2 fusion proteins, TIR1/TIR2 dimerization induced via the 
extracellular (EC) domain of CD4 caused NF-κB activation (Fig. 3.1A) (Ozinsky et al., 
2000). TIR1 and TIR2 dimerization induced through the EC domains of integrin αvβ5 
also leads to NF-κB activation (Zhang et al., 2002). These observations led to the 
hypothesis that if other receptor EC domains are fused to TIR1 and TIR2, it should 
allow the detection of interactions between these EC domains. We selected the well-
characterized IL-4 receptor to test this hypothesis. As mentioned in chapter 1 (section 
3), the IL-4 receptor consists of a high-affinity IL-4 subunit, known as the IL4Rα chain, 
and a low-affinity subunit, known as the common γ chain (γC) (Nelms et al., 1999). In 
this experiment, expression constructs were designed in a way that the EC domains of 
IL4Rα and γC were individually each fused to TIR1 and TIR2 (Fig. 3.1B). The two 
fusion proteins were co-expressed in 293T cells. NF-κB and the control Renilla 
luciferase reporter plasmids were also co-expressed. The NF-κB luciferase reporter 
expresses firefly luciferase under the NF-κB promoter whereas Renilla luciferase 
reporter expresses the luciferase under a constitutive CMV promoter. In each 
experiment, NF-κB activation is registered by the former and the latter serves as an 
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internal control. IL-4 is expected to induce interactions between the two fusion proteins 
and therefore cause the association of TIR1 and TIR2 and NF-κB activation (Fig. 3.1B). 
This assay is expected to detect IL-4 induced interactions between IL-4Rα and γC on 






















Figure 3.1 Principles underlying the TIR1/TIR2-based two-hybrid assay. This diagram 
illustrates the underlying mechanism based on which this novel two-hybrid assay was 
designed. (A) The extracellular (EC) domains of CD4 form dimers. When tmTIR1 and 
tmTIR2 are fused to the EC domains of CD4, CD4-CD4 interaction leads to tmTIR1 and 
tmTIR2 dimerization. TIR1/TIR2 dimerization causes NF-κB activation. This has been 
previously reported (Ozinsky et al., 2000). (B) In this study, the EC domains of IL-4Rα and 
γC are fused with tmTIR1 and tmTIR2. IL-4Rα and γC association is induced with IL-4. It 
was expected that IL-4 induces the dimerization of the IL4Rα-TIR1 and γC-TIR2 hybrids, 

















3.2  Expression of TIR1 and TIR2 fusion proteins  
Based on the experimental design, vectors were constructed for four fusion proteins, i.e. 
IL4Rα-TIR1, IL4Rα-TIR2, γC-TIR1 and γC-TIR2 (Fig. 2.7). IL-4 was also expressed as 
TIR1 and TIR2 fusion proteins, i.e. IL4-TIR1 and IL4-TIR2 (Fig. 2.4). This was to test 
another hypothesis that interactions between secreted protein ligands and their receptors 
may also be detected using this assay by expression of the secreted protein as an EC 
domain in fusion with TIR1 or TIR2. Overall, six expression vectors were generated, 
pIL4Rα-TIR1, pIL4Rα-TIR2, pγC-TIR1, pγC-TIR2, pIL4-TIR1, and pIL4-TIR2. The 
expression of these TIR1 and TIR2 chimeras on the cell surface was examined by flow 
cytometry. These vectors were expressed in 293T cells and the plasmids were used at 
100 ng/well. After 24 hr, the cells were stained with specific antibodies for IL4Rα, γC 
or IL-4. As shown in Fig. 3.2A, all six fusion proteins were detected on the cell surface. 
When these vectors were over-expressed individually at 150 ng/well, none was able to 
activate NF-κB (Fig. 3.2B). Addition of IL-4 at 100 ng/ml did not induce NF-κB 
activation when these hybrids were expressed individually. These results show that 
individually none of these fusion proteins induces significant NF-κB activation 
irrespective of IL-4 induction.   
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Figure 3.2 Expression of TIR1 and TIR2 fusion proteins. (A) 293T cells were singly 
transfected in 24-well plates with pIL4Rα-TIR1/TIR2, pγC-TIR1/TIR2, and pIL4-TIR1/TIR2 at 
100 ng/well. After 24 hr, the cells were stained with IL4, IL4Rα and γC antibodies and detected
by flow cytometry. The filled profiles are signals derived from 293T cells transfected with the 
pcDNA3.1 vector and the open profiles represent specific signals detected on 293T cells 
transfected with the respective TIR1 and TIR2 fusion protein vectors. (B) 293T cells were singly 
transfected with pIL4-TIR1/TIR2, pIL4Rα-TIR1/TIR2, and pγC-TIR1/TIR2 at 150 ng/well. Total 
expression vector in each experiment was normalized to 300 ng/well with pcDNA3.1. The 
p5xNF-κB-luc and pRL-CMV luciferase reporter plasmids were co-transfected in each experiment 
at 100 ng/well each. After 24 hr, the cells were stimulated with or without IL-4 (100 ng/ml) and 
NF-κB activation was determined by measuring the two luciferases. The firefly (NF-κB-directed) 
luciferase activity was normalized to the Renilla (CMV-directed) luciferase in each experiment. 
All experiments were performed in triplicate and the results were expressed as means ± SD. 
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3.3  Detection of ligand-induced receptor-receptor interactions using the 
TIR1/TIR2 based assay  
Receptor dimerization or oligomerization is a common mechanism in ligand-induced 
activation of cell signaling. For example, IL-4 activates cell signaling by inducing the 
dimerization of its two subunits, i.e. IL4Rα and γC. IL-4 binds to IL4Rα with high 
affinity and then γC is recruited to interact with IL-4 and IL4Rα (Russell et al., 1993; 
Kondo et al., 1993).  In this study, the known interactions between IL-4 and its receptor 
were used to evaluate the feasibility of this TIR1/TIR2-based assay for detecting 
protein-protein interactions. Before examining IL-4-induced IL4Rα and γC interaction 
using this two-hybrid assay, the dosages of the pIL4Rα-TIR1 and pγC-TIR2 plasmids 
were titrated to identify optimal dosages that give low background NF-κB activation in 
the absence of IL-4 induction. This was carried out in 24-well plates. 293T cells were 
co-tansfected with a series of dilutions of the two plasmids at 1:1 ratio from 9-300 
ng/well. Total plasmid in every experiment was normalized to 300 ng/well using the 
pcDNA3.1 vector. As a negative control, only pcDNA3.1 was used. Interactions 
between IL4Rα-TIR1 and γC-TIR2 were judged by the activation of NF-κB using the 
luciferase reporter plasmids. Co-expression of IL4Rα-TIR1 and γC-TIR2 resulted in 
constitutive NF-κB activation in the absence of IL-4 stimulations when high doses of 
plasmids (75 ng/well or more) were used (Fig. 3.3). Constitutive NF-κB activation was 
not obvious when plasmids were used at 38 ng/well or less (Fig. 3.3). This suggests that, 
at these plasmid dosages, IL4Rα-TIR1 and γC-TIR2 are probably not excessively over-
expressed. The transfected cells were also examined for dose-dependent response to IL-
4 at 1, 10 or 100 ng/ml. IL-4 induced NF-κB activation was observed under all three 
conditions. This is especially obvious when the vectors were used at low dosages (i.e. 
38, 19 and 9 ng/well) (Fig. 3.3). IL-4 induced NF-κB activation was not seen at the 
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plasmid dosage of  5 ng/well. This result suggests that co-expression of these two 







At the plasmid dosages of 19 ng/well or less, the expression of IL4Rα-TIR1 and γC-
TIR2 on the cell surface decreased when checked by flow cytometry (data not shown). 
Although IL-4 was able to induce NF-κB activation at these plasmid dosages, the levels 
of NF-κB activation were close to background levels (as induced by the control 
plasmid). At 38 ng/well co-expression of IL4Rα-TIR1 and γC-TIR2 vectors was well 
Figure 3.3 Detection of IL-4 induced IL-4Rα and γC interaction (NF-κB activation) using 
the TIR1/2-based two-hybrid assay. 293T cells were co-transfected with the pIL4Rα-TIR1 
and pγC-TIR2 vectors in 24-well plates. The two plasmids were used at 1:1 ratio and the 
combined dosage was as indicated. Total expression vector in every experiment was normalized 
to 300 ng/well with pcDNA3.1. As controls, the cells were transfected with 300 ng/well of the 
pcDNA3.1 plasmid. The p5xNF-κB-luc and pRL-CMV luciferase reporter plasmids were also 
co-transfected in all experiments at 100 ng/well each. After 24 hr, transfected 293T cells we
stimulated for 12 hr with increasing concentrations of IL-4 (1, 10 and 100 ng/ml) as indicated in 
the inserted legend box. After 12 hr, the activity of NF-κB-directed firefly luciferase and CMV-
directed Renilla luciferase expression were determined using the Dual luciferase assay 
(Promega). The detected NF-κB activation was normalized to the Renilla luciferase activity and 
expressed as a percentage of the latter. All experiments were performed in triplicate and the 
results were expressed as means ± SD. *p≤ 0.010 and **p≤0.023 were observed between the 
effects of different concentrations of IL-4 at 38 ng/well and 19 ng/well. 
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differentiated and at the same time not over-expressed. At this plasmid dosage of 38 
ng/well and IL-4 concentration of 100 ng/ml NF-κB activation was most pronounced as 
compared to lower plasmid dosages.  These optimized condition were then used for 
subsequent experiments. As a control, NF-κB activation was not induced by IL-4 in 
293T cells transfected with the pcDNA3.1 vector. 
 
3.4  IL-4 interacts with IL-4Rα but not γC  
The results described above showed the feasibility of the TIR1/2-based assay in 
detecting lateral receptor-receptor interactions on cell membrane. We then examined if 
this assay also allows the detection of ligand-receptor interactions, by expression of IL-
4 as the EC domain in a IL4-TIR1 hybrid receptor. When IL4-TIR1 was co-expressed 
with the IL4Rα-TIR2 hybrid receptor, it led to NF-κB activation at the plasmid dosage 
of 38 ng/well (Fig. 3.4A). As shown in Fig. 3.3, under these conditions, co-expression 
of IL4Rα-TIR1 and γC-TIR2 caused insignificant NF-κB activation unless the cells 
were stimulated with IL-4. This suggests that IL-4, expressed as the EC domain of the 
IL4-TIR1 hybrid receptor, interacts with the EC domain of IL-4Rα in the IL4Rα -TIR2 
hybrid receptor. Reducing the plasmid to 19 ng/well did not significantly reduce NF-κB 
activation and increasing each expression vector to 150 ng/well did not further enhance 
NF-κB activation (Fig. 3.4A). Addition of soluble IL-4 showed no effect on NF-κB 
activation mediated by IL4-TIR1 and IL4Rα-TIR2. This shows that NF-κB activation 
was not simply due to the over-expression of the two-hybrid receptors. These results are 
consistent with IL-4 having high affinity for IL-4Rα (Nelms et al., 1999). 
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Protein chemistry and crystallography studies revealed that IL4R is activated through a 
two-step dimerization mechanism (Hage et al., 1999; Mueller et al., 2002). At 
physiological concentrations, IL-4 was reported to bind to the IL-4Rα first via its high-
affinity binding site 1. Subsequently, its binding site 2 (a low affinity binding site) binds 
to γC (Letzelter et al., 1998). This appears to be sufficient to cause the association of γC 
with the preformed IL-4/IL-4Rα complex on cell membrane leading to the activation of 
cell signaling.  
We then examined whether the low affinity between IL-4 and γC could be detected in 
the absence of IL-4Rα, using this TIR1/TIR2-based assay. IL4-TIR1 was co-expressed 
with γC-TIR2 in 293T cells. Co-expression of these two-hybrid receptors resulted in 
NF-κB activation in a dose-dependent manner (Fig. 3.4B). Addition of soluble IL-4 
(100 ng/ml) did not inhibit or enhance NF-κB activation. This shows that NF-κB 
activation observed with IL4-TIR1 and γC-TIR2 was due to over-expression of the two-
hybrid receptors which was also observed with IL4Rα-TIR1 and γC-TIR2 co-
expression. As another control, co-expression of pIL4Rα-TIR1, pγC-TIR1 or pIL4-
TIR1 with the irrelevant pβ5-TIR2 hybrid receptor (19 ng/well for each vector) caused 
little NF-κB activation which is in contrast with potent NF-κB activation caused by 
pαV-TIR1 and pβ5-TIR2 co-expression (Fig. 3.4C). These results suggest that, despite 
the background NF-κB activation caused by over-expression, this TIR1/TIR2-based 









Figure 3.4 IL-4 interacts 
with IL4Rα but not γC. 
(A) 293T cells were co-
transfected with the pIL4-
TIR1/pIL4Rα-TIR2 
plasmid pair at a series of 
dilutions as indicated. (B) 
The pIL4-TIR1/pγC-TIR2 
plasmid pair was co-
expressed in 293T cells at 
a series of dilutions as 
indicated. As a control, 
the pcDNA3.1 vector was 
also transfected at 300 
ng/well in both 
experiments. After 24 hr, 
transfected cells were 
either left unstimulated 
(grey bars) or stimulated 
with IL-4 for 12 hr at 100 
ng/ml (black bars). After 
stimulation cells were 
lysed to measure 
luciferase activities. (C) 
Co-expression of pIL4Rα-
TIR1, pγC-TIR1, pIL4-
TIR1 or as a positive 
control, pαV-TIR1 with 
pβ5-TIR2. All vectors 
were each used at 19 
ng/well. The luciferase 
reporter plasmids were 
similarly co-transfected. 
NF-κB activation was 
measured and presented 
as described in Fig. 3.3. 
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3.5  Detection of homotypic interactions between IL-4Rα and γC receptors  
Some receptors are constitutive homodimers or higher oligomers. As shown in Fig. 3.3 
co-expression of IL4Rα-TIR1 and γC-TIR2 at 19 ng/well was unable to induce NF-κB 
activation unless the cells were stimulated with IL-4.  Similarly, co-expression of IL4-
TIR1 and γC-TIR2 led to insignificant NF-κB activation (Fig. 3.4B). However, co-
expression of either the IL4Rα-TIR1/IL4Rα-TIR2 or γC-TIR1/γC-TIR2 hybrid receptor 
pair caused NF-κB activation in a constitutive manner (Fig. 3.5A and B). NF-κB 
activation mediated by both hybrid pairs sustained when each plasmid was reduced to 9 
ng/well. Increasing each plasmid to 150 ng/well did not further enhance NF-κB 
activation (Fig 3.5A and B). It suggests that NF-κB activation through both hybrid pairs 
reflected specific interactions between the paired hybrid receptors rather than over-
expression. Addition of soluble IL-4 at 100 ng/ml had no significant effect on the 
observed NF-κB activation. These results, together with the lack of NF-κB activation by 
the IL4Rα-TIR1/γC-TIR2 and IL4-TIR1/γC-TIR2 pairs under the same conditions, 
suggest homotypic interactions between the IL-4Rα and γC hybrid receptors through the 
IL-4Rα and γC EC domains. In another word, IL-4Rα and γC are likely to form homo 









Figure 3.5 Detection of homotypic IL-4Rα and γC interactions. (A) 293T cells were co-
transfected with the pIL4Rα-TIR1/pIL4Rα-TIR2 plasmid pair at a series of dilutions as indicated.
As a control, 293T cells were also transfected with pcDNA3.1 vector at 300 ng/ml. (B) 293T cells 
were co-transfected with the pγC-TIR1/pγC-TIR2 plasmid pair at a series of dilutions as indicated. 
As a control, the cells were tranfected with pcDNA3.1 vector at 300 ng/well. The luciferase 
reporter plasmids were also co-transfected in these experiments. After 24 hr, the cells were either 
left unsitmulated (grey bars) or stimulated for 12 hr with IL-4 at 100 ng/ml (black bars). NF-κB 
activation was determined as described in Fig. 3.3. The data was expressed as means of triplicate 
experiments ±SD. 
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Homotypic dimerization has not been reported for IL4Rα or γC. To verify this 
observation obtained with the TIR1/TIR2-based assay, immunoprecipitation studies 
were performed. Specifically, the pIL4Rα-TIR2 and pγC-TIR2 expression vectors were 
modified so that the sequences encoding the TIR2 domain in each hybrid receptor was 
replaced by that encoding the short Myc/His tags in the pcDNA3.1 vector, i.e. 
pIL4Rαtm-MH and pγCtm-MH (Fig. 2.5). Here ‘tm’ indicates the presence of the 
transmembrane domain which is expected to anchor the hybrid receptor to the cell 
membrane as for the TIR2 hybrids. The TIR2 domain is approximately 20 KDa in size 
(Gay and Keith, 1991; Medzhitov et al., 1997; Xu et al., 2000). Therefore these 
Myc/His-tagged hybrid receptors are expected to be 18 to 20 kDa smaller than IL4Rα-
TIR2 and γC-TIR2 respectively. These vectors were co-expressed in 293T cells with the 
pIL4Rα-TIR2 or pγC-TIR2. The Myc/His-tagged hybrid receptors were precipitated 
from cell lysates using either a myc antibody or the Ni-NTA-agarose beads. As shown 
in Fig. 3.6A, when pIL4Rαtm-MH and pIL4Rα-TIR2 were singly expressed in 293T 
cells, proteins of approximately 50 and 70 kDa (lanes 4 and 5) were detected in the cell 
lysate by Western blotting using an anti-IL4Rα antibody. These two protein species 









Figure 3.6 Homotypic IL-4Rα and γC interactions detected by immunoprecipitation. (A) 
293T cells were singly transfected with pcDNA3.1 (lane 6), pIL4Rα-TIR2 (lane 5), 
pIL4Rαtm-MH (lane 3 and 4) or co-transfected with the pIL4Rαtm-MH/pIL4Rα-TIR2 
plasmid pair (lane 1 and 2). Cells were lysed and the cell lysates were either directly subjected 
to SDS-PAGE (lanes 4-6) or after immunoprecipitation with an anti-myc antibody (lane 1 and 
3) or control isotype mouse IgG (lane 2). The proteins were separated on 10% (w/v) gels 
under reducing conditions and detected by Western blotting using an anti-IL4Rα antibody. 
The TIR2 hybrid receptor was indicated with an arrow head and the Myc/His-tagged hybrid 
molecules in which the TIR1 domain was replaced by the Myc/His tags was indicated with an 
arrow. (B) 293 T cells were singly transfected with pcDNA3.1 (lane 1), pγC-TIR2 (lane 7), 
pγCtm-MH (lane 4 and 6) or co-transfected with the pγC-TIR2/pγCtm-MH plasmid pair 
(lanes 2 and 3). Cells were lysed and the cell lysates were either directly subjected to SDS-
PAGE (lanes 1, 6 and 7) or after immunoprecipitation with Ni-NTA-agarose, which 
precipitates γCtm-MH, followedd by elution with immidazole (lanes 2-5). The first (lane 2 
and 4) and second (lane 3 and 5) fractions of the eluted proteins were analyzed. The proteins 
were separated on 10% (w/v) gels under reducing conditions and detected by Western blotting 
using an anti-γC antibody expected to detect both γC-TIR2 and γCtm- MH. γC-TIR2 was 
indicated with an arrow head and  γCtm-MH was indicated by an arrow. 
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When the two-hybrid molecules were co-expressed in 293T cells and IL4Rαtm-MH was 
immunoprecipitated with an anti-myc antibody, a 50 kDa protein equivalent to 
IL4Rαtm-MH in size was detected using an anti-IL4Rα antibody (Fig. 3.6A, lane1). A 
70 kDa protein, which is equivalent to IL4Rα-TIR2 in size, was also detected with the 
anti-IL-4Rα antibody in the precipitated proteins (Fig. 3.6A, lane1). Neither protein was 
precipitated when an isotype-matched mouse IgG was used to mimic IL4Rαtm-MH 
precipitation (Fig. 3.6A, lane 2).  When IL4Rαtm-MH was expressed alone, the 50 KDa 
protein was precipitated with the anti-myc antibody without the co-precipitation of the 
70 kDa protein (Fig. 3.6A, lane 3.). These results show that the EC domains of IL-4Rα 
interact with each other. Whether the interactions lead to formation of stable 
homodimers or higher oligomers is unclear. Endogenous wild type IL-4Rα needs 
investigation to assess the implications of such interactions. In Fig 3.6A (lanes 4 and 5) 
a protein of approximately 60 KDa was observed. These two lanes contained lysates of 
293T cells singly transfected with pIL4Rαtm-MH or pIL4Rα-TIR2. These were not 
observed in pcDNA3.1-transfected cells. They are likely to represent differentially 
modified isoforms of IL4Rαtm-MH and IL4Rα-TIR2. Since these proteins co-migrated 
with the heavy chain of IgG, we could not determine whether they were precipitated in 
lanes 1 and 3 (Fig. 3.6A) 
The γC-TIR1/γC-TIR2 interaction detected using the two-hybrid assay (Fig. 3.6B) was 
also verified by biochemical studies. In this experiment, the anti-myc antibody was not 
used to precipitate γCtm-MH as γC-TIR2 was expected to co-migrate with the heavy 
chain of the IgG antibody on SDS-PAGE. Therefore, it was precipitated using Ni-NTA-
agarose which binds to the His tag on γCtm-MH. Bound proteins were eluted using 
immidazole. When γCtm-MH and γCtm-TIR2 were singly expressed in 293T cells and 
detected by Western bloting using an anti-γC antibody, the two hybrid receptors were 
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detected as proteins of approximately 55 and 75 kDa respectively (Fig. 3.6B, lanes 6 
and 7). When 293T cells were transfected with pcDNA3.1, neither protein was detected 
in the cell lysate (Fig. 3.6B, lane 1). When γCtm-MH and γC-TIR2 were co-expressed, 
Ni-NTA-agarose precipitated the 55 kDa protein, equivalent to γCtm-MH in size. A 75 
kDa protein, which is equivalent to γC-TIR2 in size, was co-precipitated (Fig. 3.6B, 
lanes 2 and 3). When γCtm-MH was expressed singly, it was precipitated as a 55 kDa 
protein using Ni-NTA-agarose (Fig. 3.6B lanes 4 and 5). In this case, the 75 KDa 
protein was not detected in the precipitate. These results show that the EC domain of γC 

















Figure 3.7 Detection of constitutive IL-4/IL-4 interactions. (A) Detection of homotypic 
interactions between IL-4 using the TIR1/TIR2-based assay. 293T cells were co-transfected 
with the pIL4-TIR1/pIL4-TIR2 plasmid pair at a series of dilutions as indicated. As a control, 
pcDNA3.1 (empty) vector was also transfected at 300 ng/well. After 24 hr, the cells were either 
left unstimulated (grey bars) or stimulated for 12 hr with IL-4 at 100 ng/ml (balck bars). NF-κB 
activation was measured as described in Fig. 3.4. The data are expressed as means of triplicate 
experiments. (B) Detection of homotypic IL-4 interaction by immunoprecipitation. 293T cells 
were singly transfected with pcDNA3.1 (lane 6), pIL4-TIR2 (lane 5), pIL4tm-MH (lanes 1 and 4) 
or co-transfected with the pIL4tm-MH/pIL4-TIR2 plasmid pair (lane 2 and 3). Cells were lysed 
and the cell lysates were either directly subjected to SDS-PAGE (lanes 4-6) or after 
immunoprecipitation with the anti-myc antibody (lanes 1 and 2) or isotype mouse IgG (lane 3). 
The proteins were separated on 10% (w/v) gels under reducing conditions and detected by 
Western blotting using an anti-IL4 antibody. The TIR2 hybrid receptor was indicated with an 
arrow head and Myc/His-tagged hybrid molecule was indicated with an arrow. 
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3.6  Detection of interactions between secreted proteins 
As shown in Fig. 3.7A, co-expression of pIL4-TIR1 and pIL4-TIR2 led to potent NF-
κB activation when the plasmids were used at 19 ng/well each. Reducing the plasmid 
dosage each to 9 ng/well did not significantly reduce the observed NF-κB activation and 
increasing the plasmid dosage to 150 ng/well did not enhance the observed NF-κB 
activation. This suggests that the observed NF-κB activation reflects specific homotypic 
interactions between IL-4, when expressed as the EC domains of the hybrid receptors. 
The homotypic IL-4 interaction detected with the TIR1/TIR2-based assay was also 
verified by biochemical studies. The pIL4-TIR2 plasmid was modified so that sequence 
encoding the TIR2 domain was replaced by that encoding the Myc/His-tag (Fig. 2.5). 
The resultant vector, i.e. pIL4tm-MH, expresses the IL4tm-MH molecule. When IL4tm-
MH and IL4-TIR2 were singly expressed in 293T cells, proteins of approximately 22 
kDa and 40 kDa were detected in the cell lysates using an anti-IL-4 antibody (Fig. 3.7B, 
lanes 4 and 5). These two protein species were not detected in 293T cells transfected 
with pcDNA3.1 (Fig. 3.7B, lane 6). When IL4tm-MH was singly expressed, the anti-
Myc antibody only precipitated the 22 kDa protein (Fig. 3.7B, lane 1). When IL4-TIR2 
was co-expressed with IL4tm-MH, IL4-TIR2 was co-precipitated with IL4tm-MH using 
the anti-myc antibody (Fig. 3.7B, lane 2). When a control mouse IgG was used in place 
of the anti-myc antibody, neither hybrid molecule was precipitated from the co-
transfected 293T cells (Fig. 3.7B, lane 3). Taken collectively, these results suggest 
homotypic interaction of IL-4 at least when it is expressed on the cell surface as the EC 
domains of the hybrid receptors. It is unclear  from three-dimensional crystallography 
(Walter et al., 1992; Wlodawer et al., 1992) or NMR (Powers et al., 1992; Smith et al., 
1992) study whether IL-4 exist as dimer in nature. However, it is possible that IL-4 like 
other cytokines such as MCSF (Pandit et al., 1992), IL-5 (Devos et al., 1993; Karlen et 
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al., 1998) and IFN-γ (Greenlund et al., 1993; Walter et al., 1995) may form dimer by 
presenting its distinct and identical surfaces to attract the second receptor molecule to 
the initial complex of IL-4/IL-4Rα. This binding may result in the generation of 
intracellular signals initiating their effector function.   
3.7  Conclusion 
In this part of the study, it has been shown that the TIR1/TIR2-based two-hybrid assay 
can detect the known interactions betweenIL-4 and IL-4 receptor subunits (i.e. IL4Rα 
and γC). Novel homotypic interactions of IL- 4, IL4Rα and γC were also detcted using 
this TIR1/TIR2-based assay and these interactions were further confirmed by 
immunoprecipitation studies. These findings have important implications. Firstly, this 
TIR1/TIR2-based assay proves to be an easy and direct method to investigate the 
interactions between secreted proteins, i.e. soluble and secreted proteins or membrane-
bound proteins. Secondly, many receptors transduce cell signaling through ligand-
induced dimerization of different receptor subunits. This assay allows the investigation 
of three-way protein-protein interactions in live cells i.e. ligand and two recptor 
subunits. Thirdly, the convenience to express any protein as the EC domain in fusion 
with TIR1 or TIR2 would allow the identification of novel protein-protein interactions 
at increased throughput. Finally, this method complements with the yeast two-hybrid 
method allowing detection of interaction between secreted/membrane proteins whereas 
the latter detects mainly interactions between cytoplasmic proteins. This method can be 
used for drug development by screening for inhibitors of protein-protein interactions. 
The application of this TIR1/TIR2-based two-hybrid assay in the understanding of 
CD14-CD14 interaction is documented in the next chapter.   
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Chapter 4 Investigation of CD14 dimerization and its role in CD14 
signal transduction  
In this chapter the TIR1/TIR2-based two-hybrid assay was used to examine whether 
CD14 forms dimers. CD14 is a GPI-anchored protein, expressed on the surface of 
monocytes, macrophages, and polymorphonuclear leukocytes (Simmons et al., 1989). It 
is responsible for the effects of LPS on these cells (Wright et al., 1990; Hailman et al., 
1994). The role of CD14 in LPS signaling has been confirmed using CD14 knock-out 
mice. CD14-deficient mice are highly resistant to septic shock upon injection of LPS or 
live bacteria (Haziot et al., 1996). Structurally, crystallography studies have indicated 
that CD14 may form dimers on the cell surface (Kim et al., 2005), but the functional 
relevance of CD14 dimerizaiton has not been addressed. Therefore it is of interest to 
examine CD14-CD14 interactions and how this modulates its function as the LPS 
receptor. The TIR1/TIR2-based two-hybrid assay will be applied in this investigation. 
 
4.1  Detection of homotypic interaction between CD14 using the TIR1/2-based 
assay 
Soluble mouse CD14 forms a dimer in the crystallographic asymmetric unit as well as 
in solution (Kim et al., 2005). To verify if CD14 forms dimers on the cell surface, its 
EC domain were expressed as TIR1 and TIR2 fusion proteins, i.e. CD14-TIR1 and 
CD14-TIR2 (Fig. 2.4). 293T cells were co-transfected with these two plasmids at 1:1 
ratio and different plasmid dosages were used from 19 to 300 ng/well. Total plasmid 
dosage in all experiments was normalized to 300 ng/well using the pcDNA3.1 vector. 
As a negative control, 293T cells were transfected with the plasmids pCD14-TIR1, 
pCD14-TIR2 or pcDNA3.1 individually. Luciferase reporter plasmids were also co-
transfected in every experiment. In some experiments the transfected cells were treated 
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for 12 hr with LPS (500 ng/ml) 24 hr after transfection. Interaction between CD14-TIR1 
and CD14-TIR2 was judged by the activation of NF-κB.  
Transfection of 293T cells with pCD14-TIR1 or pCD14-TIR2 alone (300 ng/well) did 
not lead to NF-κB activation (Fig. 4.1A). Similarly, NF-κB activation was not increased 
in 293T cells transfected with the pcDNA3.1 vector. However, co-transfection of 293T 
cells with pCD14-TIR1 and pCD14-TIR2 caused NF-κB activation. Decrease of 
plasmid dosage to 19 ng/well did not reduce NF-κB activation. Increasing each plasmid 
to 150 ng/well did not further increase NF-κB activation (Fig. 4.1A). This suggests that 
the NF-κB activation observed after CD14-TIR1 and CD14-TIR2 co-expression 
reflected CD14-CD14 interactions rather than over-expression of the hybrids. Addition 
of soluble LPS to the transfected 293T cells had no significant effect on the observed 
NF-κB activation (Fig. 4.1A). As another set of controls, pIL4Rα-TIR1 or pβ5-TIR1 
was used to co-transfect 293T cells with pCD14-TIR2 (each 19 ng/well). Co-expression 
of IL4Rα-TIR1 or β5-TIR2 with CD14-TIR2 caused little NF-κB activation (Fig. 4.1B). 
In contrast, co-expression of CD14-TIR1 and CD14-TIR2 led to potent NF-κB 
activation further excluding the possibility that over-expression of CD14-TIR1 and 
CD14-TIR2 caused the observed NF-κB activation (Fig. 4.1B). Collectively, these 




















Figure 4.1 Detection of CD14-CD14 homotypic interaction using the TIR1/TIR2-based 
assay. (A) 293T cells were transfected with pCD14-TIR1 and pCD14-TIR2. The two 
plasmids were used at a 1:1 ratio and the combined plasmid dosage in each experiment was as 
indicated. Total expression vector in each experiment was normalized to 300 ng/well with 
pcDNA3.1. As controls, the cells were singly tranfected with the pCD14-TIR1, pCD14-TIR2 
or the pcDNA3.1 plasmid at 300 ng/well. In all experiments, cells were also co-transfected 
with the p5xNF-κB-luc and pRL-CMV reporter plasmids each at 100 ng/well. After 24 hr, 
transfected cells were either left unstimulated (grey bar) or stimulated (black bar) with LPS 
for 12 hr at 500 ng/ml. NF-κB-directed firefly luciferase and CMV-directed Renilla luciferase 
expression were determined using the Dual Luciferase assay (Promega). NF-κB activation 
was presented after being normalized to the Renilla luciferase activity and expressed as the 
percentage of the latter. (B) pIL4Rα-TIR1, pβ5-TIR1 or pCD14-TIR1 was co-expressed with 
pCD14-TIR2. Each vectors were used at 19 ng/well. The luciferase reporter plasmids were
co-transfected and NF-κB activation was determined using luciferase assay. As a control, 
293T cells were also tranfected with pcDNA3.1 (300 ng/well). Results are shown as means 
±SD and representative of at least three independent experiments.   
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4.2  Identification of amino acid residues involved in CD14-CD14 interactions 
To investigate the amino acid residues requires for CD14 homo-dimerization, 
mutagenesis of CD14 was carried out on the conserved residues located on β13 and the 
‘loop’ between β12 and β13. This region has been indicated in CD14-CD14 
dimerization in the crystallography study (Kim et al., 2005). Firstly, two CD14 deletion 
mutants were generated in CD14-TIR1 removing amino acids 290-300 (the ‘loop’ 
between β12 and β13) or 301-315 (β13) which were named loopdelCD14-TIR1 and 
β13delCD14-TIR1 respectively. Details of the deletions are described in section 2.5. 
293T cells were co-transfected with CD14-TIR2 and one of these deletion mutants 
(each 19 ng/well). After 24 hr, luciferase activity of 293T cells was measured. Co-
expression of either deletion mutant with CD14-TIR2 showed significantly reduced NF-
κB activation compared to 293T cells co-transfected with CD14-TIR1 and CD14-TIR2 
(Fig. 4.2A).  
 
Next, specific amino acids in β13 and the ‘loop’ between β12 and β13 of CD14 were 
mutated into alanine by site-directed mutagenesis (chapter. 2.5, Table 2.5). Alanine 
substitution is widely used because it is a small amino acid commonly found in proteins, 
occurring in all secondary structures without particular steric requirement (Wells, 1991). 
Such substitutions allows for the elimination of functional properties of the original 
residues without disturbing local protein conformation. The follwoing alanine 
substitutions were introduced to the pCD14-TIR1 vector, i.e. L290A, P294A, E298A, 
L299A, P300A, V302A, L305A, and L307A. These CD14-TIR1 mutants were co-
transfected with CD14-TIR2 into 293T cells and each plasmid was used at 19 ng/well. 
After 24 hr, luciferease activity was measured. As shown in Fig. 4.2B, co-expression of 
P294ACD14-TIR1 or P300ACD14-TIR1 with CD14-TIR2 caused partially but 
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significantly reduced NF-κB activation compared to the CD14-TIR1/CD14-TIR2 co-
expression. Co-expression of L290ACD14-TIR1 or L307ACD14-TIR1 with CD14-
TIR2 caused more significant reduction in NF-κB activation compared to CD14-
TIR1/CD14-TIR2 co-expression (Fig. 4.2B). However, co-expression of double mutants 
CD14-TIR1 (L290A,L307A) with CD14-TIR2 caused reduction of NF-κB activation to 
almost background level (as shown by the control pcDNA3.1). The rest alanine 
substitutions on CD14-TIR1 (i.e. E298A, L299A, V302A and L305A) had no effect on 
its ability to cause NF-κB activation when co-expressed with CD14-TIR2 (Fig. 4.2B). 
These results suggest that L290 in the ‘loop’ and L307 in β13 are critical to CD14-



















Figure 4.2 Effects of CD14 deletions and point mutations in its loop between β12/β13 and 
β13 on its dimerization. (A) 293T cells were co-transfected with pCD14-TIR1/pCD14-TIR2 
as a positive control. 293T cells were also co-transfected with ploopdelCD14-TIR1 or 
pβ13delCD14-TIR1 deletion mutant and pCD14-TIR2 (each at 19 ng/well). (B) 293T cells 
were co-transfected with CD14-TIR2 and either pCD14-TIR1 or one of the residue specific 
pCD14-TIR1 mutants as indicated. As a negative control, pcDNA3.1 was used to transfect 
293T cells at 300 ng/well in both experiments. The luciferase reporter plasmids were also co-
transfected. NF-κB activation was determined using the luciferase assay. Results are 
expressed as mean ±SD of triplicate experiments and each is representative of three similar 
experiments. * Significant difference (p≤ 0.002) was observed between specific mutants 
CD14-TIR1/CD14-TIR2 and CD14-TIR1/CD14-TIR2. 
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4.3  Effect of CD14 mutations on LPS-induced NF-κB activation and IL-8 
production 
While CD14 binds to LPS, it requires the TLR4/MD-2 complex to activate cellular 
signaling (Shimazu et al., 1999; Akashi et al., 2000; Yang et al., 2000). TLR4-mediated 
NF-κB activation was investigated in association with WtCD14 and CD14 mutants. 
Vectors for WtCD14 and mutant CD14 were used at 20 ng/well and vectors for TLR4 
and MD2 were each used at 5 ng/well. After 24 hr, the cells were stimulated with LPS 
(500 ng/ml) for another 12 hr. As shown in Fig. 4.3A, the P294A and P300A CD14 
mutants exhibited reduced NF-κB activation in response to LPS compared to WtCD14. 
The E298A, L299A, V302A, and L305A CD14 mutants showed no difference from 
WtCD14 (Fig. 4.3A). The L290A and L307A mutants exhibited markedly reduced NF-
κB activation compared to WtCD14 (Fig. 4.3A). These two mutations, when introduced 
in CD14-TIR1, also caused the most reducion in NF-κB activation (Fig. 4.2B). The 
effects of these CD14 mutations on LPS-induced IL-8 production from 293T cells were 
also examined. 293T cells co-transfected with the L290A and L307A CD14 mutants 
also produced the least IL-8 upon LPS stimulation (Fig. 4.3B). However, double 
mutation of two leucine (L290A and L307A), reduced NF-κB activation and IL-8 
production to 70% of WtCD14. Whether the loss of LPS responsiveness by these 
double mutants is due to their low level of surface expression will be addressed in the 
following section. Other CD14 mutations showed no difference from WtCD14 in 
mediating LPS-induced IL-8 production (Fig. 4.3B). The P294A and P300A mutants 
rendered slightly reduced IL-8 production (Fig. 4.3B). In summary, amino acids L290 
and L307, which are required for CD14-CD14 interactions (Fig. 4.2B), are also 












Figure 4.3 Effect of CD14 mutations on its response to LPS.  (A) 293T cells were transfected 
either with wild-type (Wt) CD14 plasmid (40 ng), or the mutant CD14 plasmid indicated (40 
ng), together with TLR4 (5 ng) and MD2 (5 ng) plasmids. As a control, the cells were 
transfected with the pcDAN3.1 plasmid at 300 ng/well. The cells were also co-transfected with 
the p5xNF-κB-luc and pRL-CMV luciferase reporter plasmid (200 ng/well). After 24 hr, 
transfected cells were stimulated with LPS at 500 ng/ml for 12 hr and processed for the 
determination of both NF-κB-directed firefly luciferase and CMV-directed Renilla luciferase 
activities using Dual luciferase assay system (Promega). Firefly luciferase activity, which 
reflects NF-κB activation, was normalized to the Renilla luciferase activity. The final values 
were expressed as a percentage of the latter. All results are representative of at least three 
similar experiments and are presented as means ± S.D. (B) Cell free supernatants were assayed 
for IL-8 production from the same experiments by ELISA. Results are the average of triplicate 
wells ± S.D.  * Significance difference (p< 0.05) was observed between specific mutantsCD14 
indicated and WtCD14. 
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LPS. It also shows that CD14 dimerization or oligomerization is physiologically 
relevant and can potentially modulate host response to LPS. 
 
4.4  Cell surface expression of CD14 and its mutants 
Differential expression of the CD14 mutants may also occur which in turn affects NF-
κB activation. This was examined by surface biotinylation of transfected 293T cells 
using a membrane-impermeable biotinylaion reagent. The biotinylated proteins were 
precipitated with streptavidin-agarose beads and the proteins were eluted in an SDS-
sample buffer. The proteins were analyzed by Western bloting with an anti-CD14 
polyclonal antibody. As a control, a duplicate copy of the blot was probed using an anti-
β-actin monoclonal antibody (Fig. 4.4A). Without surface biotinylation, CD14-TIR1 
and CD14-TIR2 were not detected in the precipitate lysates showing that CD14-TIR1 
and CD14-TIR2 were not specifically precipitated with strepavidin beads (Fig. 4.4A). 
With surface biotinylation, CD14-TIR1 and CD14-TIR2 were detected in the cell 
lysates with a molecular weight of 75 KDa (Fig. 4.4A). The deletion mutants 
loopdelCD14-TIR1 and β13delCD14TIR1 showed similar levels of expression as 
CD14-TIR1 (Fig. 4.4A). The total proteins loaded for each lysate were similar as shown 
by the similar levels of β-actin detected in the blot (one on a parallel blot) (Fig. 4.4A,). 
It shows that these deletions had no significant effect on CD14 expression. But these 
mutations reduced CD14-CD14 interaction and response to LPS (Fig. 4.2 and Fig 4.3) 
The CD14-TIR1 single residue mutants, i.e L290A, P294A, E298A, L299A, P300A, 
V302A, L305A and L307A were similarly expressed in 293T cells and detected by 
western bloting. As a negative control, the cells were also transfected with the 
pcDNA3.1 vector. No signal was detected in the lysates of control 293T cells (Fig. 
4.4B, upper panel). Biotinylated CD14-TIR1 mutants, i.e. L290A, P294A, E298A, 
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L299A, P300A, V302A, L305A and L307, were all detected in the respective cell 
lysates as a 75 KDa band. All CD14-TIR1 mutants were efficiently expressed on the 
cell surface. No significant difference was observed between the different mutants and 
the original CD14-TIR1 (Fig. 4.4B).  
 
The expression of full-length CD14 on transfected 293T cells was also examined by 
surface biotinylation and Western blotting. WtCD14 and CD14 mutants (i.e.L290A, 
P294A, E298A, L299A, P300A, V302A, L305A and L307A) were expressed in 293T 
cells and later subjected to biotinylation and Western blotting. As shown in Fig.  4.4C 
(upper panel), the expression levels of the CD14 mutants are largely compatible to that 
of WtCD14 despite some minor variations. The protein band detected on this blot is 55 
KDa in size which is equivalent to full-length CD14. As a negative control, CD14 was 
not detected in the lysates of pcDNA3.1-transfected cells. Protein loading for each 
sample was indicated based on the level of β-actin which is apparently similar (Fig. 
4.4B and 4.4C, lower panels). These results suggest that the reduced NF-κB activation 
and/or IL-8 induction by some CD14 mutants, especially L290A and L307A, is not due 
to significantly differential expression of these mutants. However, double mutation of 
two leucine (L290 and L307) in CD4-TIR1 (Fig. 4.4B) and full-length CD14 (Fig. 
4.4C) resulted in the complete loss of surface expression compared to the respective 
single leucine mutants. These double mutants have significantly reduced CD14-
TIR1/CD14-TIR2 mediated NF-κB activation (Fig. 4.2B) and LPS responsiveness (Fig. 
4.3). Double mutation of L290 and L307 probably affected the structural integrity of the 
region, resulting in loss of expression levels of both CD14-TIR1 and the full-length 
CD14.   
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Figure 4.4 Cell-surface expressions of CD14 and CD14 mutants. (A) 293T cells were 
transfected with either pCD14-TIR1, pCD14-TIR2 or the CD14-TIR1 deletion mutants 
(loopdelCD14-TIR1 and β13delCD14-TIR1) in 6-well plates (3 µg/well). (B) 293T cells were 
transfected with pcDNA3.1, pCD14-TIR1, or vectors for the CD14-TIR1 single residue mutants 
(L290A, P294A, E298A, L299A, P300A, V302A, L305A and L307A) and double mutants 
(L290A,L307A) in 6-well plates (3 µg/well). (C) 293T cells were similarly transfected with 
pcDNA3.1, WtCD14, or CD14 single residue mutants (3 µg/well). After 36 hr, the cells were 
surface biotinylated with membrane-impermeable biotin, and then lysed with lysis buffer. 
Biotynylated membrane proteins were precipitated from the lysates by incubation with 
streptavidin-agarose beads. After washing, the beads were boiled in SDS sample buffer under 
reducing conditions. The eluted proteins were separated on 10% (w/v) SDS-PAGE gels and 
analyzed by Western blotting using an anti-CD14 polyclonal antibody and a similar blot was 
probed using an anti-β-actin monoclonal antibody.  
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4.5  Detection of CD14 homotypic interaction on the cell surface by cross-
linking studies 
Having shown that CD14 form homotypic interactions using the TIR1/TIR2-based two-
hybrid assay, identified specific residues involved in CD14-CD14 interactions, and 
demonstrated that mutation of these residues altered CD14 signaling for NF-κB 
activation and IL-8 production, the roles of these residues in CD14-CD14 interaction 
were further verified using a conventioned cross-linking method. 293T cells were 
transfected to express WtCD14 or the CD14 mutants (L290A, P294A, E298A, L299A, 
P300A, V302A, L305A or L307A). pcDNA3.1-transfected 293T cells were used as a 
control. Cell surface proteins were cross-linked using dithiobis (sulphosuccinimidyl 
propionate), a membrane-impermeable bifunctional cross-linking reagent. It has an 
amine reactive N-hydroxysulfosuccinimide (sulfo-NHS) ester at each end of the 
molecule with a cleavable 12-A◦ spacer arm containing a disulfide bridge. Thus proteins 
that are in close proximity on the cell surface are cross-linked with this reagent. The 
cells were then lysed and total proteins were seperated on SDS-PAGE in the presence or 
absence of the reducing agent β-mercaptoethanol that breaks the disulfide bridge and 
allows cross-linked proteins to be separated and migrate as separate bands on SDS-
PAGE. Without a reducing reagent, cross-linked proteins migrate together on SDS-
PAGE as dimers or oligomers. 
 
Under reducing conditions a 55 KDa band corresponding to CD14 monomers was 
detected in 293T cells that were tranfected to express WtCD14 and the CD14 mutants 
(Fig. 4.5A). The levels of expression were similar. Under non-reducing conditions, 
besides the 55 KDa band, a heterogenous group of high molecular weight CD14-
containing complexes (> 80 kDa) were also detected in 293T cells that were transfected 
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to express WtCD14 (Fig. 4.5B). Thus CD14 may exist as monomer on the cell surface, 
but dimers or higher oligomers also exist. The existance of CD14 dimers was also 
indicated in crystallographic structure and it showed that these dimers were made up of 
the same CD14 monomer subunits. The subunit was indicated to be the β13 and the 
loop of β12 and β13 (Kim et al., 2005). The CD14-containing high molecular weight 
materials were also found in the lysates of CD14 mutants that exhibited normal NF-κB 
activation and IL-8 induction. But it is poorly detected in cell lysates of CD14 mutants 
that exhibited reduced capacity in mediating LPS-stimulated signaling in transfected 
293T cells (i.e. L290A, L307A, P294A and P300A) (Fig. 4.5B). After inter-molecular 
linkages are disrupted, the high molecular weight materials returned to the 55 kDa form 
(Fig 4.5A). These proteins were not detected in cells tranfected with pcDNA3.1 
showing the specificity of the anti-CD14 antibody (Fig. 4.5A and B). These results 
suggest that amino acids L290, L307 and possibly P294 and P300 contribute to CD14 














            
 






Figure 4.5 Detection of CD14-CD14 dimers. 293T cells were singly transfected either 
with WtCD14 or CD14 mutants (i.e. L290A, P294A, E298A, L299A, P300A, V302A, 
L305A and L307A) in 6-well plates (3 µg each). After 36 hr, the cells were washed and 
exposed to the membrane-impermeable cross-linking reagent. Cell lysates were prepared 
using a lysis buffer and separated on 10% (w/v) SDS-PAGE gels under reducing (Fig. 4.5A)
and non-reducing (Fig. 4.5B) conditions. The proteins were detected by Western bloting 
using a polyclonal antibody against human CD14. The molecular weight standards were 
indicated on the left.  
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4.6  Conclusion 
In this study, the TIR1/TIR2-based two-hybrid assay has been used to investigate 
CD14-CD14 interactions and it showed that the CD14 EC domain form homo-dimers or 
homotypic interactions. The β13 sheet and the ‘loop’ between β12 and β13 were 
predicted, based on the CD14 crystal structure, to mediate CD14-CD14 interactions. By 
mutagenesis studies, in combination with the two-hybrid assay, allowed the 
identification of amino acids L290 and L307 in this region was found to be important in 
CD14-CD14 inteactions. These two residues are also required for TLR4-mediated LPS 
signalling of NF-κB activation. These findings have provided new insights into the 
mechanism by which CD14-CD14 interaction regulates LPS signalling and new assays 
















Chapter 5 Investigation of FcγR activation 
5.1  Investigation of FcγRIIA signalling through IL-4 induced dimerization: a 
modified two-hybrid assay 
In chapters 3 and 4, the TIR1/TIR2-based two-hybrid assay has proved to be a feasible 
method in detecting protein-protein interactions on cell membrane. The IL-4-induced 
IL-4Rα and γC dimerization was used to demonstrate the feasibility of using TIR1 and 
TIR2 to detect protein-protein interactions. Here, the IL-4/ IL-4R system was also used 
to investigate whether FcγRs can be activated upon induction of dimerization. In this 
case, the transmembrane and cytoplasmic domains of TLR1 in the IL4Rα-TIR1 and γC-
TIR1 chimeras were replaced by that of FcγRIIA to generate the IL4Rα-FcγRIIA and 
γC-FcγRIIA chimeras. The rationale is that, IL-4 induces the EC domains of IL-4Rα 
and γC to dimerize and this should cause dimerization of the FcγRIIA cytoplasmic 
domain. Whether FcγRIIA dimerization elicits FcγRIIA signaling is monitored by 
examining NF-κB activation and IL-8 production. 
  
The expression of the pIL4Rα-FcγRIIA and pγC-FcγRIIA chimeras on transfected 293T 
cells was examined by flow cytometry using the anti-IL4Rα and anti-γC antibodies as 
described in chapter 3 (section 2) and both chimeric receptors were detected on the cell 
surface (Fig. 5.1A). To examine whether FcγRIIA dimerization activates FcγRIIA 
signaling, the two chimeras were co-expressed on 293T cells and the cells were 
stimulated with IL-4. NF-κB activation was measured. As shown in Figure 5.1B, co-
expression of pIL4Rα-FcγRIIA and pγC-FcγRIIA in 293T cells did not induce NF-κB 
activation irrespective of the plasmid dosages (38 or 300 ng/well). Addition of IL-4 also 
failed to induce NF-κB activation in the transfected cells. As a positive control, while 
co-expression of pIL4Rα-TIR1 and pγC-TIR2 (38 ng/well) did not cause NF-κB 
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activation, it was induced by IL-4 (Fig. 5.1B). This seems to suggest that FcγRIIA 
dimerization might not be sufficient to cause FcγRIIA signaling and induce NF-κB 
activation. It is unclear from this experiment whether other siganling events may be 
elicited in the IL-4 induced FcγRIIA dimerization. Similarly, while IL-8 production was 
induced with IL-4 when 293T cells were transfected with p IL4Rα-TIR1 and γC-TIR2, 
it was not induced when the cells were transfected with IL4Rα-FcγRIIA and γC-



























FcγRIIA and pγC-FcγRIIA 
were individually expressed 
in 293T cells at 150 ng/ml 
and the expression of these 
hybrid receptors were 
examined by flow 
cytometry using specific 
monoclonal antibodies for 
IL4Rα and γC. The filled 
profiles are signals obtained
from 293T cells transfected 
with the pcDNA3.1 vector. 
Open profiles represent 
signals detected on 293T 
cells transfected with the 
expression vectors. (B) The
pIL4Rα-FcγRIIA/pγC-
FcγRIIA and pIL4Rα-
TIR1/pγC-TIR2 vector pairs 
were co-expressed in 293T 
cells as indicated and NF-
κB activation was 
determined using the 
luciferase assay. As a 
control, the pcDNA3.1 
vector was used to transfect 
293T cells. (C) Cell free 
supernatants were assayed 
for IL-8 production from the 
same experiments by 
ELISA. Results are the 
average of triplicate wells 
±SD. 
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5.2  Full-length FcγRIIA can mediate NF-κB activation and IL-8 production in 
transfected 293T cells in response to IgG-opsonized DH5α but not IgG-beads 
Since IL-4, which was expected to induce FcγRIIA dimerization in this experimental 
setting in 293T cells, did not induce NF-κB activation, it was asked whether wild type 
FcγRs were able to activate NF-κB upon expression in 293T cells. Full-length (FL) 
FcγRIIIA and FcRγ were also cloned and expressed in 293T cells as comparison. The 
surface expression of FcγRIIA and FcγRIIIA on transfected 293T cells was examined 
by flow cytometry. FcγRIIIA was undetectable on the cells unless FcRγ was co-
expressed (Fig. 5.2). However, FcγRIIA expression on transfected 293T cells was 
independent of FcRγ co-expression (Fig. 5.2). It was previously reported that FcRγ 
expression facilitated cell surface expression of some Fc receptors and FcγRIIIA was 
not detected on the surface of cells derived from FcRγ knock out mice (Takai et al., 
1994). When FcγRIIIA was expressed in COS-1 cells, only trace amounts of the 
receptor was detected on the cell surface if FcRγ was not co-expressed (Park et al., 
1993). The structural requirement of FcRγ for cell surface expression of FcγRIIIA was 
demonstrated in transfected COS-1 cells (Lanier et al., 1991; Kim et al., 2003). These 
data indicated that specific sequences in the transmembrane domain of FcRγ including 
cysteine Cys7 and aspartic acid Asp11 govern its interaction with FcRγIIIA which 









Next, FcγRIIA and FcγRIIIA signaling, in the transfected 293T cells were examined by 
stimulating these cells with IgG-beads. A previous study showed that IgG-beads (which 
represent IgG-coated bacteria) can induce TNF-α secretion from macrophages 
(Loegering and Lennartz, 2004). In our system, when 293T cells were transfected to 
express FcγRIIA, it did not induce significant NF-κB activation in response to IgG-
beads (Fig. 5.3). Co-expression of FcγRIIIA and FcRγ chain also did not induce NF-κB 
activation. In contrast, 293T cells transfected to express FcγRIIA showed increased NF-
κB activation and produced IL-8 upon IgG-DH5α stimulation (Fig. 5.4A and B). It is 
unclear why the IgG-DH5α, but not the IgG-beads, could acitvate FcγRIIA signaling? 
An explanation could be that E.coli DH5α being more complex, has other molecules on 
Figure 5.2 Surface expression of wild type (WT) FcγRIIA and FcγRIIIA on transfected 
293T cells. 293T cells were transfected with expression vectors for wild type FcγRIIA and 
FcγRIIIA or co-transfected with vectors for FcγRIIIA and FcR γ chain. All plasmids were 
used at 150 ng/well in 24-well plates. These receptors were detected by flow cytometry using 
monoclonal antibodies specific for FcγRIIA and FcγRIIIA. The filled profiles are signals 
obtained from 293T cells transfected with pcDNA3.1. Open profiles represent specific signals 
detected on 293T cells transfected with the FcγRIIA and FcγRIIIA expression vectors. 
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the cell surface that possibly interact with receptors on 293T cells. There may also be a 
co-receptor involved in eliciting NF-κB activation. Cross-talk between receptors is 
biologically relevant; as cells in vivo are not stimulated by one receptor in isolation (i.e. 
293T cell transfected single receptor) but rather by many surface receptors working 








However, 293T cells that were co-transfected to express FcγRIIIA and FcRγ did not 
induce NF-κB activation and IL-8 produciton (Fig. 5.4A and B). It is not clear whether 
the functional discrepancy between FcγRIIA and FcγRIIIA was due to the different 
levels of expression of these receptors on the 293T cells (Fig. 5.2) or it was due to 
intrinsic differences between the two receptors in their signaling properties (Indik et al., 
1995; Kim et al., 2001).  
Figure 5.3 Full-length (FL) FcγRIIA mediates NF-κB activation in response to IgG-
beads.  293T cells were transfected to express FcγRIIA or co-transfected to express FcγRIIIA 
and FcRγ. All plasmids were used at 150 ng/well. After 24 hr, the transfected cells were 
stimulated with IgG-beads or beads for 6 hr in serum-free media or untreated (No beads). The 
beads:cell ratios were 100:1. As controls, the pcDNA3.1 vector was used to transfect 293T 
cells (300 ng/well). All results are representative of at least three similar experiments and are 









Nonetheless, 293T cells can clearly support FcγRIIA signaling of NF-κB activation and 
the inability of IL-4, expected to induce IL4Rα-FcγRIIA and γC-FcγRIIA dimerization 
to elicit NF-κB activation implied that FcγRIIA dimerization might not be sufficient to 
Figure 5.4 Full-length (FL) FcγRIIA mediates NF-κB activation and IL-8 production in 
response to IgG-opsonized DH5α (IgG-DH5α). 293T cells were transfected to express
FcγRIIA or co-transfected to express FcγRIIIA and FcRγ. All plasmids were used at 150 
ng/well. After 24 hr, the transfected cells were stimulated with DH5α or IgG-DH5α for 6 hr in 
serum-free media or untreated (No DH5α). The bacteria:cell ratios were 100:1. As controls, 
the pcDNA3.1 vector was used to transfect 293T cells (300 ng/well). After 6 hr, NF-κB 
activation was determined using the luciferase reporter assay. All results are representative of 
at least three similar experiments and are presented as means ±SD.
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induce NF-κB activation. Further oligomerization may be required which can be 
achieved by immune complexes such as IgG-DH5α.  
 
5.3  FcγRs mediate the production of different cytokines from macrophages in 
response to IgG of different degrees of aggregation          
The results obtained with 293T cells led us to investigate whether different FcγRs may 
be activated by different immune complexes reflecting different degrees of IgG 
aggregation, i.e. dimerization is not sufficient to activate these receptors. In this case, 
macrophages were used and FcγR activation was assessed by the induction of cytokine 
production from macrophages. Human GM-CSF macrophages were generated by 
culturing human monoctyes with recombinant human GM-CSF for 6 days. Colony 
stimulating factors (CSFs) such as granulocyte macrophage-CSF (GM-CSF) and 
macrophage-CSF (M-CSF) are hematopoietic growth factors that play important roles 
in the survival and differentiation of monocytes/macrophages (Burdach et al., 1998; 
Motoyoshi, 1998). Two phenotypically distinct types of macrophages can be generated 
from human monocytes when GM-CSF or M-CSF was used  (Akagawa et al., 2006). 
 
Three different types of FcγRs (FcγRI, FcγRII and FcγRIII) are expected to be  
expressed on monocytes and macrophages (van de Winkel and Anderson, 1991). This 
was examined on the cultured macrophages in this study by flow cytometry. As shown 
in Fig. 5.5, all three FcγRs were detected on these macrophages. The expression of 








It has been reported that when FcγRs are cross-linked with immune complexes on 
monocytes/macrophages, it induces the production of IL-1 (Chou et al., 1985; Remvig 
et al., 1990), IL-6 (Krutmann et al., 1990; Ling et al., 1990), TNF-α (Debets et al., 1988; 
Debets et al., 1990; Polat et al., 1993), IL-8 (Marsh et al., 1995), IL-10 (Berger et al., 
1996), and GM-CSF (Ishiguro et al., 1991; Herrmann et al., 1992).  In this study, 
macrophages were stimulated with different forms of aggregated IgG and the 
productions of different cytokines were examined using a cytokine antibody array blots 
which are dotted in duplicate with anti-cytokine antibodies. Macrophages were treated 
with soluble IgG, heat-aggregated IgG (HA-IgG), IgG-coated latex beads (IgG-beads) 
or IgG-coated plates (ImIgG). The culture media were collected and used to probe 
human cytokine antibody arrays. Data from representative arrays are shown in Fig. 5.6 
Figure 5.5 FcγR expression on macrophages. Monocytes were cultured for 6 days with 
20 ng/ml GM-CSF to yield macrophages. Macrophages (3 x 105) were surface-stained with 
the indicated antibodies. Filled profiles were signals obtained with isotype IgG and open 
profiles were signals detected with the respective specific antibodies. 
 141
and are also summarized in Table 5.1. Analysis of the cytokine array data indicated that 
some cytokines were differently induced by the different forms of IgG. 






The cultured GM-CSF macrophages constitutively produce IL-8, MCP-1 and TIMP-2 
(tissue inhibitor of metaloprotinase-2) and, to less extents, IL-6 and MIP-1β 
(macrophage inflammatory protein 1 β). Soluble IgG increased IL-6 production and also 
induced low levels of eotaxin-2, MIP-1β and GM-CSF (Fig. 5.6). HA-IgG showed 
similar induction of these cytokines as free soluble IgG except that it induced a more 
prominent GM-CSF production than soluble IgG. IgG-beads showed further increased 
IL-6, IL-10 and MIP-1β induction than soluble and HA-IgG, but it did not induce GM-
CSF. Overall, all these IgG forms are poorer cytokine inducer than ImIgG (Fig. 5.6). 
ImIgG effectively induced GM-CSF, IL-1α, IL-1β, IL-10 IL-12p40, RANTES, TNF-α, 
soluble TNFRII (tumour necrosis factor receptor II) and MIP-1β. Based on this 
Figure 5.6 Cytokine inductions from macrophages by IgG of different forms. Human 
cytokine arrays were incubated with media of macrophages which were stimulated with 
different forms of IgG. The arrays were obtained from RayBiotech, Inc. (Cat# H0128003, 
Human Inflamamtion Antibody Array III). Autoradiographs of the arrays were scanned 
and differences in the density between different arrays were referred to the intensity of 
the positive control spots (1 & 2). The relative signal intensities for detectable cytokines 
have been arbitrarily evaluated and summarized in Table 5.1. This is representative of 
two experiments. 
 142
experiment, IL-1β, TNF-α and RANTES were only effectively induced by ImIgG 
among all these IgG forms. Previous reports showed that ImIgG could not induce IL-1β 
from monocytes unless the cells were primed with LPS (Arend et al., 1991). 
Interestingly, LPS-priming is apparently not required for ImIgG to induce IL-1β from 
GM-CSF macrophages.  MIP-1δ (macrophage inflammatory protein 1 δ) is only 
induced by IgG-beads. These are also shown in Table 5.1. 




ImIgG IgG-Beads BSA-beads HA-IgG IgG Control 
 
IL-6        6        6        3      4      4       2 
TNF-α        4        -       -       -                   -       - 
sTNFRII       2        1       1       -                  -        - 
GM-CSF        5        -       -                  2       1       - 
IL-1β        3        -        -       -       -       - 
IL-1α       2        -       -       -        -       - 
IL-8        6        6          6      4        4       4 
IL-10       5         2       -      1          1       - 
IL-12p40       1        -       -          -        -           - 
Rantes       2        -       -         -        -       - 
This table shows relative cytokine induction by different forms of IgG as detected using 
the human cytokine arrays (Fig. 5.5). The values were obtained arbiturily based on 
visual assesments of the array spots. 
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Although the cytokine arrays are useful for examining cytokines expression in a more 
global manner, it does not yield quantitative data. Therefore, ELISA was used to 
Figure 5.7 Induction of selected cytokines by macropahges in response to ImIgG and 
IgG-bead. (A) 1 x 105 macrophages were stimulated with ImIgG (100 µg/ml) or IgG-
beads (beads:cell ratio=50:1). Cell-free supernatants were used to measure the production 
of different cytokines by ELISA. (B) 1 x 105 macrophages were stimulated with ImIgG
(100 µg/ml) in the presence or absence of polymyxin B (20 µg/ml)). After 24 hr, cell-free 
supernatants were assayed for different cytokines by ELISA. As a negative control, BSA-
coated plates were used to stimulate macrophages.  
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quantify the expression of some cytokines that were differentially induced by the 
different forms of IgG. Macrophages were stimualted with ImIgG or IgG-beads before 
ELISA for IL-6, TNF-α IL-10, GM-CSF and IL-1β.  
As shown in Figure 5.6A, while IL-6 and TNF-α was induced by ImIgG and IgG-beads, 
ImIgG induced 50 folds more IL-6 and TNF-α than IgG-beads (Fig. 5.6A). Similarly, 
while IL-10 was induced by both ImIgG and IgG-beads, ImIgG induced 4~5 folds more 
IL-10 than IgG-beads (Fig. 5.7A). Some inconsistent results were obtained with 
cytokine arrays and ELISA. TNF-α induction by IgG-beads was detected by ELISA 
(Fig. 5.7A) but not the array (Fig. 5.6). The IL-6 levels induced by ImIgG as compared 
with IgG-beads showed strong differences depending on whether antibody array or 
ELISA was employed. By ELISA, ImIgG induced 50 folds more IL-6 than IgG-beads 
whereas, based on the array methods IgG-beads induced more IL-6 than ImIgG. 
Consistent levels of GM-CSF, IL-1β and IL-10 were detected with ELISA (Fig. 5.7A) 
and the antibody arrays (Fig. 5.6). 
 GM-CSF macrophage mimics inflammatory macrophages (Hamilton et al., 1980). This 
is refelcted in some cytokine production by the cells without stimulation. The 
interesting observation was that these cells produce high levels of GM-CSF in response 
to ImIgG but not IgG-beads (Fig. 5.7A). IgG-beads also failed to induce IL-1β which 
was induced by ImIgG. It is possible that ImIgG provides more prolonged stimulation 
to macrophages than other forms of IgG and this elicit additional signaling pathways 
which are not activated by IgG-beads. The ability of ImIgG to induce GM-CSF from 
GM-CSF cultured macrophages means that ImIgG primes macrophages for 
inflammatory responses. 
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Since contaminating LPS may induce similar cytokines from macrophages, this 
possibility was assessed using the LPS inhibitor, polymyxin B, a peptide antibiotic that 
binds and neutralizes LPS (Cooperstock, 1974). 20 µg/ml polymyxin B showed no 
inhibition of ImIgG-induced cytokine production (Fig. 5.7B). As another control, 
macrophages were stimulated with BSA-coated plates to eliminate non-specific protein 
stimulation. Macrophages cultured in BSA-coated plates showed none of these 
cytokines induction (Fig. 5.7B). In addition, complement-induced cytokine production 
was also unlikely in these experiments because heat-inactivated FCS was used in all 
experiments. In summary, data from both cytokine array and ELISA suggest that (i) 
ImIgG is more potent in cytokine induction than IgG-beads and (ii) IgG-beads do not 
significantly induce certain cytokines, such as IL-1β and GM-CSF, which were induced 
by ImIgG.  
5.4  Role of different FcγRs in the induction of IL-6, TNF-α and IL-10 by ImIg 
and IgG-beads  
 IL-6, TNF-α, and IL-10 production vary significantly depending on whether ImIgG or 
IgG-beads were used to stimulate macrophages (Fig. 5.7A). ImIgG is apparently more 
potent than IgG-beads. From these experiments, the types of FcγR involved in cytokine 
induction are not clear. This was examined by pre-incubation of macrophages for 1 hr at 
4°C with FcγR-blocking antibodies (20 µg/ml) before stimulation with ImIgG or IgG-
beads for another 12 hr. As shown in Fig. 5.8A, IL-6 produciton was markedly inhibited 
by the FcγRI and FcγRIII antibodies, compared to control mouse IgG. In both cases, > 
50% inhibition was observed (Table 5.2). The anti-FcγRIIIA antibody was particularly 
inhibitory which reduced IL-6 induction by ImIgG to 68% (Table 5.2). Blocking of 
FcγRII showed less inhibition. When macrophages were pre-incubated with a 
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Figure 5.8 Roles of 
different FcγRs in 
ImIgG-induced IL-6, 
TNF-α and IL-10 
production. 
Macrophages were pre-
incubated with FcγR 
blocking antibodies (20 
µg/ml) for 1 hr on ice and 
then stimulated with 
ImIgG (100 µg/ml)) for 
another 12 hr. Cell-free 
supernatants for IL-6, 
TNF-α and IL-10 were 
measured by ELISA. 
Results are presented as 
means ±SD of triplicate 
experiments. One 
representative of three 
independent experiments 
is shown.  
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Table 5.2 ImIgG-induced IL-6, TNF-α and IL-10 production upon antibody 
blocking of different FcγRs 
Cytokines Mouse IgG Anti-CD64 Anti-CD32 Anti-CD16            Anti-
CD64+CD32+CD16
IL-6 0% 51% 21% 68% 80% 
TNF-α 0% 27% 0% 24% 61% 
IL-10 0% 73% 82% 84% 87% 
 
TNF-α production was reduced to 61% when macrophages were pre-incubated with all 
three FcγR-blocking antibodies (Fig. 5.8B) (Table 5.2). Individually, each FcγR 
antibody only caused slight inhibition of TNF-α production. It shows that IL-6 and 
TNF-α are differently induced by ImIgG. FcγR synergy is not key to ImIgG-induced 
TNF-α production. For IL-6 induction, FcγRIII and, to a lesser extent, FcγRI play more 
important roles than FcγRII. ImIgG-elicited IL-10 production appeared to require all 
three FcγRs as the blocking of any of these FcγRs markedly inhibited ImIgG-induced 
















Figure 5.9 The roles of 
specific FcγR in IgG-
beads-induced IL-6, 
TNF-α and IL-10 
production. 
Macrophages were pre-
incubated with blocking 
antibodies (10 µg/ml) for 
1 hr on ice and then 
stimulated with IgG-
beads for another 12 hr. 
Cell-free supernatants 
were measured for IL-6, 
TNF-α and IL-10 by 
ELISA. Results are 
presented as means of 
±SD of triplicate 
experiments. One 




Table 5.3 IgG-bead-induced IL-6, TNF-α and IL-10 production upon antibody 
blocking of different FcγRs 
Cytokines Mouse IgG Anti-CD64 Anti-CD32 Anti-CD16            Anti-
CD64+CD32+CD16 
IL-6 0% 45% 61% 60% 62% 
TNF-α 0% 26% 52% 40% 76% 
IL-10 0% 37% 57% 55% 64% 
 
The roles of different FcγRs in IgG-bead induction of cytokines are also assessed using 
the FcγR-blocking antibodies. As shown in Figure 5.9A, IL-6 induction by IgG-beads 
was similarly and significantly reduced by each of the three antibodies. Pre-incubation 
with either the FcγRII or FcγRIII antibody reduced IL-6 to levels similar to that 
observed in PBS addition to macrophages. Compared with IL-6, TNF-α production was 
less inhibited by individual antibodies (Fig.5.9B). However, incubation of macrophages 
with a combination of all three FcγR antibodies reduced TNF-α production 
approximately 76% (Table 5.3) to the backround levels induced by BSA-beads and 
PBS. IL-10 production by IgG-beads appears to be less sensitive to FcγR blocking (Fig. 
5.9C). While all antibodies showed inhibition, the degree of inhibition was much less 
compared with ImIgG-induced IL-10 production (Table 5.2).  
 
5.5  Specific FcγR requirement for IL-1β and GM-CSF induction by ImIgG.  
As shown in Fig.5.6 and Fig. 5.7A, ImIgG but not other forms of IgG induced 
signifcant IL-1β and GM-CSF production. The FcγR which is involved in the induction 
of these two cytokines is here also examined. Macrophages were pre-incubated for 1 hr 
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at 4°C with specific FcγR antibodies (20 µg/ml) before stimulation with ImIgG for 











Figure 5.10 Roles of different FcγRs in ImIgG-induced IL-1β and GM-CSF 
production. Macrophages were pre-incubated with blocking antibodies (10 µg/ml) for 
1 hr on ice and then stimulated in ImIgG (100 µg/ml) for another 12 hr. Cell-free 
supernatants were measured for IL-1β and GM-CSF by ELISA. Results are the means 
±SD of triplicate wells. One representative of three independent experiments is shown.  
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Table 5.4 ImIgG-induced IL-1β and GM-CSF production upon antibody blocking 
of different FcγRs 
Cytokines Mouse IgG Anti-CD64 Anti-CD32 Anti-CD16            Anti-
CD64+CD32+CD16
IL-1β 0% 27% 49% 66% 87% 
GM-CSF 0% 70% 44% 69% 87% 
 
IL-1β secretion was not significantly inhibited by the FcγRI blocking antibody (Fig. 
5.10A). However, it was markedly inhibited by the FcγRIII antibody (66%, Table 5.4). 
The FcγRII antibody also showed ~50% inhibition. When macrophages were pre-
incubated with a combination of all three FcγR antibodies, IL-1β production was almost 
completely blocked, i.e reduced to 87% (Table 5.4).  
 
GM-CSF secretion was inhibited by all three FcγR blocking antibodies (Fig. 5.10B) 
especially the FcγRI and FcγRIII antibodies which showed ~70% inhibition. When 
macrophages were pre-incubated with a combination of three FcγR antibodies, it almost 
completely blocked GM-CSF production (Table 5.4).  These results suggest a more 
prominent role for FcγRIII in mediating GM-CSF and IL-1β production. While FcγRI is 
as potent as FcγRIII in mediating GM-CSF induction, it is the weakest among the three 
FcγRs in IL-1β induction (Table 5.4). 
 
5.6  IL-8 production is not sensitive to the blocking of any of the three FcγRs 
FcγR cross-linking with ImIgG was known to activate IL-8 production effectively from 
monocytes (Marsh et al., 1995). Similarly, FcγR cross-linking with either ImIgG or 
IgG-beads also effectively induced IL-8 production from macrophages (Fig. 5.11). 
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BSA-beads induced some IL-8 production which is un-related to IgG or FcγRs. As 
shown in Fig. 5.6, GM-CSF macrophages constitutively produced IL-8 even in PBS-





























Nonetheless, the FcγR which is involved in ImIgG and IgG-bead induction of IL-8 
production was similarly examined using the blocking antibodies. As shown in Fig. 
5.12A and B, elicited IL-8 production by ImIgG and IgG-beads was not inhibited by the 
FcγRI, FcγRII or FcγRIII antibody individually or in combination. This suggests the 
involvement of other unidentified receptors in mediating IgG induction of IL-8 
production from macrophages. In summary, IL-8 production may be induced by ImIgG 
Figure 5.11 ImgG and IgG-bead induction of IL-8 from macrophages. Macrophages 
(1 x 105) were stimulated with either ImIgG (100 µg/ml), IgG-beads or BSA-beads (50:1) 
for 12 hr. As a control, PBS-treated plates (PBS) were used. IL-8 was measured by 
ELISA. Results are presented as means ±SD of triplicate wells. One representative of 
three independent experiments with similar results is shown. 
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or IgG-beads from macrophages through any of the three known FcγRs examined or 
potentially other receptors that regulate IgG. Another explanation is that IL-8 is easily 



























Figure 5.12 Roles of different FcγRs in ImIgG and IgG-beads-induciton of IL-8
from macrophages. Macrophages were pre-treated with FcγR-blocking antibodies (20 
µg/ml) for 1 hr on ice and then stimulated with either ImIgG (100 µg/ml) (A) or   IgG-
beads (50:1) (B) for another 12 hr. IL-8 was measured by ELISA. BSA-beads were used 
as a negative control (B). Results are presented as means ±SD of triplicate wells. One 
representative of three independent experiments is shown. 
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Table 5.5  FcγR  involvement in IgG-elicited IL-8 production. 
IL-8 Mouse IgG Anti-CD64 Anti-CD32 Anti-CD16            Anti-
CD64+CD32+CD16
ImIgG 0% 0% 11% 14% 20% 
IgG-beads 0% 0% 0% 0% 14% 
 
5.7  Conclusion 
Based on the above results, the following conclusions can be drawn: 
i) Dimerization is not sufficient to induce FcγRIIA signaling for NF-κB activation and 
cytokine induction. To induce FcγR signaling, higher degrees of FcγR oligomerization 
is probably required. 
ii) ImIgG is a more potent stimulus of cytokine production compared to IgG-beads or 
HA-IgG. IgG-beads can not induce IL-1β and GM-CSF production which was induced 
by ImIgG. 
iii) FcγRIII and, to lesser extents, FcγRI play important roles in ImIgG-elicited IL-6 
production.  In the case of TNF-α induction, all three FcγRs are potent mediators. In 
contrast, ImIgG requires synergy of all three FcγRs for effective IL-10 induction.  
FcγIII plays prominent roles in IL-1β and GM-CSF induction by ImIgG. While FcγR1 
is as potent as FcγIII in GM-CSF induction, it is the weakest mediator of all three FcγRs 
in IL-1β induction. 
FcγRII and FcγRIII play significant roles in IgG-beads-elicited IL-6 and IL-10 
production. All FcγRs appears to be potent inducer in IgG-beads-elicited TNF-α 
production.  
iv) ImIgG or IgG-beads-induction of IL-8 is not sensitive to the blocking of any of the 
three FcγRs, suggesting the involvement of other receptors. Alternatively, IL-8 
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induction from GM-CSF macrophages may not need substantial involvement of IgG or 
its receptors 
The biological implications of these findings are that different FcγRs may have distinct 
roles in FcγR mediated effector functions. Understanding of the roles of specific FcγRs 



















Chapter 6 Discussion 
6.1  Development of a TLR-based two-hybrid assay for the detection of protein-
protein interactions 
While the yeast two-hybrid assays have enabled the identification and investigation of 
numerous cytoplasmic protein interactions, the application of such assays in the 
investigation of the interactions between membrane-bound receptors, between receptors 
and the protein ligands, and between secreted proteins, are limited. In the present study, 
we evaluated an assay for detecting protein-protein interactions based on the mechanism 
of TLR2-mediated NF-κB signaling is activated (Ozinsky et al., 2000). TLR2 
transduces signals when it dimerizes with TLR1, which causes the dimerization of 
cytoplasmic TIR domains of TLR1 and TLR2 (i.e. TIR1 and TIR2). The sensitivity and 
specificity of this TIR1/TIR2-based two-hybrid assay have been evaluated on whether 
this assay can reflect known interactions between IL-4 and/or its two receptor subunits 
(Nelms et al., 1999), i.e. IL4Rα and γC. Our results (Fig 3.3) showed that the TIR1/2-
based two-hybrid assay could detect the lack of interaction between IL4Rα and γC when 
fused to TIR1 and TIR2 as hybrid receptors and stimulated with IL-4. The assay also 
demonstrated direct IL-4 interaction with IL4Rα (Fig. 3.4A) and the lack of direct IL-4 
interaction with γC (Fig. 3.4B). These results are largely consistent with current 
knowledge of interactions between IL-4 and its receptors (Duschl and Sebald, 1996; 
Russell et al., 1993).  IL-4 primarily binds with IL4Rα. Subsequently, this intermediate 
IL-4/IL-4Rα complex recruits the γC to form an IL-4Rα/ γC heterodimer. These results 
highlight the potential of TIR1/TIR2-based two-hybrid assay in the detection of 
receptor-receptor and receptor-ligand interactions. The relatively small TIR1 and TIR2 
reporter domains approximately 20 KDa permit easy expression of relatively large test 
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proteins using plasmid vectors. Therefore, this assay can be conveniently employed in 
detecting interactions between extracellular proteins and/or the EC domains of 
membrane proteins. 
 The sensitivity and specificity of this novel two-hybrid assay has been demonstrated, 
but this is apparently only achieved when the assay is carried out in a well controlled 
manner. For example, co-expression of IL4Rα-TIR1 and γC-TIR2, which were not 
expected to interact unless stimulated with IL-4, led to constitutive NF-κB activation 
when both hybrid receptors were excessively over-expressed (Fig. 3.3). Over-expression 
of IL4-TIR1 and γC-TIR2 also led to constitutive NF-κB activation (Fig. 3.4B). There is 
no evidence that such interactions occur under physiological conditions. The fact that 
NF-κB activation was only observed at high plasmid dosage suggests that it probably 
results simply from over-expression of the TIR1 and TIR2 hybrid receptors. When the 
plasmids were used at reduced dosages, i.e. 38 ng/well, such NF-κB activation also 
decreased in a dose dependent manner. 
Over-expression of the IL4-TIR1/TIR2 (Fig 3.5A), IL4Rα-TIR1/TIR2 (Fig. 3.5B), and 
γC-TIR1/TIR2 (Fig. 3.7A) hybrid pairs also led to potent NF-κB activation. However, 
when the dosage of these plasmids were reduced to levels at which co-expression of the 
IL4Rα-TIR1/γC-TIR2 and IL4-TIR1/γC-TIR2 pairs elicited insignificant NF-κB 
activation, NF-κB activation by IL4-TIR1/TIR2 (Fig. 3.5A), IL4Rα-TIR1/TIR2 (Fig. 
3.5B), and γC-TIR1/TIR2 (Fig.3.7A) hybrid pairs was sustained. The observed NF-κB 
activation by IL4-TIR1/TIR2, IL4Rα-TIR1/TIR2, and γC-TIR1/TIR2 hybrid pairs 
suggest that the NF-κB activation associated with these 3 hybrid pairs was probably not 
simply due to over-expression but a result of homotypic interactions between the pairs 
of IL-4, IL4Rα and γC. The homotypic interactions between pairs of IL-4, IL4Rα and 
γC based on TIR1/TIR2 hybrid assay was verified by immunoprecipitation studies. This 
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technique also confirmed homotypic interactions between IL-4, IL4Rα and γC pairs. 
The observed homotypic interactions of IL-4, IL4Rα and γC are not in conflict with the 
known mechanism of IL-4 mediated receptor interaction.  
This assay detected interactions between the EC domains of IL4Rα and γC largely in 
the context of their natural microenvironments except that their TM and Cyt domains 
were replaced by TIR domains. In contrast, homotypic interaction of IL-4 and 
interactions between IL-4 and its receptor EC domains were examined under artificial 
conditions where the IL-4 was anchored to the cell surface of the hybrid receptors. The 
anchoring of IL-4 on the cell surface could potentially enhance or inhibit its lateral 
homotypic interaction and its interaction with the EC domains of IL4Rα and γC. 
Therefore, it is less certain whether IL-4 would similarly form homodimers in its native 
soluble form. Nevertheless, IL-4 has apparently, retained its binding properties and 
specificity after it has been expressed in the form of hybrid receptors.  
A weakness of the TIR1/TIR2-based two-hybrid assay is that the assay is over-sensitive. 
This can be over come in two ways: Firstly, the NF-κB activation due to over-
expression can be titrated down to background level with the reduction of plasmid 
dosages as low as 38 ng/well. In this condition, this TIR1/TIR2-based two-hybrid assay 
then can report the true interaction of the two different test proteins. Secondly, 
background NF-κB activation derived from the over-expression of this two-hybrid assay 
can be reduced through selective mutations in any of the TIR1 or TIR2 domain of the 
two-hybrid proteins. An additional shortcoming of this TIR1/TIR2-based two-hybrid 
assay was its poor quantitative quality in reporting interactions between two hybrid 
molecules. The assay relies on the activation of endogenous NF-κB, which is required 
for multiple essential cellular activities. NF-κB activation was apparently tolerated in 
the transfected 293T cells. But its activity was tightly regulated through feedback 
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mechanisms. For example, NF-κB is activated through the degradation of IκBα, but 
activated NF-κB rapidly induces IκBα expression (Karin and Ben Neriah, 2000). This 
means that the time window during which linear correlation between hybrid receptor 
interactions and the extent of NF-κB activation is likely to be very narrow. 
Despite the above weaknesses, the TIR1/TIR2-based two-hybrid assay remains a 
convenient supporting assay for detecting interactions between receptors, between 
receptors and ligands, and between soluble secreted proteins. This assay may also be 
improved to detect interactions between membranes and/or secreted proteins in a high 
throughput manner. 
 
6.2  Investigation of CD14 dimerization and its role in CD14 signal 
transduction  
 In this study, we have applied the TIR1/TIR2-based two-hybrid assay to investigate the 
interactions between the EC domains of CD14. In chapter 6.1, we have validated the 
feasibility of this two-hybrid assay by using known interactions between IL-4 and/or its 
two receptor subunits, i.e. IL4Rα and γC (Wang et al., 2004). Co-expression of IL4-
TIR1/TIR2 (Fig. 3.5A), IL4Rα-TIR1/TIR2 (Fig. 3.5B), and γC-TIR1/TIR2 (Fig.3.7A) 
hybrid pairs at 38 ng/well, NF-κB actiavation was sutained. Similarly, Co-expresssion 
of CD14-TIR1 and CD14-TIR2 hybrid pairs at 38 ng/well led to NF-κB activation (Fig. 
4.1A). In addition, the control IL4Rα-TIR1/CD14-TIR2 and β5-TIR1/CD14-TIR2 
hybrid pairs at the same concentration did not induce NF-κB activation (Fig. 4.1B). 
These results clearly show that the observed NF-κB activation by CD14-TIR1/CD14-
TIR2 pairs was not simply due to over-expression of the hybrid receptors but a result of 
homotypic interactions between CD14-CD14. CD14 may form dimers is reported in a 
recent crystallography study (Kim et al., 2005). The dimerization may mediated by the 
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residues located in β13 and in the ‘loop’ between β12 and β13.  Based on this study, 
two CD14 deletion mutants were generated in CD14-TIR1 by removing amino acids 
289-300 (the ‘loop’ between β12 and β13) or 302-315 (β13) which were named 
loopdelCD14-TIR1 and β13delCD14-TIR1 respectively. The results showed that 
deletion of these regions caused the loss of CD14-TIR1/CD14-TIR2-induced NF-κB 
activation (Fig. 4.2A), indicating an important role of these regions in CD14-mediated 
cell signaling. The specific amino acids in β13 and in the ‘loop’ between β12 and β13 of 
CD14 were further investigated in details. Alanine substitution mutation study showed 
that L290ACD14-TIR1 or L307ACD14-TIR1 abrogated CD14TIR1/CD14TIR2-
mediated NF-κB activation (Fig. 4.2B). Mutant P294ACD14-TIR1 or P300ACD14-
TIR1 with CD14-TIR2 caused partial reduciton of NF-κB activation (Fig. 4.2B). These 
results indicate that L290 in the ‘loop’ and L307 in β13 are critical to CD14-CD14 
dimerization. P294 and P300 in the same ‘loop’ may also be involved in CD14-CD14 
dimerization 
While CD14 binds to LPS, it requires the TLR4/MD-2 complex to activate cellular 
signaling (Shimazu et al., 1999; Akashi et al., 2000; Yang et al., 2000). TLR4-mediated 
NF-κB activation and IL-8 production was investigated in association with WtCD14 
and CD14 mutants. Similarly, TLR4-mediated NF-κB activation (Fig. 4.3A) as well as 
IL-8 (Fig. 4.3B) production was significantly reduced by L290A or L307A CD14 
mutants in response to LPS. This suggests that these two amino acids are important in 
TLR4-mediated LPS signaling. Another mutant of CD14, i.e P294 and P300 partially 
reduced TIR1/TIR2-mediated NF-κB activation also reduced TLR4-mediated NF-κB 
activation as well as IL-8 production. These amino acids may also be important in 
TLR4-mediated LPS signalling. 
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To exclude the possibility that mutant CD14 had lost its ability to induce TIR1/TIR2 
and TLR4-mediated NF-κB activation due to differences in their cell surface 
expression, we tested both CD14-TIR1 and CD14 mutants for membrane surface 
expression. The results showed that they expressed on the cell surface. This suggests 
that deletion or alanine substitution in the ‘loop’ between β12-13 and β13 does not alter 
cell surface expression. Double mutation of two leucines (L290 and L307) in these 
regions (‘loop’ between β12-13 and β13), affected the structural integrity of CD14, 
resulting in reduced expression in both the CD14-TIR1 (Fig. 4.4B) and full-length 
CD14 (Fig. 4.4C). For the same reason, these double mutants also caused significant 
reduction of CD14-TIR1/CD14-TIR2 mediated NF-B activation (Fig. 4.2B) and LPS 
rsponsiveness (Fig. 4.3).  
 On leukocytes CD14 exists as a GPI protein having a molecular weight of 
approximately 55 Kda (Haziot et al., 1988; Simmons et al., 1989; Haziot et al., 1993). 
As mentioned earlier, CD14 may form dimer in a crystallography study (Kim et al., 
2005). However, there have been no detailed experimental studies to show that CD14 
exists as dimer and the molecualr mechanism of dimer in LPS signaling. In our study, 
the existence of both monomeric and dimeric form of CD14 was showed by cross-
linking assay (Fig. 4.5). Under non-reducing conditions, besides the 55 KDa band, a 
heterogenous group of high molecualr weight CD14 containing complexes (> 80Kda) 
were also detected in 293T cells that were transfected to express Wt CD14 (Fig. 4.5B). 
Thus CD14 may exist as monomer on the cell surface but dimers or higher oligomers 
also exist. The existance of CD14 dimers was also indicated in crystallographic 
structure and it showed that these dimers were made up of the same CD14 monomer 
subunits. The subunit was indicated to be the β13 and the loop of β12 and β13 (Kim et 
al., 2005). Our study also showed that CD14 mutants, i.e. L290 and L307 that reduced 
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the dimer/oligomer formation (Fig. 4.5B) also exhibited reduction capacity in mediating 
LPS-stimulated signaling (Fig. 4.3). Some CD14 mutants, i.e. P294 and P300 partially 
retained dimer formation also exhibited partial reduction in LPS signaling. This implies 
that dimers or oligomers may be critical for the propagation of external stimuli across 
the cell membrane and to the CD14 receptor complex and therefore underlie the basis of 
the signaling. 
CD14 contains 10 LRR motif spanning amino acids 67 to 312 (Ferrero et al., 1990). The 
binding sites for LPS in CD14 have been extensively studied by mutagenesis and by 
epitope mapping of antibodies that block LPS binding. Four LRR have been identified 
as LPS binding sites which correspond to N-terminal 152 amino acids of CD14 (Juan et 
al., 1995c; Juan et al., 1995a; Viriyakosol and Kirkland, 1995; Cunningham et al., 
2000). All these studies clearly indicated that the remaining LRR which corresponds to 
C-terminal amino acids do not play a part in LPS receptor functions. As pointed out by 
Juan et al (Juan et al., 1995c), the above is unexpected because the LRR have been 
thought to be important for interactions between proteins and was predicted to contain 
the activation domain. In addition, a study has shown that a deletion mutant of human 
CD14 consisting of the N-terminal 152 amico acids has the capacity to mediate the 
stimulation of different cell types by LPS (Stelter et al., 1999). These mutants were in 
amino acids 9-13 and 91-101 that are not essential for LPS binding but important for 
cellular activation. The alanine substituion of these amino acids significanlty reduced 
LPS induced IL-6 production in U373 astrocytoma and human vascular endothelial 
cells. Very little investigation has been done on the functional impact of C-terminal 
region of CD14. However a study has shown that the amino acids in the region 273-275, 
corresponding to C-terminal of mouse CD14 was required for TLR4-mediated NF-κB 
activation (Muroi et al., 2002). In addition to this, our results indicate that the amino 
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acids in the region 290-300 (‘loop’ between β12-13) and 301-315 (β13) are required for 
CD14-CD14 dimerization. Mutation of these amino acids significantly reduced TLR4-
mediated LPS signalling. 
In summary, this study revealed the new mecahnism by which CD14-CD14 interaction 
regulates LPS signaling and its implication as a therapeutic agents for LPS-induced 
shock.  
 
6.3  Investigation of FcγRIIA activation 
 
6.3.1  Dimerizaiton is not sufficient for the induction of FcγRIIA signaling 
As discussed above (chapter 6.1 and 6.2), the TIR1/TIR2-based two-hybrid assay has 
proved to be a feasible method in detecting protein-protein interactions. Here, the IL-
4/IL-4R system was also used to investigate whether FcγRs can be activated by 
inducing dimerization with IL-4. The Tm/Cyt domains of TLR1 in the IL4Rα-TIR1 and 
γC-TIR1 chimeras were replaced with the TM/Cyt domain of FcγRIIA. It is known in 
human three different classes of FcγRs, i.e. FcγRI, FcγRII and FcγRIII are expressed on 
monocytes/ macrophages (van de winkel and Anderson, 1991; Hulett and Hogarth, 
1994). The reason to choose FcγRIIA rather than other FcγRs in this system, it is the 
only known FcγR that contains both extracellular IgG-like domains and cytoplasmic 
signaling domain, ITAM (immunoreceptor tyrosine-based activation motif) in a single 
polypeptide (Ravetch and Kinet, 1991). Our result in 293T cells co-transfected with 
IL4Rα-FcγRIIA and γC-FcγRIIA (Fig. 5.1B) showed that dimerzation of FcγRIIA was 
not sufficient to induce NF-κB activation. FcγRs induce target effects if the receptors 
are cross-linked by immune complexes (complexes between antigens and IgG 
molecules) (Ravetch and Bolland, 2001). Previous studies showed that binding of IgG 
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to both specific antigens (Ags) and FcγR is required for cell activation (MacIntyre et al., 
1989). It appears that binding of IgG by the Fab (fragment of antibody) portion to 
specific Ag increases the affinity of the FcγR for the Fc, end of the same antibody 
molecule. However in our study, IgG-opsonized DH5α effectively activated FcγRII 
signaling in 293T cells, but not FcγRIII signaling (Fig. 5.3A and B). The functional 
discrepancy between these FcγRs may be due to differences in interaction of IgG with 
FcγRII and FcγRIII, although these receptors exihibit substantial amino acid sequence 
conservation and similar IgG binding affinities and specificities (Hibbs et al., 1994; 
Hulett et al., 1995). Another possibility is that FcγRIIA has unique structural, signaling, 
and biologic features. Unlike, other receptor such as FcαRI, FcγRI and FcγRIIIA, 
FcγRIIA can signal without the homodimeric FcR γ chain. FcγRIIA contain both the 
ligand binding site and the ITAM are in the same polypeptide (Ravetch and Kinet, 
1991). It has previously been shown that there are indeed functional differences 
between FcγRIIA and the FcγRI/FcγRIIIA γ chain in their ability to transmit a 
phagocytic signal (Kim et al., 2001).  
 
6.3.2  ImIgG is a potent inducer of cytokine production 
Monocyte/macrophage FcγR mediate a large spectrum of functions including 
phagocytosis and endocytosis of IgG-coated particles (Anderson et al., 1990; Davis et 
al., 1995), antibody-dependent cell-mediated cytotoxicity (ADCC) (Graziano and 
Fanger, 1987), and production of inflammatory cytokines (Sanchez-Mejorada and 
Rosales, 1998). Previous studies have shown that cross-linking of FcγR on monocytes 
resulted in at least two potent immunomodulating cytokines, IL-6 (Krutmann et al., 
1990) and TNF-α (Debets et al., 1990; Polat et al., 1993). Similarly, results from 
cytokine-array (Fig.5.6) and ELISA (Fig. 5.7A) showed that IL-6 and TNF-α production 
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was induced by both ImIgG and IgG-beads. ImIgG induced IL-6 and TNF-α production 
is relevant to disease states such as rheumatoid arthritis caused by tissue-fixed immune 
complexes (Feldmann et al., 1996). This disease is frequently accompanied by fever 
owing to the pyrogenic properties of TNF-α (Dinarello et al., 1986) and IL-6 production 
(Kishimoto et al., 1995). These cytokines also contribute to the articular damage 
observed in rheumatoid arthritis.  Induction of IL-6 (Helfgott et al., 1989) and TNF-α 
(Debets et al., 1988) by IgG-beads is relevant to the course of antibody-coated 
pathogens against bacteria and viral infection. However, our data showed that ImIgG is 
more potent in cytokine induction compared to IgG-beads (Fig. 5.7A). The reasons for 
the differential responses in the cytokines production by two different composition of 
ICs i.e. ImIgG versus IgG-opsonized particles can be explained as follows: i) an 
elevated amount of IL-6 and TNF-α released by ImIgG stimulated macrophages is 
relevant to the disease states such as rheumatoid arthiritis, where production of pro-
inflammatory cytokines fails to cease, resulting in sustained changes in receptor 
expression, augmentation of macrophage effector function, and sometimes tissue injury 
(O'Shea et al., 2002). ii) The relatively lower amount of IL-6 and TNF-α produced by 
IgG-beads may be due to the different form of IgG (IgG opsonized latex beads) used in 
this experiment. ImIgG may provide more prolong stimulation to macrophages than 
other forms of IgG and hence more potent in cytokine induction.  
 
FcγR cross-linking also induces IL-1β (Remvig et al., 1990) and GM-CSF (Herrmann et 
al., 1992) production. Results from cytokine-array (Fig. 5.6) and ELISA (Fig. 5.7A) 
assay showed that IL-1β and GM-CSF was only induced by ImIgG. Previous studies 
reported that ImIgG does not induce IL-1β unless stimulated with low doses of LPS in 
monocytes (Arend et al., 1991; Kindt et al., 1993). This is in contrast to our study that 
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ImIgG induces IL-1β production. The possibility of LPS contribution in this experiment 
was eliminated by using polymyxin B to inhibit LPS response (Fig. 5.7B). However, IL-
1β (Buchan et al., 1988; Mullazehi et al., 2006) and GM-CSF (Xu et al., 1989; Alvaro-
Gracia et al., 1991) production can be seen in tissue-fixed immune complex mediated 
chronic disease such as RA. During RA, the dominant cell type in the joint is the 
macrophage (Kinne et al., 2000). In our experiment, the cell type we used was GM-CSF 
macrophage which mimicks proinflammatory macrophage (Hamilton et al., 1980). The 
proinflammatory role of GM-CSF has been demonstrated using various models of 
inflammation and immunity. It is shown that administration of rGM-CSF accelerates 
onset and exacerbates the pathology of murine collagen-induced arthritis (CIA) 
(Campbell et al., 1997) while GM-CSF-deficient mice show decreased susceptibility to 
CIA (Campbell et al., 1998). GM-CSF-deficient mice also showed exacerbated 
susceptibility to infection with Listeria monocytogenes, which correlates with a poor 
inflammatory response and failure to maintain a supply of phagocytic cells over the 
long term (Zhan et al., 1998). Moreover, GM-CSF can prime monocytes/macrophages 
for cytokine production (Hart et al., 1988; Hamilton, 1993a), led to to the proposal of a 
cytokine stimulating factor (CSF) network loop in RA where GM-CSF has a central role 
in maintaining joint inflammation (Hamilton, 1993b). Therefore, it is not surprising that 
ImIgG can induce IL-1β and GM-CSF in macrophages. The possibility of IgG-beads 
not inducing IL-1β and GM-CSF could be due to different forms of IgG that was given 
to stimulate FcγRs. 
  
However, in addition to these pro-inflammatory cytokines, FcγR cross-linking induces 
anti-inflammatory cytokines, IL-10 (Berger et al., 1996). It showed that TNF-α, IL-6 
and IL-10 was produced when two different immune-complexes formed of tetanus 
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toxoid and polyclonal anti-tetanus toxoid antiserum, as well as heat-aggregated human 
IgG stimulated human monocytes. In this study, cytokine was induced in dose 
dependent and antigen/antibody ratio-dependent manner. Additionally, this investigator 
demonstrated that endogenously synthesized IL-10 limited the immune complex 
induced secretion of pro-inflammatory cytokines TNF-α and IL-6 (Berger et al., 1996). 
This anti-inflammatory property is associated with the T helper type 2 (Th2) immune 
responses. Therefore, this study concluded that immune complexes, besides their well-
known ability to cause acute and chronic inflammation, can mediate 
immunosuppressive effects and influence the balance of Th1/Th2 responses. Similarly, 
our data showed that IL-10 was induced by both ImIgG and IgG-beads (Fig. 5.6). The 
presence and the role of IL-10 were investigated in RA condition. IL-10 produced 
spontaneously by the RA cultures was shown by neutralization experiments to play an 
important regulatory role in RA in the synovial membrane cultures (Katsikis et al., 
1994). Blocking IL-10 in these cultures with a neutralizing monoclonal antibody 
resulted in two to threefold increase in the levels of TNF-α and IL-1β whereas, 
exogenous rIL-10 decreases these cytokines in RA culture (Katsikis et al., 1994). 
Similarly, IL-10 produced by IgG-beads down regulates the pro-inflammatory effects in 
the course of bacterial infection (Sutterwala et al., 1998).  
 
6.3.3  The role of three classes FcγRs are different for different cytokine 
production 
FcγRs cross-linking is known to induce different cytokine production. The particular 
FcγRs involved in cytokine induction is not clearly addressed. It would be very 
interesting to know what type of FcγR is responsible for the induction of cytokine 
production by macrophages. In this study, it was determined by using blocking antibody 
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specific for FcγRI, FcγRII and FcγRIII in response to immobilize IgG and IgG-beads. 
Instead of cross-linking each FcγR separately we took this approach because cross-
linking assay would give rise to inadequate binding affinity of antibody to each FcγRs. 
This would make it difficult to assess the differences of cytokine production induced by 
FcγRs. Previous study showed that IL-6 was produced when FcγRI was cross-linked 
with solid-phase bound mouse IgG1. Stimulation of FcγRII with solid-phase bound 
mouse IgG1 did not significantly induce IL-6 production from monocytes (Krutmann et 
al., 1990). Our antibody blocking study showed that ImIgG induced IL-6 production 
was significantly inhibited by FcγRIII and to lesser extent by FcγRI antibodies (Fig. 
5.7A). This suggests that either FcγRIII or FcγRI may play important role in IL-6 
induction. In the case of IgG-beads induced IL-6 prodcution, either FcγRIII or FcγRII 
play important role (Fig. 5.9A). A study showed that cross-linking of monocyte FcγR 
by solid-phase human IgG induces secretion of TNF-α (Debets et al., 1988). This 
investigator further showed that cross-linking of FcγRI by solid-phase mouse IgG1 
induced TNF-α secretion from monocytes (Debets et al., 1990). FcγRII does not induce 
TNF-α release from monocytes but triggers this effect after exposure of cells to 
proteolytic enzymes. In addition, immune complex mediated TNF-α production 
occurred via FcγRII has been shown in transgenic mouse model (Tan et al., 2005). 
FcγRII-transgenic mice spontaneously developed a feature like rheumatoid arthritis 
(RA) and systemic lupus erythrematosus (SLE) diseases. Elevated levels of TNF-α 
production was observed from the same FcγRII-trangenic macrophages. In another 
study on synovial macrophages from RA patients showed increased expression of 
FcγRII and FcγIII compared with controls (Blom et al., 2003). Macropahges from these 
patients showed much higher production of TNF-α and IL-1β after immune complex 
sitmulation. This study suggests that enhanced expression of FcγRII and FcγRIII is 
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associated with higher TNF-α and IL-1β production (Blom et al., 2003). Our antibody 
blocking data showed that each FcγR independently is a potent inducer of TNF-α 
induction by both ImIgG (Fig. 5.8B) and IgG-beads (Fig. 5.9B). As shown earlier IL-1β 
and GM-CSF was induced only by ImIgG. Previous study showed that tetanus toxoid 
human anti-tetanus toxoid IC induces FcγRs on monocytes to release IL-1β (Remvig et 
al., 1990). Specific FcγR involved in induction of this cytokine has not been shown. Our 
data suggest that FcγRIII play a more prominent role in IL-1β induction (Fig. 5.9A). 
FcγRI cross-linking by solid-phase mouse IgG2 have been shown to induce GM-CSF 
production from monocytes. Neither endotoxin, nor phorbol compounds have been 
shown to elicit GM-CSF by monocytes (Herrmann et al., 1992). Similar to this report, 
our data showed it is only induced by human ImIgG and FcγRI play important role for 
this cytokine nduction (Fig. 5.9B). Over all, our data from antibody blocking study 
suggest that the different FcγRs determine for different cytokine induction and the 
requirement of different FcγRs are different. Also our data is not contradicted with 
previous report the role of different FcγRs for different cytokine production. Only that 
the requirement of different FcγRs for different cytokines was not clarified.  
In addition to these pro-inflammatory cytokines, the production of anti-inflammatory 
cytokines IL-10 production was observed by both ImIgG and IgG-beads stimulated 
macrophages (Fig. 5.7). In this regard, a study from knockout mice identified the 
specific FcγR responsible for IL-10 induction. Macrophages from mice lacking the 
FcRγ-chain, which is required for assembly and signaling FcγRI and FcγRIII, failed to 
up regulate IL-10 in response to IgG-opsonized sheep red blood cell (Sutterwala et al., 
1998). However, mice lacking either the FcγRII or the FcγRIII were fully capable of up 
regulating IL-10 production, implicating FcγRI in this process. In this mouse models 
tested, the ligation of FcγR promoted the production of IL-10 and inhibited the secretion 
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of IL-12. This reciprocal alteration in the pattern of macrophage cytokine production 
illustrated an important role for FcγR-mediated clearance in suppressing macrophage 
pro-inflammatory responses. The findings in our study that ImIgG-elicited IL-10 
production was inhibited by all three FcγRs antibody (Fig. 5.8C) suggest that IL-10 
induction required all the three FcγRs. In the contrast, IgG-beads induced IL-10 
production was inhibited by either FcγRII or FcγRIII antibody (Fig. 5.9C). This 
suggests that these two receptors play important role in IL-10 induction. In summary, all 
these data suggest that different cytokines are differently induced by different FcγRs.  
 
6.3.4  IL-8 production is not sensitive to the blocking of any of the three FcγRs 
Cross-linking of monocyte FcγR on LPS free human immobilized IgG induced 
bioactive IL-8 release (Marsh et al., 1995). Our study showed that ImIgG and IgG-
beads induced GM-CSF macrophages to produce huge amount of IL-8 (Fig. 5.11). The 
induction of IL-8 is mediated by FcγRs has clinical relevance, because high levels of 
IL-8 and activated neutrophils are found in immune complex-mediated diseases such as 
the joint space in rheumatoid arthritis (Seitz et al., 1991; Verburgh et al., 1993) or the 
lung in pulmonary idiopathic fibrosis (Lynch, III et al., 1992; Car et al., 1994). The 
mechanism of IL-8 production in these diseases has been postulated to occur through 
monocyte and macrophage IL-1β and TNF-α induction fibroblast and epithelial cell IL-
8 (Standiford et al., 1990; Rathanaswami et al., 1993). However, in the absence of LPS, 
monocytes or macrophage FcγR cross-linking does not induce IL-1β (Marsh et al., 
1994) and releases relatively low concentrations of TNF-α (Kindt et al., 1993). Because 
neither rheumatoid arthritis nor idiopathic pulmonary fibrosis is associated with 
circulating LPS, immune complexes may directly induce local IL-8 production.  LPS 
contamination in our study was excluded by using LPS inhibitor polymyxin B (data not 
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shown). Thus it is conceivable that ImIgG and IgG beads may induce larger amount of 
IL-8 from macrophages. 
 
The role of specific FcγRs in induction of IL-8 production was determined by using 
anti-FcγR antibodies (Marsh et al., 1996). It showed that IL-8 was stimulated directly 
through FcγRI cross-linking and indirectly through an FcγRIII-stimulated soluble 
lymphocyte factor. The role of different FcγRs was also demonstrated in  transgenic 
mice (Sylvestre and Ravetch, 1994). These mice were deficient for the homodimeric γ 
subunit required for signaling through FcγRI, FcεRI and FcγRIII, while control mice 
had intact γ subunits. Interestingly, IgG-containing immune-complexes did not cause 
neutrophil recruitment in the transgenic γ subunit deficient mice, but did in the controls 
(Sylvestre and Ravetch, 1994). Because FcεRI also requires a γ subuint for signal 
transduction, FcεRI-deficient mice with intact FcR γ chain was subsequently found to 
recruit neutrophils. This was observed in the control mice as well. Thus, immune 
complex-mediated neutrophil recruitment is dependent on functional FcγRI and 
FcγRIII. This study is in contrast to our study where blocking of all the three FcγRs did 
not inhibit IL-8 production by both ImIgG and IgG-beads (Fig. 5.12). 
 
Importantly, sustained amount of IL-8 release by ImIgG and IgG-beads where 
combination of any of these FcγRs did not block IL-8 production raises the possibility 
that lymphocytes in the macrophage preparations are producing some factors that 
further stimulates macrophage IL-8 release. Although in our experiment, the target cell 
population of macrophage did have lymphocyte contamination, the percentage was 
negligible as more than 90% cells are adherent macrophages. It has been described 
previously, that FcγR-mediated IL-8 release is primarily a monocyte product, since 
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equivalent numbers of autologous lymphocytes and neutrophils released significantly 
less amount of IL-8 (Smyth et al., 1991). In regard to this, Marsh et al (Marsh et al., 
1996) demonstrated that supernatants from ImIgG or anti-FcγRIII-stimulated 
lymphocytes induced monocytes to release more IL-8 than lymphocytes incubated on 
plastic alone. They also showed that THP-1 cells, which do not produce IL-8 in 
response to FcγR cross-linking, also released IL-8 in response to supernatants from IgG 
or FcγRIII-stimulated lymphocytes. This result suggests that there may be unknown 
soluble secretor factors produced by the stimulated lymphocytes which could stimulate 
IL-8 production by monocytes. However, they could not block this activity using 
recombinant cytokines or neutralizing anti-cytokine Abs (Marsh et al., 1996). Since 
none of the FcγR antibody blocks IL-8 release, it can be explain that the macrophage 
express some other receptors that regulate ImIgG and IgG-beads. Another explanation is 
that IL-8 is easily induced from macrophages. However, further investigation needs to 
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LB-broth (Luria-Bertani medium) 
 
Bacto-tryptone 1.0% 
Yeast extract  0.5% 
NaCl   0.5% 
Adjust pH to 7.5 with 5 M NaOH prior to autoclaving. 
Media was sterilized by autoclaving at 15 LB/in2 for 15 min. 
Thermolabile antibiotics were filter-sterilized through 0.2 µm filters and added to the 
autoclaved LB-broth. A final concentration for ampicillin was 100 µg/ml.   
  
LB agar plates 
 
LB-broth was prepared as above with 15 g/L of Bacto-agar added. Media was sterilized 
by autoclaving. 
 
50 x TAE buffer (for DNA gel electrophoresis) 
 
Tris base  2 M 
Acetic acid  1 M 
EDTA   0.1 M 
pH 7.8 
 
10 x DNA loading buffer 
 
Ficoll400  20% (w/v) 
EDTA(pH 8.0) 0.1 M 




The stock solution was made at 10 mg/ml and stored in a light-tight bottle. Final 
















1 x PBS 
 
KH2PO4  1.76 mM 
Na2HPO4  10.4 mM 
NaCl   137 mM 
KCl   2.7 mM 
 
2 x HBS buffer 
 
NaCl   280 mM 
KCl   10 mM 
Na2HPO4.2H2O 1.5 mM 
KCl   2.7 mM 
D.Glucose anhydrous 12mM 





































Cell lysis buffer  
 
Tris-HCl, pH 7.4 50 mM 
NaCl   150 mM 
EDTA   2mM 
EGTA   2mM 
KCl   20mM 




Tris-HCl, pH 7.4 50 mM 
NaCl   300 mM 
KCl   20mM 
EDTA   2mM 




Tris-HCl, pH 8.0 20 mM 
NaCl   500 mM 
Imidazole  250 mM 
CaCl2   1 mM 
MgCl2   1 mM 
 
Protease inhibitors were added to all these buffers just before using: 
PMSF   2 mM 
Aprotinin  10 µg/ml 
Leupeptin  10 µg/ml 
 
 
Reagents for SDS-PAGE gel electrophoresis 
 
Stacking gel preparation (for 1 mini SDS-PAGE gel)  
 
dH2O       3.05 ml 
0.5 M Tris-HCL, pH 6.8    1.25 ml 
10% (w/v) SDS     50 µl 
30% Acrylamide/Bis Solution 29:1 (3.3%C)  0.65 ml 
10% APS       25 µl 










Separating gel preparation (for 1 mini SDS-PAGE gel)  
 
% of gel 5% 7.5% 10% 12.5% 15% 
dH2O (ml) 5.1 4.85 4 3.17 2.35 
1.5 M Tris-HCL, pH 8.8 (ml) 2.25 2.5 2.5 2.5 2.5 
10% (w/v) SDS (µl) 90 100 100 100 100 
30% Acrylamide/Bis Solution 
29:1 (3.3%C) (ml) 
1.5 2.5 3.33 4.16 5 
10% APS (µl) 45 50 50 50 50 
TEMED (µl) 6 5 5 5 5 
 
10 x SDS-PAGE electrophoresis buffer 
 
Tris base  25 mM 
Glycine  192 mM 
SDS   1% (w/v)   
Adjust the pH to 8.3. 
 
SDS-PAGE electrophoresis was carried out at a constant voltage of 100V.  
 
5 x Reducing sample loading buffer 
 
Tris-HCL, pH 6.8 1 M 
Glycerol  50% (v/v) 
SDS   10% (w/v) 
Bromophenol Blue 1% (w/v) 
β-mercaptoethanol 0.5 ml in 10 ml of sample loading buffer 
 
Non-reducing sample loading buffer is prepared as above without the addition of β-
mercaptoethanol. 
 
10 x Western blot transfer buffer  
 
Tris base  25 mM 
Glycine  192 mM 
 








Non-fat milk  5% 
Buffer prepared in TBST 
  
 
 
